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Abstract 
Aggregation of α-synuclein (α-syn) into toxic fibrils is a pathogenic hallmark of Parkinson’s 
disease (PD). This research aimed to develop peptides capable of inhibiting α-syn 
aggregation using a semi-rational design combined with a multiplexed intracellular Protein-
fragment Complementation Assay (PCA) library screening system. Successfully selected 
peptides must bind to full length α-syn and lower its toxicity to confer bacterial growth. PCA 
selected peptides were characterized using several biophysical assays and a cell viability 
assay. The peptides were screened using library templates based on α-syn71-82 initially and 
later on the α-syn45-54 region in which many key mutations associated with early onset PD 
are found. In both cases we targeted the peptide libraries at the wild type protein or again 
by using mutated versions of α-syn. Results demonstrate that some of those selected 
peptides had the effect of delaying or even preventing the aggregation process, with others 
providing more subtle effects in reversing the fully formed amyloid fibrils. PCA peptides 
selected against 71-82 region of wild type α-syn showed a moderate level of efficacy 
whereas against mutants, it showed a low level of efficacy in inhibiting amyloid fibril 
formation. In the final part of the study, the peptide selected against 45-54 region of wild 
type α-syn was capable of preventing the aggregation and reducing the amyloid cytotoxicity 
at an equimolar ratio. We have thus demonstrated that the PCA strategy can be used as a 
generalised method for deriving peptide antagonists of α-syn aggregation, together with a 
new region; α-syn45-54 as an inhibitor target and produced a peptide inhibitor expected to 
provide a scaffold for future drug candidates to slow or even prevent the onset of PD. 
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Chapter 1: Introduction 
1.1 Parkinson’s disease  
Parkinson’s disease (PD) is a neurodegenerative disorder that is caused by the loss of 
dopamine producing neurons. The symptoms of PD include movement disorders, tremor 
(involuntary shaking of particular parts of the body), rigidity due to stiff and inflexible 
muscles, slowness of movement, walking difficulty and gait. Neuropsychiatric (cognitive, 
behavioural, sensory, sleep, emotional) problems may also arise in the advanced stages of 
the disease which eventually leads to dementia. It has been estimated that one in every 500 
individuals has PD, leading to about 127,000 cases in the UK (Parkinson’s UK, 2015). The 
average age of onset for PD is 50 or over, but it is also found in younger people, with one in 
20 patients under the age of 40. In particular, PD is caused by the death of dopaminergic 
neurons in the ventral component of pars compacta region within the substantia nigra of 
the mid brain. The substantia nigra plays an important role in reward, addiction and 
movement. It consists of two parts, the pars compacta and the pars reticulata, in which the 
former serves as input to the basal ganglia circuit, supplying the dopamine and the latter 
serves as output, conveying signals to other brain structures (Damier et al., 1999). The most 
important function of the pars compacta is motor control. The depletion of dopaminergic 
neurons in this region causes PD symptoms which usually do not appear until up to 50-80 % 
of neuronal death occurs (Parkinson’s UK, 2015).  PD is one among many age related 
disorders that are thought to be caused by amyloid fibrils. There is a growing body of 
evidence that suggests that neuronal death in PD is due to amyloid fibrils comprising a 
protein known as α-synuclein (α-syn) (Gallea and Celej., 2015; Chiti and Dobson., 2006; Yagi 
et al., 2005; Conway et al., 2000; Takeda et al., 1998; Spillantini et al., 1997). Misfolding and 
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loss of function of this normally soluble functional protein leads to the formation of thread-
like, well-defined amyloid structures. Amyloid fibrils are composed of β-sheets with 
intermolecular interactions, oriented perpendicularly to the fibril axis (Serpell, 2000). Most 
proteins fold as they are being synthesised on the ribosome. A wide range of molecular 
chaperones in the ER and Golgi apparatus are involved in the guidance of the folding 
process in order to avoid the untimely interaction of protein in the cell environment. If a 
protein misfolds by chance, it will be directed into the ubiquitin-proteasome degradation 
system and autophagy (Pirkkala et al., 2000). Some proteins with a high tendency to misfold 
are able to bypass all these protective mechanisms and form insoluble aggregates in the 
tissues. Protein misfolding can give rise to the abnormal functioning of the cell and leads to 
disease (Knowles et al., 2014). 
 
Figure 1.1: The different states in which a protein can exist during its synthesis-degradation 
mechanism. Inter-conversion rates are determined by various thermodynamic factors and free 
energy barriers thereby determining the rate of synthesis and degradation (Image source: Knowles 
et al., 2014). 
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PD is one of a collection of α-synucleinopathies, with others including dementia with Lewy 
bodies (LBs), and multiple system atrophy (McCann et al., 2014). All these diseases are 
characterized by misfolding and aggregation of α-syn in the dopaminergic neurons. α-syn 
aggregation causes neuronal inclusion deposits known as ‘Lewy bodies’ (LBs) which are the 
most distinctive neuropathological feature of PD. ‘Lewy neurites’ (LNs) also coexist with LBs 
in PD, which are abnormal neurites (projections from the axons or dendrites) containing α-
syn filaments (Spillantini et al., 1998; Kanazawa et al.,2008). The deposition of LBs or LNs 
leads to neuronal cell death in PD.  
1.2 Genetics of PD and Parkinsonism 
Studies estimate that only 5 % of PD cases may be inherited which is rare compared to 
idiopathic PD (Parkinson’s UK, 2015). However, the mutations found in the SNCA gene [α-
syn (PARK 1/4)] that cause familial PD are typically mis-sense in which single nucleotides are 
changed, or are duplications and triplications of the SNCA containing locus. The known 
SNCA mutations lead to protein aggregation, LB/LN formation and neuronal cell death 
which are a significant in the early onset of PD symptoms in patients carrying familial α-syn 
mutants (Giasson et al., 2000; Singleton et al., 2003; Berg et al., 2005; Lesage et al., 2009). A 
clinical definition of a variety of movement related disorders of which PD is just one is 
known as Parkinsonism. The other genes involved in Parkinsonism are: LRRK2 [Leucine rich 
repeat kinase 2/ dardarin (PARK8)], PRKN [parkin (PARK2)], PINK1 (PARK6), DJ-1 (PARK7) 
(Hardy et al., 2006). The LRRK2 gene encodes two distinct enzymes, a protein kinase and a 
GTPase. The mutations (G2019S, R1441G and I2020T) on LRRK2 enhance its kinase activity 
relative to the wild type protein. An increase in the kinase activity leads to neuronal toxicity, 
but in some cases the cell death is not identified as a result of inclusion body formation 
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(Khan et al., 2005; Mata et al., 2006; Masso et al., 2015). The natural known function of 
parkin is as an E3 ligase that can control protein turnover via ubiquitin chain addition, 
whereas PINK1 functions as a mitochondrial serine/threonine kinase, and the DJ1 functions 
as anti-oxidant thereby protecting cells against mitochondrial damage. The mutations in 
these genes which cause its loss of function lead to early onset of Parkinsonism (Hardy et al., 
2006).  When the substantia nigra is severely affected it can lead to Parkinsonism whereas 
when Lewy pathology and associated cell loss are seen in any other parts of the brain (e.g.: 
the cortex), the predominant symptoms would lead to dementia (Hardy et al., 2006). The 
mutations in the parkin gene are known to be linked to some forms of early onset of PD 
(diagnosed under the age of 40). The mutation in DJ-1 is found to be linked with some 
inherited forms of PD.  The parkin, PINK1, and DJ-1 gene mutations are related with 
Parkinsonism with limited evidence of protein inclusion body formation (Lucking et al., 2000; 
Bonifati et al., 2002; Mata et al., 2006).  
1.3 Structure and Role of α-syn  
α-syn is a neuronal protein with a molecular weight of 14 kDa, containing 140 amino acids, 
encoded by the SNCA gene (Serpell et al., 2000; Baba et al., 1998; Spillantini et al., 1997). 
The structure of α-syn has three domains; the N-terminal region consists of (i) an 
amphipathic region (1-60) and (ii) a hydrophobic non amyloid component (NAC) region (61-
95). The C-terminal comprises of (iii) an acidic proline rich region (96-140) (Fig 1.2).  
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Figure 1.2: α-syn residues: consisting of three overlapping regions, N-terminal amphipathic and 
hydrophobic NAC region along with acidic C-terminal region. The seven 11-mer imperfect sequences 
(XKTKEGVXXXX) containing highly conserved KTKEGV hexameric motif (highlighted in yellow) are 
believed to be involved in lipid interaction, NAC region in aggregation and C-terminal region for 
binding of different ions and proteins. The residues highlighted in red are where point mutations 
(A30P, E46K, H50Q, G51D and A53T) identified associated with the early onset of PD.  
The 12 amino acid sequence (71VTGVTAVAQKTV82) found in the middle of the hydrophobic 
region is widely identified to be responsible for the fibril formation (Bedard et al., 2014; 
Waxman et al., 2009; Giasson et al., 2001). Structural studies show that α-syn is monomeric 
and natively unfolded in the solution (Vilar et al., 2008; Lundvig et al., 2005; Uversky et al., 
2002). The N-terminal region forms an α-helical conformation upon interaction with 
phospholipid membranes. α-syn forms cross β-amyloid structures spontaneously when 
exposed to various physical and chemical factors. In the cross β structure, the central spine 
of fibril is formed by stacking of intermolecular β-sheets. The hydrogen bonds that connect 
β-strands into a pleated β-structure are aligned parallel to the fibril axis and the side chains 
define the intra-intermolecular interactions within the plane of the fibril cross-section 
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(Fandrich et al., 2009). This structural conversion of a natively unfolded structure to cross-β 
amyloid structure leads to α-syn toxicity in PD. 
There are some structural ambiguities of native α-syn which remain as a critical challenge to 
understand PD pathology. Recent studies suggested that, α-syn is able to form a stable 
helically folded tetrameric structure which is able to resist aggregation (Wang et al., 2011; 
Bartels et al., 2011). According to their studies, the higher lipid binding capacity of α-syn 
confirms that the monomer species is not fully functional and is found less abundant in the 
normal cells. According to Wang (2011), the tetrameric structure does not perforate 
membranes unlike oligomeric α-syn. The proposed tetramer is believed to undergo 
destabilization before the formation of α-syn aggregates as abnormal oligomeric and fibrillar 
assemblies that induce cytotoxicity in PD. Thus the stabilisation of tetrameric structure and 
prevention of α-syn from aggregation and toxicity, may lead to a significant therapeutic 
strategy against PD. In addition, the structure of α-syn depends on subunit concentration 
and environmental factors. Perturbations caused by physical factors or disease associated 
mutations enhance its aggregation propensity. 
1.4 Expression and Normal Function of α-syn in the Brain 
α-syn is predominantly expressed in the neocortex, hippocampus, substantia nigra, 
thalamus and cerebellum of the brain. In mammalian neurons, it is extensively localized in 
the nucleus (Yu et al., 2007) and in the pre-synaptic termini in both free or membrane 
bound forms (Lee et al., 2002). Recent studies showed that α-syn has been localized in 
neuronal mitochondria found in olfactory bulb, hippocampus, striatum, and thalamus. 
However, the cerebral cortex and cerebellum have more cytosolic, but less mitochondrial α-
syn (Liua et al., 2009). α-syn located in the synaptic nerve terminals, functions mainly in the 
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vesicular homeostasis and neurotransmission. It exists as monomeric form in cytosolic pool 
where as both monomeric and oligomeric species in the pool associated with synaptic 
vesicle. The protein dissociates from the vesicles and re-associates slowly during synaptic 
activity when there is an electrical stimulation inside the neurons. α-syn concentration is 
also a key factor in determining the complex I activity of mitochondrial respiratory chain 
(Fortin et al., 2005). It can also bind to lipids and is associated with plasma membrane 
interactions (Jo et al., 2000; Eliezer et al., 2001). The impairment in the folding/unfolding 
mechanisms of α-syn due to several factors lead to the formation and accumulation of LB 
inside the dopaminergic neurons. Thus its unavailability during the formation of synaptic 
vesicles (for the storage of dopamine) at pre-synaptic terminal leads to the mis-regulation of 
dopamine pathway (Fig 1.3) and finally to the movement related symptoms of PD (Mizuno 
et al. 2008).  
 
Figure 1.3: Schematic representation of substantia nigral neuronal death in PD. The various genetic 
and environmental risk factors initiate the pathological sporadic PD while the SNCA point mutations 
lead to mutant α-syn causes familial PD. DA: dopamine (Image source: Mizuno et al. 2008) 
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1.5 Aggregation of α-syn 
α-syn aggregation in vitro is found to be a nucleation dependent process which demands a 
minimum concentration of monomers required under which there would be no aggregation. 
The aggregation is characterized by; (i) a slow nucleation phase or lag phase where the 
protein undergoes various thermodynamically unfavourable steps to oligomeric nuclei, (ii) a 
growth phase or an elongation phase where rapid association of monomers into the cross-β 
structure nuclei when the monomeric concentration reaches a threshold, and (iii) a 
saturation/stationary phase where there exists an equilibrium between soluble α-syn 
species and insoluble aggregates (Fig 1.4). A recent study shows that once a critical 
concentration of small amyloid fibrils seen to be accumulated, the further toxic species are 
primarily formed by a fibril-mediated secondary nucleation reaction rather than classical 
primary nucleation mechanism (Cohen et al., 2013). Thus an addition of nucleation 
competent filaments to α-syn reaction mixture above the critical concentration can reduce 
the lag phase, so called ‘seeding’ in which monomers can attach, and elongate into fibrils 
(Lundvig et al., 2005).  
 
Figure 1.4: Nucleation dependent α-syn fibrillisation process showing three phases (i) lag phase 
(aggregation of misfolded monomers into intermediate oligomeric species) (ii) growth phase (re-
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arrangement oligomers into an organized cross-β conformation), and (iii) a saturation phase 
(formation of proto-fibrils and finally into fibrils). Several factors can reduce the lag phase and 
stimulate the aggregation (Image source: Iannuzzi et al., 2015). 
Oligomers which can dissociate into monomers and simultaneously re-associate into larger 
assemblies are formed during the aggregation progresses.  These oligomers which are more 
likely to be unfolded, with a lower amount of secondary structure are also identified to re-
associate as toxic cross-β structure. Along with fibrils, the assembly of these toxic oligomers 
are also found to be involved in the pathogenesis of PD (Roberts et al., 2015; Kalia et al., 
2013; Winner et al., 2011; Outeiro et al. 2008). The oligomeric species can be stabilized 
through covalent cross linking techniques; and it can be analysed using SDS PAGE or size 
exclusion chromatography. Studies have been undertaken using novel proximity ligation 
assay (PLA) which selectively detects oligomeric forms of α-syn in neuro-anatomical areas 
relevant to early PD pathology (Roberts et al., 2015). The in vitro transition of oligomers into 
amyloid fibrils occurs during a maturation process.  α-syn can form fibrils with 5-10 nm in 
height, 10-20 nm wide and ~500 nm to 2.5 µm length as characterised by atomic force 
microscopy and electron microscopy (Khurana et al., 2003). The fibril structure can be 
studied by dye binding assays, microscopic and spectroscopic studies. The filaments formed 
in vitro are usually found to be straight, unbranched (homo-aggregate) similar to that found 
in LB and glial cytoplasmic inclusions. Although in some cases due to the association of α-syn 
aggregate binding proteins, the filaments can form mesh like structures possessing frequent 
branching.  It shows that several protein factors could have been involved in the α-syn 
aggregation in vivo (Lundvig et al., 2005).  
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The functional effect of α-syn aggregation includes dysregulation of the microtubule 
network which is very important for the long transport pathways in the axons. The 
microtubule-associated proteins, such as MAP-1A, MAP-1B, tau, and p25α have been 
identified in LB along with α-syn. An increased concentration of MAP-1B, tau and p25α 
enhances α-syn aggregation. The mis-functioning of α-syn expression causes its interaction 
with p25α and leads to their co-localization as oligodendroglial cytoplasmic inclusions which 
are commonly seen in neuronal LB in PD. The transcriptional factors NF-kB and Elk-1 have 
been also found in LB. High Mobility Group B-1 protein (HMGB-1) has been found to bind 
directly with α-syn in vitro and also found as a component in LB. α-syn oligomers result an 
increased permeability of calcium ions in liposomes. The membrane permeabilisation in vivo 
is still not clear, but it may be due to the existence of its structural similarity with the 
bacterial pore forming toxins. It disturbs the ionic homeostasis inside the cells by forming 
pores in the membrane and thus leads to the cell lysis (Lundvig et al., 2005). The 
accumulation of ubiquitinated proteins found in the LB shows an imbalance between the 
proteasome production and its catabolic capacity. Dysregulated ubiquitin-proteasome 
system is found in most α-synucleinopathies. A decreased level of certain proteasomal 
subunits and an impaired function of chymotrypsin-, trypsin-, and caspase- like activities of 
proteasomes have been investigated in PD. In contrast, some studies show that the 
ubiquitinated α-syn in LB pathology is found to have partly phosphorylated and not 
complete impairment of proteolytic activity of proteasome occurs (Tofaris et al., 2003). The 
misfolded α-syn also shows resistance to proteinase-K digestion in PD (Neumann et al., 
2002). 
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1.6 Factors causing α-syn aggregation 
Various chemical and physical factors such as mis-sense mutations in the N-terminal regions, 
a number of post translational modifications in the 20 residue C-terminal region (truncation, 
nitration, phosphorylation or methionine oxidation), concentration, pH, temperature, ionic 
strength, metals, lipids, pesticides, and other proteins are found to have important roles in 
controlling α-syn in its membrane binding, aggregation and toxicity properties.  
The N-terminal region is relatively inaccessible to the post translational modifications due to 
its interaction with the membranes. Rare familial point mutations such as A53T, A30P, E46K 
along with recently identified H50Q and G51D have been recognized in the formation of 
amyloid fibrils that contribute to the early onset of PD. These mutations are seen to increase 
the β–sheet propensity of α-syn (Spira et al., 2001; Zarrenz et al., 2004; Greenbaum et al., 
2005; Ki et al., 2007; Seidel et al., 2010; Cresswell et al., 2013; Proukakis et al., 2013; Lesage 
et al., 2013; Rutherford et al., 2014). Though the wild type α-syn and all mutants possess 
identical structural properties and conformational behaviour, the propensity to form 
aggregates is strongly enhanced by the familial PD point mutations (Scira et al., 2013; Li et 
al., 2001). Hydrophobic interactions are observed to play an important role in aggregation 
as a decreased hydrophobicity leads to an increased aggregation propensity. For instance, 
A30P and A53T cause the reduction of hydrophobicity relative to the wild type α-syn (Li et 
al., 2001). Some mutations like E46K can cause a change in the net charge of α-syn and the 
replacement of an existing residue that stabilizes the structure which can lead to increased 
β-sheet propensity (Scira et al., 2013; Rospigliosi et al., 2009; Uversky et al., 2000). The point 
mutations can reduce α-helical propensity of N-terminal region which actively participates 
in lipid binding makes the mutants more likely to form β-sheet structure. The point 
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mutations might not be involved in conformational change but can affect the nature and 
rate of α-syn aggregation.  
A wide range of post translational modifications of α-syn in the pathological nerve cell 
lesions and brain tissue have been identified which increases its β-sheet propensity. Some 
modifications are found in the C-terminal region of α-syn. In oxidatively stressed neurons, 
Tyr-125 in α-syn is found to be phosphorylated, nitrated or aminated suggesting that this 
residue is highly susceptible to different modifications. In addition, Tyr-133 is identified to 
be never phosphorylated but nitrated or aminated indicating it is not targeted by kinases 
(Mirzaei et al., 2006). Nitrating agents such as nitric oxide, nitrogen dioxide and 
peroxynitrite are strong oxidants which induce α-syn aggregation by promoting Tyr 
oxidation (Periquet et al., 2007). A recent study suggests that Tyr-125 phosphorylation 
functions as a primary step leads to the phosphorylation of Ser-129 by CK-1 in vitro (Kosten 
et al., 2014).  
Oxidative stress is believed to aggravate PD pathogenesis. α-syn undergoes enhanced 
methionine oxidation in oxidatively stressed neurons with impaired mitochondrial complex-I 
activity (Uversky et al., 2002). According to their findings, since α-syn doesn’t have Trp or 
Cys residues, all four Met residues get oxidised to corresponding sulphoxides. The 
fibrillisation of such oxidised α-syn is inhibited by facilitating the formation of soluble stable 
oligomers at normal physiological conditions. Though in the presence of a high number of 
oxidatively stressed neurons along with some environmental metal pollution leads to an 
enhanced fibrillisation process. In addition to that, the met- oxidized forms of α-syn would 
not get repaired by methionine sulfoxide reductases leads to its accumulation (Glaser et al., 
2005; Hald et al., 2005; Mirzaei et al., 2006). There is an increase in evidence that calcium 
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dysregulation and lysosome dysfunction plays an important role in PD pathogenesis. Thus, it 
may be therapeutic strategy to design calcium channel blockers that may reduce the risk of 
PD (Pasternak et al., 2012; Tofaris, 2012; Mattson, 2012). 
Considering the physical factors that influence α-syn aggregation, most in vitro 
investigations are carried out at much higher concentrations in order to reduce the lag 
phase, under physiological temperature and ionic strength. The lowering of pH enhances 
the fibrillisation rate as it decreases the lag phase due to the shielding of negative charges 
by protonation. But a neutral pH is better for in vitro studies since the acidic pH may affect 
the structure of aggregates. An increase in temperature causes the filaments to differ 
morphologically from that in physiological conditions but it is found to affect the 
aggregation process (Ariesandi et al., 2013). The binding of metals to the acidic residues 
region corresponding 116 to 136 of α-syn is found to favour the oxidative modifications and 
thereby increases its aggregation. Various metals are found to influence α-syn aggregation 
in vitro, such as Al3+, Fe3+, Co3+, Mn2+, Ca2+, and Cu2+ (Uversky et al., 2001). The interaction of 
Al3+ to the acidic C- terminus induces structural perturbations in α-syn which leads to an 
increased aggregation rate. Some metals are found to inhibit the aggregation effect induced 
by other metals, for example Mg2+ inhibits the iron induced α-syn aggregation (Mirzaei et al., 
2006; Uversky et al., 2001). Various fatty acids, anionic detergents and anionic lipids are 
found to enhance the α-syn fibrillisation in vitro. Amorphous aggregates and small filaments 
are formed as a result of interaction between soluble α-syn and planar bi-lipid layers. The 
recombinant α-syn when exposed to poly unsaturated fatty acids, leads to the formation of 
SDS resistant multimers. Pesticides induce conformational changes in α-syn and accelerate 
the formation of α-syn inclusions in the nerve cells. For instance, the effect of paraquat; a 
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herbicide and rotenone inducing inhibition of mitochondrial complex I, due to oxidative 
stress and following death of neurons have been studied on various animal models 
(Maturana et al., 2015; Lundvig et al., 2005). α-syn is identified to have high capacity to form 
non-specific interactions with  other proteins. Many proteins are found to accelerate the α-
syn aggregation while some shows inhibitory effect on aggregation rate in vitro. Proteins 
such as tau, histones, brain specific protein p25α, and tubulin are found to accelerate the 
aggregation (Paytona et al., 2001). Except histones all the other proteins have been 
identified in LB or glial cytoplasmic inclusion components along with α-syn. These 
interactions of α-syn with other proteins may have effects in the morphology of α-syn 
aggregates in their branching and interactions with cellular constituents. The presence of 
non-fibrillogenic human homologues, β-synuclein and γ-synuclein are found to be inhibiting 
α-syn aggregation in vitro (Karyo et al., 2010; Uversky et al., 2002; Hashimoto et al., 2001).  
There are some protective proteins expressed by the cells to lessen the proteasomal 
inhibitory properties of aggregated α-syn. The heat shock protein-70 (hsp-70) and 
glyceraldehyde-3-phosphate dehydrogenase that binds to α-syn reduces its anti-
proteasomal effects (Pirkkala et al., 2000). 
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1.7 Therapeutic approaches against PD 
A better understanding through wide spread research on structure of α-syn and its role in 
cellular degeneration are yet to be evolved for developing new therapeutic interventions 
towards this second most dreadful neurodegenerative disorder. There are many studies 
going on to identify a potential drug to stop or slow down the aggregation of α-syn and 
thereby mitigate PD symptoms. Most of the inhibitors are found to attach covalently with α-
syn. The structural analysis of inhibitor bound α-syn oligomers is essential for the better 
understanding of the inhibitory mechanism. There are several mechanisms by which 
compounds can inhibit α-syn fibrillisation: (i) stabilizing the native state of amyloid, (ii) 
blocking the different intermediates on amyloid pathway from their conversion to fibrils, (iii) 
alteration of aggregation pathway and leads to the formation of non-amyloidogenic, non-
pathogenic aggregates, (iv) breakdown of toxic fibrils, and (v) prevention of prion-like 
spread. 
Levodopa (L-DOPA) which has trade names duodopa™, sinemat, atamet, madopar etc is one 
of the main drugs used currently to alleviate PD symptoms. L-DOPA is co-administered with 
benserazide (as co-beneldopa) or carbidopa (as co-careldopa) to cross the blood-brain 
barrier efficiently. The decarboxylation of L-DOPA converts it into dopamine. Although there 
are some side effects such as nausea, hypotension, insomnia, auditory-visual hallucinations 
and many more associated with L-DOPA administration, it is found to be effective in 
alleviating PD symptoms in the early or later stages of disease progression. The oxidation of 
dopamine is required to stabilize the soluble oligomeric α-syn intermediates and thereby 
inhibit fibrillisation.  This kinetic stabilization is dependent on the non-covalent interaction 
between oxidised dopamine and the amino acids 125Tyr-Glu-Met-Pro-Ser129 of α-syn. This 
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interaction induces reversible conformational change of α-syn which prevents it from 
fibrillisation. Dopamine has the ability to auto-oxidize more rapidly than any other 
compounds containing catechol ring in vivo under physiological pH. 
In PD, oxidative or nitrative damage of tyrosine hydroxylase (the catecholamine synthesis 
rate-limiting enzyme) causes a decrease in its catalytic activity, thereby leads to the 
decrease in catecholamine levels. Studies show that the intracellular catechol levels are 
critical in the development of PD. An increased cytosolic catechol level can inhibit the 
formation of α-syn aggregates in vitro (Mazzulli et al., 2006). Some molecules such as 
Catechol O-methyltransferase inhibitors; entacapone and tolcapone have shown some anti-
amyloidogenic property that inhibits the α-syn aggregation (Giovanni et al., 2010). It is now 
available in the market and being used as drugs to alleviate PD symptoms in the early or 
later stages of progression. There are some drugs which act as dopamine receptor agonist. It 
includes apomorphine, bromocriptine, cabergoline, lisuride subcutaneous, ropinirole, 
rotigotine and pramipexole. These drugs are administered at the early or late stages of PD 
progression. Case studies showed that pramipexole has neuroprotective properties and 
found to cause a delay in the disease progression (Schapira et al., 2014). Another 
therapeutic intervention against PD is based on monoamine oxidase (MAO) inhibitors. These 
inhibitors act upon MAO and prevent the breakdown of monoamine neurotransmitters 
including dopamine and thereby increasing their availability. The common drugs available 
under this category are selegiline and rasagiline which specifically acts upon MAO-B. 
Although these drugs can be used in the early stages of PD and also it delays its progression, 
MAO inhibitors are reserved as a last line of treatment as it causes lethal dietary side effects 
(Bartl et al., 2014; Am et al., 2004; Youdim et al., 2001). A recent study developed some 
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neuro-protective agents; arylalkenylpropargylamines against MAO-B marks the survival of 
PC-12 cells in vitro (Huleatt et al., 2015). Other drugs administered are zonisamide; which 
targets the ion channels, rivastigmine; which is an acetylcholinesterase inhibitor, ropinirole 
and amantadine; both reduce dyskinesias associated with PD (Chan et al., 2013; Murata et 
al., 2001; Emre et al., 2004; Rascol et al., 2000). The role of human silent information 
regulator-2 (Sir-2 or sirtuins), a nicotinamide adenine dinulceotide-dependent histone 
deacetylase (HDAC) enzyme in maintaining neuronal cell protection and cell cycle regulation 
have been widely studied. It protects the axons from its degeneration from increased NAD+ 
biosynthesis. There are seven distinct sirtuin proteins, SIRT1 to SIRT7 identified in humans. 
The selective inhibition of SIRT2 is found to modulate the α-syn toxicity and rescue the 
neurons from cell death, by reducing the small LB formation. SIRT2 deacetylates α-tubulin at 
Lys40 and enhances the co-localization of tubulin with α-syn in the LB formation. AGK2 (2-
cyano-3-[5-(2, 5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide) found to be an 
effective inhibitor of SIRT2. AGK2 inhibits the deacetylation activity of SIRT2 and thereby 
increases the acetylated α-tubulin concentration in the cell (Chen et al., 2014; Outeiro et al., 
2007). Some poly-aromatic inhibitors like cyclic tetrapyrrole phthalocyanine tetrasulfonate 
(PcTS) are found to disassemble tau proteins and inhibit α-syn filament assembly eventually 
leading to non-toxic aggregates. The tetrapyrrolic ring occupied by different metal cations in 
phthalocyanine moiety and the negatively charged tetrasulfonate groups are responsible for 
modulating anti amyloidogenic activity of PcTS on α-syn. The anti-amyloid effect exerted by 
PcTS on α-syn and its mode of interaction depends on the nature of metal ion (PcTS [Ni(II)], 
PcTS [Zn(II)], and PcTS [Al(III)] ) bound to it and the propensity of PcTS species to self-
associate (Lamberto et al., 2011). The molecular interaction between α-syn and β-synuclein 
were found to reduce both amyloid fibrils and soluble oligomer formation in vitro. β-
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synuclein lacks the NAC region and does not aggregate into amyloid fibrils. It binds 
specifically to α-syn in a dose dependent manner and reduces its aggregation propensity 
(Karyo et al., 2010). Several small polyphenol molecules have been identified to inhibit the 
formation of amyloid fibrils and its associated cyto-toxicity. Polyphenols act as free radical 
scavengers and thus possess anti-oxidative property. Polyphenols such as α-tocopherol, β-
carotene, curcumin, baicalein, delphinidin, epigallocatechin gallate, exifone, gallo-catechins, 
gossypetin, hinokiflavone, hypericin, procyanidins, rosmarinic acid, theaflavine, dopamine 
chloride and many more are found to be strong inhibitors of α-syn assembly (Ahsan et al., 
2015; Ahmad et al., 2012; Caruana et al., 2011; Masuda et al., 2006; Porat et al., 2006 ). 
They were identified to interact with the C-terminal end of α-syn. The structural constraints, 
adjacent phenolic -OH groups present in polyphenolic compounds and specific aromatic 
interactions play an important role in the inhibition of α-syn aggregation. The over-
expression of Hsp-70 is found to inhibit both oligomeric formation and toxicity of α-syn by 
preventing the formation of prefibrillar α-syn. The Hsp-70 substrate binding domain is found 
to interact with the prefibrillar species and causes the C-terminal domain bind to the α-syn 
nuclei and thereby retarding the fibril elongation (Huang et al., 2006; Pirkkala et al., 2000). 
Inhibition of prolyl oligopeptidase (PREP) may be an important therapeutic strategy against 
PD as PREP can accelerate α-syn aggregation in cell models and in vitro. PREP inhibitor; KYP-
2047 was found to be effective in decreasing α-syn aggregation via increased autophagy and 
normalizes cell functioning in vivo and in vitro (Savolainen et al., 2014; Myohanen et al., 
2012). A study shows that antibodies can interfere with α-syn fibrillisation and inhibit 
amyloid formation by altering the aggregation pathway in a catalytic manner (Breydo et al., 
2015). Emadi and coworkers (2004 & 2007) showed that the human single chain antibody 
fragments (scFv’s) isolated from phage display antibody libraries decreasing the aggregation 
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rate of monomeric α-syn and also inhibiting the formation of oligomeric and protofibrillar α-
syn structures. 
1.7.1 Strategy for developing peptide antagonist 
The strategy for developing specific amyloid peptide inhibitors includes the addition of small 
compounds, groups, or amino acid residues into the α-syn partial sequence. As NAC region 
is responsible for the aggregation of α-syn into fibrils, peptide fragments ETVK or KTVE 
based on NAC template was identified as a strong binder to NAC region. The high affinity 
corresponds to the Val-Thr and Thr-Val motifs repeated amino acid sequence of NAC. An 
oligopeptide based on template ETVK or KTVE would become an effective inhibitor against 
α-syn aggregation (Kuroda et al., 2004). The N-methylated (at Gly73) analogue species of α-
syn is found to be anti-amyloidogenic. The addition of N-methyl group causes the 
replacement of the amide hydrogen and thereby disrupts the chance of peptide bond 
formation required for a stable β-sheet structure (Bodles et al., 2004). Madine and 
colleagues (2008) studied the inhibitory effect of N-methylated peptides on α-syn 
aggregation. The designed peptides were found to be highly soluble in aqueous and organic 
solvents, resistant to proteolytic degradation and can diffuse across membranes which are 
essential along with the inhibitory properties. Seven residues in 71-82 region (four valine, 
one glycine and two alanine) were considered and has more possibility for introducing N-
methyl group to induce inhibitory property to α-syn. But the double methylation found to 
be unsuitable as an inhibitor of α-syn aggregation due to its increased hydrophobicity and 
greater size of 1000 nm which leads to the formation of non-amyloid aggregates.  
Pyrroloquinoline quinine (PQQ) modified α-syn36-46, partial peptide modified with quinine 
molecules; baicalein and epigallocatechin gallate (EGCG) were reported to prevent α-syn 
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amyloid fibril formation (Yoshida et al., 2013). Some groups used in silico panning for 
screening peptide ligands against α-syn targeting the hydrophobic amyloid core forming α-
syn68-78 region. The peptides derived such as QSTQ and AQTQ at five fold molar excess were 
seen to interact with α-syn and found to promote fibrillisation (Abe et al., 2007).  
Peptide inhibitors against α-syn aggregation can be generated using a multiplexed 
intracellular Protein-fragment Complementation Assay (PCA) library screening system 
(Acerra et al., 2013; Mason et al., 2006; Pelletier et al., 1998). The PCA system involves 
transformation or transfection of cell lines using library containing plasmids to screen and 
select for peptide antagonists. Successfully selected peptides must bind to the target 
protein; α-syn, inhibit amyloid growth thereby reducing amyloid cytotoxicity and confer 
bacterial cell growth. The parameter checked during peptide selection is that, whether the 
peptides bind to α-syn such that the two halves of a reporter enzyme is recombined and 
expressed which facilitates the cell survival under selective conditions. The advantage of 
PCA is that since it is an in vivo selection system, only stable, protease resistant, non-
aggregating (soluble), non-toxic and target-specific peptides can be selected. In PCA, the 
possible artifacts are that we will get colonies growing where the peptides does not really 
bind the target strongly. The problem can be solved by increasing the stringency of the 
conditions by an increased amount of Tmp which I used is a bit arbitrary. Another artefact is 
that the GS linkers on the peptide and target could interact with each other which are 
probably not enough to make a peptide that doesn’t bind the target look like it does, but 
could increase the apparent affinity so that the colony of that peptide grows faster than it 
should. In this thesis, PCA has been used to screen peptides from a library containing many 
thousands of members for an interaction with full length wild type α-syn or its mutants. 
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Antagonistic peptides were designed scaffolding two targets; α-syn71-82 (against wild type α-
syn and its mutants) and α-syn45-54 (against wild type α-syn).  
 
Figure 1.5: Protein fragment complementation assay (PCA). Peptide library members that bind to α-
syn reconstitute murine dihydrofolate reductase (mDHFR) activity and induce cell growth under 
selective condition containing trimethoprim. Subsequent passages in liquid media were undertaken 
in competition selection process to isolate potential peptides with highest efficacy (Image source: 
Cheruvara et al., 2015). 
 
 
 
 
 
 
 
22 
 
1.8 Conclusion 
Symptomatic treatments like introducing L-DOPA, cell replacement therapies or deep brain 
stimulations is being provided for the more advanced stages of PD. Some of the events such 
as oxidative stress, mitochondrial dysfunction, kinase phosphorylation, inflammation, 
protein handling, and ubiquitin-proteasome pathways appear to be important in the 
pathogenesis of PD which led to the identification of molecular targets for designing 
potential drug candidate to slow or reverse the disease progression. PD has been classified 
as a cell autonomous disease. However some studies reported a prion-like intercellular 
transfer of misfolded α-syn leads to question the basic understanding of the disease 
(Olanow et al., 2013; Li et al., 2008). The knowledge about the genetic cause and different 
risk factors contributing to the various events that leads to neurodegeneration should 
provide new targets for developing neuroprotective drugs. The hypothesis of designing 
small inhibitor molecules is that it can manipulate biochemical pathways, genes or proteins. 
The strategies for developing such drugs can be designing modulators that can enhance 
specific pathways for clearance of proteins or degradation of toxic oligomers or aggregates. 
Phosphorylation pathways are suitable targets for developing peptide drugs as α-syn 
undergo such pathways in several sites during aggregation process.  
In this thesis, I have successfully demonstrated that the PCA strategy can be used as a 
generalised method for deriving peptide inhibitors against α-syn aggregation. In the future, 
these newly designed inhibitors can be modified into drugs to slow or even prevent the 
onset of PD.  
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Chapter 2: Materials and Methods 
2.1 Purification of wild type α-synuclein (α-syn) and mutants 
The hexa-His tag containing pET21b expression vector (ampicillin resistance) was used for 
protein expression. This vector was fused with a 100 residues long ‘SUMO’ (small ubiquitin 
related modifier) tag to increase protein solubility (Malakhov et al., 2004; Butt et al., 2005; 
Marblestone et al., 2006; Lee et al., 2008). The inserts terminated with a ‘stop’ codon were 
cloned into the vector via NheI and AscI restriction sites.  The enzyme SUMO protease (ULP1) 
was used to remove the His-SUMO tag. 
Protein purification overview: 
  
 
 
 
 
 
 
 
 
 
 
pET21b-6xHis-SUMO-protein-stop                       E coli BL21 Gold strain 
Transformation 
Centrifugation to get cell pellets, 
resuspension in binding buffer, sonication 
Centrifugation to remove debris, supernatant 
loading to Ni-NTA column, elution using buffer 
containing 500 mM imidazole, Protein exchanged 
to standard buffer,  
 
SUMO cleavage using ULP1  
 
       6xHis-SUMO-------protein-stop 
 
Removal of SUMO-His tag leaving 
unmodified pure protein using SEC 
purification  
E coli culture (Amp + Cm) 
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2.1.1 Bacterial strain: Escherichia coli (E coli) 
E coli strain XL1Blu was used for construction and cloning of libraries, BL21-Gold were used 
for transformation and protein purification protocols. BL21-Gold cells were used as they 
show high degree efficiency in transformation and protein expression. 
E coli strain Genotype 
BL21-Gold  B F- dcm+ Hte ompT hsdS(rB- mB-) gal λ (DE3) endA Tet
r 
XL1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIq 
Z∆M15 Tn10 (Tetr )] 
Table 2.1 E coli strain BL21-Gold and XL1 Blue showing genotype (source: Stratagene). 
 
Antibiotics (Sigma aldrich UK) 
Antibiotics Dilution factor Concentration Composition 
Ampicillin (Amp) 1000 X 100 mg/ml 1 g in 10 ml 70 % EtOH 
Chloramphenicol (Cm) 1000 X 25 mg/ml 250 mg in 10 ml 70 % EtOH 
Kanamycin (Kan) 1000 X 50 mg/ml 500 mg in 10 ml 100 % H2O 
Tetracycline (Tet) 1000 X 25 mg/ml 250 mg in 10 ml 70 % EtOH 
Trimethoprim (Tmp) 1000 X 1.0 mg/ml 10 mg in 10 ml 70 % 
MetOH 
Table 2.2 List of antibiotics and its concentrations. 
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Media and reagents : Protein purification 
Media & reagents Composition 
Luria Bertani (LB) broth pH:7.0 (1 
liter) 
10 g Bacto-tryptone, 5 g NaCl, 5 g Yeast extract. 
2xYT media broth (2xYT) pH7.0 (1 
liter) 
16 g Bacto-tryptone, 5 g NaCl, 10 g Yeast extract. 
2xYT-antibiotics media broth 2xYT media autoclaved, cooled to 250C, then 
added appropriate antibiotics ampicillin (100 
µg/ml) and chloramphenicol (100 µg/ml) 
LB Agar (LA) (1 liter) LB broth + 15 g granulated bacto-agar (0.15 %) 
LA-antibiotics petri plate LB agar, autoclaved, cooled to 550C, then added 
appropriate antibiotics ampicillin (100 µg/ml) 
chloramphenicol (100 µg/ml), kanamycin (50 
µg/ml). 
Transformation buffer I (TBI) pH 
5.8 
30 mM CH3CO2K (2.94 g), 50 mM MnCl2.4H2O (9.9 
g), 100 mM RbCl (12.09 g), 100 mM CaCl2 (1.1 g), 
15 % (w/v) glycerol (pH the solution to 5.8 with 
acetic acid and filter sterilize).  
Transformation buffer II (TBII) pH 
5.8 
10 mM Na MOPS (2.092 g), 75 mM CaCl2 (8.3 g) 
10 mM RbCl (1.209 g), 15 % (w/v) glycerol.  
Electroporation salts (100x) 0.25 M KCl, 1 M MgCl2 
Isopropylthiogalactoside (IPTG) 1 M (2.4 g in 10 ml ddH2O) 
Table 2.3 Media and reagents used for protein purification. 
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2.1.2 Protein expression in bacterial culture 
The vector containing the peptide sequence was transformed into E.coli (BL21-Gold) using 
electroporation. This was then plated onto LB agar plates with the antibiotics Amp and Cm 
at 370C, non-transformed cells were plated alongside as controls. Single colonies were sent 
for sequencing to confirm the correct sequence had been introduced.  
Colonies were picked and cells were inoculated in 5ml LB broth containing 5μl each of Amp 
and Cm. 1 ml of overnight culture was inoculated into 1 litre of 2xYT containing appropriate 
antibiotics. The cells were grown at 370C, 220 rpm, in an Innova-43 incubator shaker, until it 
reached the mid log phase growth (OD600 nm: 0.6). Once the appropriate OD had been 
reached, cells were induced by 1 mM IPTG for 3 hours at 370C.  
The cells were harvested by centrifugation at 40C, 2988xg for 20 mins in a SLC-6000 rotor 
using a Sorvall RC superspeed centrifuge. The cell pellets were resuspended in 30 ml binding 
buffer (Table 2.4). The resuspended cells were homogenised using a magnetic stirrer for 15 
mins. The cell suspension was divided into 3x50 ml falcon tubes and stored on ice for lysis by 
sonication.  The cells in the falcon tubes were sonicated using a Diagenode Bioruptor 
sonicator, keeping in ice cold water at 200 W for 60 cycles. Each cycle consisted of 10 
seconds ‘on’ and ‘off’. The viscous lysate was then centrifuged at 40905xg for 20 mins at 40C 
using a SS-34 rotor (Sorvall RC superspeed centrifuge). The supernatant containing the 
protein was stored at -200C. 
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2.1.3 Nickel-NTA column (Affinity chromatography) purification 
Following cell lysis, the hexa-His tagged protein was purified using 5 mL Ni-NTA column 
(Qiagen). Ni-NTA columns have a capacity to yield up to 50 mg/ml of pure protein without 
altering the protein structure.  
Protein purification buffers 
Buffers Composition 
Binding buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.1 % 
tween 
Wash buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole, 0.1 % 
tween 
Elution buffer pH 8.0 50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole 
Standard buffer (1x) pH 
8.0 
20 mM Tris HCl, 0.5 mM DTT 
MES buffer pH 8.0 10 mM MES, 150 mM NaCl 
Table 2.4 Buffers used for protein purification. 
The column was calibrated using 10 ml of ddH2O, then 10 ml of 0.5 M EDTA (pH 8.0), 
washed by 10 ml of ddH2O, followed by 10 ml of 0.45 M NaOH, then 10 ml of  ddH2O again 
at a flow rate of 5 ml/min to eliminate any residual proteins or nickel from the previous 
purification processes. The white coloured column was then reloaded with 100mM NiSO4 
(approximately 5 ml), washed excess unbound Ni ions using 10 ml of ddH2O and calibrated 
using 10 ml of binding buffer at a reduced flow rate of 3 ml/min. Finally the supernatant of 
sonicated sample was loaded continuously 3 times to ensure the column was bound to its 
full capacity. 
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Using an AKTA prime purification system (GE healthcare), the protein loaded column was 
washed by programming to run in wash buffer (30 mM imidazole) at a flow rate  of 1 ml/min 
until the Abs280nm showed a base line at 0.0 absorbance unit relative to wash buffer. After 
washing for approximately 30 mins, the inlet filters of AKTA were transferred to elution 
buffer (500 mM imidazole) and started the run at 1 ml/min. After around 10 mins, a clear 
peak appeared on the absorbance graph indicating the elution of His-tagged protein which 
was collected in 1 ml fractions for further purification steps. The high imidazole 
concentration can adversely affect the SUMO protease activity in the cleavage reaction later. 
Thus the protein in elution buffer was exchanged to standard buffer using a PD10 desalting 
column (GE healthcare). The PD10 columns were calibrated using 25 ml of standard buffer 
which was allowed to flow through 8.5 ml Sephadex resin under gravity. Next, added 2.5 ml 
of protein sample to the column and discarded the flow through. Finally the protein was 
eluted by adding 3.5 ml of standard buffer. The diluted protein was concentrated using a 
centrifugal filter column (Millipore) having molecular weight cut off 3000 daltons. The 
column was then centrifuged at 1702xg using balanced bench top centrifuge (Eppendorf 
5810 R) until desired volume remained in the column filter. The process repeated with 
newly added buffer to ensure the complete removal of salts before cleavage reaction. 
2.1.4 SUMO-tag cleavage reaction 
The SUMO conjugated protein eluted from Ni-NTA column underwent cleavage reaction to 
remove SUMO-His tag using highly specific SUMO protease (ULP1) enzyme leaving the final 
unmodified protein. 1 mg/ml of purified ULP1 was added at a ratio of 1:4 (enzyme: protein) 
and cleaved at 300C for 16 hours without shaking. 
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Purification of SUMO protease enzyme: The hexa-His tag containing pET21b expression 
vector (Amp resistance) was used for ULP1 expression in E coli BL21 Gold cells and purified 
using Ni-NTA column method as described above. The enzyme was stored in standard buffer 
as aliquots at -800C. 
2.1.5 Cleaved protein purification (G75; Size exclusion chromatography) 
After the cleavage reaction the protein, SUMO-His tag, un-cleaved protein and other non-
specific proteins were separated by size exclusion chromatography (Sephadex 75, GE 
healthcare). The G75 has exclusion limit of 70 kDa.  The column was attached to an AKTA 
prime purification system and washed by programming with three column volumes (120 ml) 
of ddH2O, and calibrated by 120 ml of MES buffer at a flow rate of 0.8 ml/min. After that 2 
ml of protein was injected to the column and eluted by fractionation according to the 
molecular size. Larger proteins eluted first as they bypass the gel pores, while smaller 
proteins enter the gel pores and eluted later in the profile. The elution profile was detected 
as an Abs280nm graph. Samples according to their sizes collected as 1 ml fractions using a 
programmed sample collector. To standardize the G75, a set of protein standards (67 kDa 
BSA, 43 kDa CsoR1, 27.2 kDa cytochrome C prime L16I, 12.5 kDa cytochrome C) of known 
sizes were applied through the column. The molecular weight of protein eluted was 
calculated using linear plot between log value of mass vs. elution volume. Actual mass was 
calculated using the equation below: 
MW= Inverse log (
(Ve-Vo)
[(Vt-Vo)-intercept] / slope
)  
 
 
Where; Ve= elution volume 
              Vo= void volume 
              Vt= total gel bed volume 
(Eq: 1) 
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2.1.6 13C and 15N labelling of α-syn for NMR analysis 
Components for NMR minimal media Amount 
Salt solution (1 litre) 
KH2PO4 13 g 
K2HPO4 10 g 
Na2HPO4 9 g 
Na2SO4 2.4 g 
Trace elements solution (100 ml) 
FeSO4.7H2O 0.6 g 
CaCl2.2H2O 0.6 g 
MnCl2.4H2O 0.12 g 
CoCl2.6H2O 0.08 g 
ZnSO4.7H2O 0.07 g 
CuCl2.2H2O 0.03 g 
H3BO3 0.002 g 
EDTA 0.5 g 
Vitamin mix solution (100 ml) 
Biotin 10 mg 
Choline chloride 10 mg 
Folic acid 10 mg 
Niacinamide 10 mg 
Pantothenate 10 mg 
Pyridoxal 10 mg 
Riboflavin 1 mg 
Table 2.5 List of salts, trace elements and vitamins used for the preparation of NMR minimal media. 
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Minimal media preparation for labelled NMR samples: 1 litre of salt solution prepared in a 
2 litre conical flask and autoclaved. Then added 10 ml of filter sterilised trace elements 
solution along with filter sterilised 10 ml vitamin mix solution. Then added 10 ml of filter 
sterilised 1 M MgCl2 along with 6 ml of freshly prepared 30 mg Thiamine solution in sterile 
ddH2O. Then 5 g of 
13C-glucose and 0.8 g of 15NH4Cl was added to the medium. Finally, 1 ml 
of Amp (100 mg/ml) was added. 
Protein was expressed in E.coli (BL21-Gold) grown in similar minimal media conditions as 
described in the above section. Growth in minimal media is slow, needing approximately 6-7 
hours to reach an OD600 nm of 0.6. Finally the protein was purified by affinity and gel 
chromatography techniques and purity was checked by SDS PAGE. The pure protein was 
sent for NMR analysis in our collaborator’s lab along with the PCA peptides. 
 
 
 
 
 
 
 
 
 
32 
 
2.1.7 Protein characterisation using Sodium dodecyl sulphate poly acrylamide gel 
electrophoresis (SDS PAGE) 
SDS PAGE buffers and reagents 
Gel Components 
15 % Resolving gel (5 ml) 2.50 ml 30 % bis acrylamide,  
1.30 ml 1.5 M Tris (pH 8.8),  
50 µl 10 % SDS,  
50 µl 10 % Ammonium per sulphate (APS), 
3 µl TEMED,  
1.10 ml ddH2O 
5 % Stacking gel (2 ml) 330 µl  30 % bis acrylamide,  
250 µl 1 M Tris (pH 6.8),  
20 µl 10 % SDS,  
20 µl 10 % APS,  
2 µl TEMED,  
1.40 ml ddH2O 
SDS lysis buffer (1x) pH 6.8 50 mM Tris, 100 mM DTT, 2 % SDS 
SDS running buffer (5x) pH 8.3 25 mM Tris, 250 mM glycine, 0.1 % SDS 
SDS staining buffer 1.25 g Coomassie R-250, 225 ml methanol, 
225 ml H2O, 50 ml glacial acetic acid 
SDS destaining buffer (1 liter) 300 ml methanol, 100 ml acetic acid, 600 ml 
H2O 
Table 2.6 List of SDS PAGE buffers and reagents. 
 
33 
 
The SDS PAGE gel was used to determine the purity and expected molecular mass of protein. 
The samples from G75 column were run on a 15 % acrylamide gel along with a pre-stained 
protein ladder with a molecular weight range of 250 kDa to 10 kDa (SpectraTM multicolour 
broad range protein ladder, #SM1841 Fermentas). Before loading to the gel, 10 µl of each 
sample was mixed with lysis buffer and boiled for 5 mins at 950C. Gels were set up using 
glass plates. The resolving gel according to the composition given in the Table 2.6 was made 
and added between the plates and allowed to set for approximately 20 mins. A layer of 
ddH2O was added to get a bubble free top surface.  Once the gel is formed the water was 
removed and added the stacking gel followed by the insertion of a well comb immediately. 
Gels were polymerised by 0.02 % (v/v) TEMED (Fisher) and 0.05 % (v/v) APS (Fisher). 
Proteins were denatured with SDS and resolved at 170 V in 1x running buffer.  
Protein of interest underwent buffer exchanges and the molecular mass was confirmed by 
using electro-spray mass spectroscopy. The protein concentration was determined in a 
spectrophotometer by carrying out an absorbance scan from 200-300 nm or measuring the 
absorbance at 280 nm using 1 cm path length cuvette and calculated by using molar 
extinction coefficient of tyrosine 1209 M-1 cm-1 (Mason et al,  2007). The purified protein 
was transferred to ddH2O and lyophilized in aliquots using a freeze drier (Christ Alpha 2-4 LO 
plus) under vacuum at -800C for approximately 18 hours.  Samples were stored at -800C for 
long term preservation.  
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2.2 Cellular and Molecular biology protocols 
2.2.1 Preparation of XL1 Blue/ BL21 Gold electro-competent cells 
The entire protocol was carried out at 40C and each centrifugation step at 2500g for 10 mins. 
The plasmid containing cells were inoculated in 5 ml LB media with appropriate antibiotics 
and incubated overnight at 370C. The overnight grown culture was added to 500 ml pre-
warmed 2xYT and incubated at 370C, shaken at 5xg until the cells reached OD600: 0.6-0.8. 
The culture was transferred to 10x50 ml falcon tubes, then cooled on ice for 15 mins and 
centrifuged. The pellets were resuspended in pre-cooled ddH2O and centrifuged to remove 
residual media and salts in the cells. Pellets were resuspended in 50 ml of ddH2O and 
transferred to 8 falcon tubes, and again centrifuged. Pellets were resuspended in 25 ml of 
ddH2O and transferred to 4 falcon tubes, and again centrifuged. 25 ml of pre-cooled 10 % 
DMSO was added to the pellets and the resuspension was allowed to stand on ice for 5 mins 
and then centrifuged. Pellets were resuspended in 5 ml of 10 % DMSO, allowed to stand for 
5 mins and again centrifuged. Thereafter, the pellet was resuspended in 1 ml of 10 % DMSO 
solution. To ensure the correct concentration needed for transformation, the OD600 was 
measured for 100 fold dilution of the pellet and was continuously diluted using 10 % DMSO 
until it reached OD600: 0.4. Aliquots of 80 µl were snap frozen in liquid nitrogen and stored 
at -800C 
 
 
 
 
35 
 
2.2.2 Transformation of XL1 Blue/ BL21 Gold electro-competent cells 
80 µl of electro-competent cells was allowed to thaw on ice for 30 mins. 100 ng of plasmid 
or ligated DNA was added to the thawed cells, mixed gently by tapping or pipetting and was 
kept on ice for 10 mins. The mixture was transferred to a pre-cooled electroporation cuvette 
(EQUIBIO) and inserted into a gene pulser. The cell membranes were destabilized for the 
DNA uptake by introducing a large electric pulse of 1.7 kilovolts, 400 Ω and 25 µFD. 
Immediately added 920 µl of pre-warmed, antibiotic free 2xYT media (10 µl electroporation 
salts + 990 µl 2xYT) to the cuvette and transferred to 1.5 ml Eppendorf tube followed by 
incubation at 370C shaken at 209xg for 75 mins. After that, the cells were centrifuged, 
removed supernatant and pellets resuspended in 50 µl of 2xYT. The entire solution was 
plated on pre-warmed LB plates containing appropriate antibiotics and incubated overnight 
at 370C. 
2.2.3 Preservation of bacterial cell stock containing plasmid of interest 
Overnight 5-10 ml cultures were grown in LB or 2xYT broth containing appropriate 
antibiotics at 370C, 5xg by using a bench top shaker (IKA® Incubator Shaker KS 4000) in glass 
universal tubes. The cell cultures then preserved as glycerol stocks for future uses. The 
glycerol stocks were prepared by adding 600 µl of 30 % glycerol to 1.4 ml of cell culture, 
mixed well, snap frozen and stored at -800C. 
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2.2.4 Recombinant DNA protocols 
Buffers and solutions: Molecular biology experiments 
Reagent Composition Source 
Ethanol (EtOH) 100 %, absolute, extra pure Fisher Scientific, UK 
1-Butanol 100 % Fisher Scientific, UK  
Isopropanol  100 % Fisher Scientific, UK 
Ethidium bromide  Sigma Aldrich, UK 
DNA loading buffer (6x) 0.03 % Bromophenol blue, 10 
mM Tris HCl (pH 7.6), 0.03 % 
Xylene Cyanol FF, 60 % 
glycerol, 60 mM EDTA 
Fermentas, UK 
TAE buffer (1x) 40 mM Tris, 20 mM Glacial 
acetic acid, 1 mM EDTA 
 
Fast Alkaline phosphatase  Fermentas, UK 
Fast Digest® enzymes  Fermentas, UK 
GeneRulerTM DNA ladder   Fermentas, UK 
T4 DNA ligase  Fermentas, UK 
GeneJETTM Plasmid miniprep  Fermentas, UK 
QIAquick gel extraction kit 
buffers 
 Qiagen, UK 
Table 2.7 Buffers and solutions used for molecular biology experiments. 
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2.2.5 Plasmid DNA extraction  
Extraction of plasmid DNA from E. coli cultures was carried out using GeneJETTM Plasmid 
Miniprep Kit (Fermentas). Colonies from glycerol stock or single clones were used to 
inoculate 5 ml LB medium containing appropriate antibiotics and incubated at 370C 
overnight. The cell culture was centrifuged at 6810xg for 2 mins. Supernatant removed and 
the pellets were resuspended in 250 µl of resuspension solution (RNAse added). Then added 
250 µl of lysis buffer and mixed the solution by inverting the tube for 4-6 times. After that, 
350 µl of neutralisation buffer added and gently mixed until a white precipitate appeared. 
The solution was centrifuged at 17982xg for 5 mins. The supernatant containing plasmid 
DNA was carefully transferred to the supplied GeneJET spin column placed in 2 ml collection 
tube and centrifuged for 1 min at 13000 rpm. The column was then washed twice with 500 
µl of wash buffer (containing ethanol) and centrifuged for 1 min. The flow through discarded 
and an additional centrifugation of emptied column was performed to remove the residual 
ethanol from the column. The column was then transferred to a new 1.5 ml eppendorf. 50 
µl of elution buffer was added to the centre of the column and allowed it to stand for 2 mins. 
The column was centrifuged at 17982xg for 2 mins, determined the concentration using 
NanoDrop 2000/2000c spectrophotometer (Thermo Scientific) and stored at -200C. 
2.2.6 DNA desalting 
Desalting was undertaken by adding 500 µl of butanol to 50 µl of diluted DNA (10 µl of 
DNA+ 40 µl of ddH2O), mixed well and centrifuged for 30 mins at 20854xg. After that, the 
supernatant was aspirated and the pellet was air dried at 300C for 30 mins. Finally the pellet 
was resuspended in 10 µl of sterile ddH2O and the concentration was determined by using 
NanoDrop.  
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2.2.7 Restriction digestion of the plasmid DNA 
Approximately 0.5 µg of plasmid DNA was used in a digestion reaction carried out for 1 hour 
at 370C.  Following the FastDigest® (Fermentas) protocol, the digestion mixture was 
prepared as shown in Table 2.8. 
Restriction digestion 
Component  Volume/concentration   
Plasmid DNA ̴0.5 µg 
Restriction enzyme 1 2 µl 
Restriction enzyme 2 2 µl 
10x FastDigest® buffer 5 µl 
ddH2O X µl 
Total 50 µl 
Table 2.8 Components used for restriction digestion reactions. 
2.2.8 Dephosphorylation of the plasmid DNA 
Dephosphorylation of the vector is a prerequisite to reduce vector background and also it 
minimize re-ligation and circularisation of linearized plasmids. The reaction mixture was 
prepared as shown in Table 2.9.  
Dephosphorylation 
Component  Volume  
Digestion mixture 50 µl 
10x buffer 6 µl 
Alkaline phosphatase (Fermentas) 2 µl 
ddH2O 2 µl 
Total 60 µl 
Table 2.9 Components used for dephosphorylation reactions. 
39 
 
The reaction was carried out at 370C for 15 mins. The mix was then incubated at 750C for 5 
mins to deactivate the alkaline phosphatase enzyme. 
2.2.9 Agarose gel electrophoresis 
Following restriction digestion, the plasmid DNA sizes were determined by using agarose gel 
electrophoresis. 50 µl of digested DNA was mixed with 10 µl of 6x DNA loading buffer and 
loaded in to 1 % agarose gel along with GeneRulerTM 6x DNA ladder (Fermentas). The gel 
was made by boiling standard agarose in 1x TAE buffer until the agarose dissolved 
completely. The solution was allowed to cool for 5 mins and added 0.5 µg/ml EtBr. The 
loaded gel was run at 80 V until the dye front reached 3/4th of the gel. Later the gel was 
examined under UV illumination at wavelength 365 nm. 
2.2.10 Purification of DNA from Agarose gel using QIAquick gel extraction kit (Qiagen) 
The plasmid of interest identified using a UV transilluminator was excised from the Agarose 
gel using a clean sharp scalpel and placed in individual eppendorf tubes. The gel slices were 
weighed. Three times the volume of Buffer QG was added to 1 volume of the gel slice and 
incubated at 500C allowing the gel slice to melt completely. An equal volume of isopropanol 
was added to the solution and inverted to mix thoroughly. The mixture was transferred to a 
QIAquick spin column and centrifuged at 17982xg for 1 min. The flow-through was 
discarded, then added 0.5 ml of Buffer QG to the column and again centrifuged. The column 
was washed by centrifuging with 0.75 ml of Buffer PE. Finally DNA was eluted into a sterile 
eppendorf tube by centrifuging with 30 µl of elution buffer (10 mM Tris-HCl, pH 8.5). The 
concentration of DNA was determined by NanoDrop and stored at -200C.  
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2.2.11 Polymerase chain reaction (PCR) 
The amplification of the DNA inserts of interest was carried out by using overlap extension 
PCR for various cloning protocols. The reaction was undergone in a TC-412 Thermal cycler 
(TECHNE). The preparation of PCR mixture and the reaction cycles was done as shown in 
Table 2.10.  
PCR mixture 
Component Volume 
Test Control 
Forward primer (100 µM) 0.5 µl 0.5 µl 
Reverse primer (100 µM) 0.5 µl 0.5 µl 
dNTPs (10 mM) (Fermentas, UK) 1 µl 1 µl 
10x Pfu buffer with MgSO4 (Fermentas, UK) 5 µl 5 µl 
10x Pfu DNA polymerase  (Fermentas, UK) 0.5 µl - 
ddH2O 42.5 µl 43.0 µl 
Total 50 µl 50 µl 
PCR cycles 
Steps Conditions 
Initial denaturation 950C, 3 mins 
Denaturation 950C, 45 seconds 
Annealing          30 cycles 2-50C below Tm of the primers, 1min/kb 
Extension 720C, 45 seconds 
Final extension 720C, 10 mins 
Table 2.10 Components used for PCR reactions and PCR cycles. 
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2.2.12 Designing a peptide library: α-syn45-54 scaffold 
The library was designed by incorporating the wild-type sequence while introducing two, 
three or six residue options at each of the ten amino acid positions at 45-54 region (shown 
in results: chapter 5). This corresponded to a library size of 209,952 members. 
Code letters used to design primers for amino acid randomisation in α-syn45-54 region 
Code Encoded bases 
A A 
B CGT 
C C 
G G 
H ACT 
R AG 
T T 
V ACG 
W AT 
  Primers used to include degenerate  codons for residue options 
Primers Sequence 
Forward (Invitrogen) 5’- C TGG GCT AGC RAA VAW GBG VTT VTT VAW GBG 
VTT RHA RCC GGC GCG CCG CTA GAG GCG -3’ 
Reverse (Invitrogen) 5’- T TTT TTT TTA TAA TAT ATT ATA CGC CTC TAG CGG 
CGC GCC -3’ 
Table 2.11 List of code letters encoding amino acids during randomisation and primers used to 
include degenerate codons for residue options. 
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2.2.13 Ligation 
The vectors and the inserts used for various studies were gel purified for ligation. The 
fragments were mixed at a molar ratio of 1:3 (vector: insert). The digested, 
dephosphorylated, purified plasmid DNA vector was added to the required amount of insert 
in a sterile 0.5 ml eppendorf tube. Digested plasmid alone without insert was plated as 
negative controls to ensure the success of ligation. Ligation mixture was prepared as shown 
in Table 2.12 and incubated at 180C overnight. The following equation was used to calculate 
the volume of insert required for ligation reaction. 
Insert (ng)=
[Vector(ng) x Insert size(kb)]
Vector size (kb)
x 3 
Ligation 
Component  Volume/concentration   
10x ligase buffer (Fermentas) 1 µl 
T4 DNA ligase (Fermentas) 1 µl 
Plasmid vector ̴250 ng 
DNA insert 20 ng 
ddH2O X µl 
Total 10 µl 
Table 2.12 Components used for ligation reactions. 
2.2.14 DNA sequencing 
The constructs for correct sequence insert was checked by GATC-Biotech (Germany) initially 
and Source Bioscience (UK) later. 30 µl of samples containing concentration more than 50-
100 ng/µl were sent for sequencing. Samples were analysed using an ABI sequencer and 
chromatograms 
(Eq: 2) 
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2.3 Protein fragment complementation assay (PCA) 
Plasmids: PCA 
Plasmid Description  Source 
pES300d-α-syn1-140-DHFR2 Cloning vector containing 
target α-syn1-140 gene 
with restriction sites 
NheI, AscI 
Derived from pQE16 (Qiagen, 
UK) 
pES230d-Lib-α-syn45-54-
DHFR1 
Cloning vector containing 
α-syn45-54 library gene 
with restriction sites 
NheI, AscI 
Derived from pQE16 (Qiagen, 
UK) 
pREP4 For the expression of lac 
repressor protein 
Qiagen, UK 
Table 2.13 Plasmids used for PCA. 
 
Media and reagents: PCA protocol 
Medium & Reagents Composition 
M9 minimal media (M9) (1 litre) 200 ml 1x M9 salts, 2 ml MgSO4.7H2O (1 M), 100 
µl CaCl2 (1 M), 20 ml glucose (20 %), made up to 1 
litre with ddH2O. 
M9 Salts : 5x (1 litre) 200 mM Na2HPO4, 100 mM KH2PO4, 100 mM 
NH4Cl, 50 mM NaCl 
M9 Agar (M9A) (1 litre) M9 medium + 15 g Bacto agar (0.15 %) 
M9A-antibiotics petri plate M9 agar, autoclaved, cooled to 550C, then added 
appropriate antibiotics Amp (100 µg/ml) Cm (100 
µg/ml), Kan (50 µg/ml), IPTG (250 µg/ml) and 
Tmp (1 µg/ml). 
Table 2.14 Media and reagents used for PCA. 
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2.3.1 Single step selection 
Once the library was generated, PCA was performed between the target protein and the 
pooled library members. The target plasmid pES300d-α-syn1-140 (Cm
R) encoding mDHFR2 
and pREP4 (Qiagen; for the expression of lac repressor protein, KanR) were co-transformed 
(electroporated) into electrocompetent BL21 gold cells and plated on to LB agar plates with 
the appropriate antibiotics (Kan 50 μg/ml and Cm 25 μg/ml). The transformed BL21 gold 
cells were made electrocompetent using 10 % DMSO, so that the library plasmids (pES230d-
Lib encoding DHFR1, AmpR) could then be transformed into electrocompetent BL21 gold 
cells. The transformants were plated on three different conditions: 
(a) Positive control: LB media agar plate with three antibiotics (Kan 50 μg/ml, Amp 100 
μg/ml, and Cm 25 μg/ml) to demonstrate successful transformation of library plasmid. The 
colonies were grown in one overnight as LB provides sufficient nutrients. 
(b) Negative control: M9 minimal media agar plate with the three appropriate antibiotics as 
above mentioned along with Tmp 1 μg/ml excluding IPTG upon which no growth was 
expected. The plates were incubated for 5-10 days along with the large PCA plate as the 
nutrients in the M9 media is minimal. 
(c) PCA plate: A large M9 minimal media agar plate containing Amp, Cm, Kan, Tmp and 1 
mM IPTG (to induce expression of the two DHFR fragment fused protein).The plates were 
Incubated for 5 to 10 days depending on the affinity of interaction between the target and 
the library members. 
 
 
45 
 
2.3.2 Competitive selection 
Growth competition experiments were performed to increase the selection stringency of 
peptides. Colonies that grew from the single step selection M9 plate were pooled and 
grown in 50 ml of M9 minimal media containing 1 μg/ml Tmp, 1 mM IPTG, 50 μg/ml Kan, 
100 μg/ml Amp and 25 μg/ml Cm. Cells were incubated at 370C with continuously shaking at 
5xg for approximately 3-4 days until it reaches OD600:0.4. When the cell density reached 
OD600: 0.4, 50 µl was used to inoculate a freshly made 50 ml M9 medium and allowed to 
grown. The process of serial dilution was carried out over many passages (P1, P2, P3 and so 
on). At each passage 30 % glycerol stocks (stored at -800C) were prepared and sequencing 
results were obtained for DNA pools as well as individual colonies. The sequencing results 
showed many background peaks as there were several peptides competing in the early pool 
passages. Finally a clear, dominant peak with a fewer background noise was obtained and 
considered it as the strongest affinity binding candidate from the library. 
 
 
 
 
 
 
 
 
46 
 
2.4 Peptide synthesis 
Among the PCA peptides, only peptide 45-54W was synthesized in the lab as other PCA 
peptides were commercially bought from Peptide Synthetics, UK. The peptide 45-54W was 
synthesized using a Liberty BlueTM microwave peptide synthesizer (CEM; Matthews, NC).  
Fmoc-l-aminoacids / Reagents Composition Source 
Alanine 0.16 g in 2.63 ml DMF AGTC Bioproducts (UK) 
Aspargine 0.63 g in 5.25 ml DMF ,, 
Aspartate 0.43 g in 5.25 ml DMF ,, 
Glycine 0.47 g in 7.88 ml DMF ,, 
Isoleucine 0.37 g in 5.25 ml DMF ,, 
Lysine 0.98 g in 10.5 ml DMF ,, 
Valine 0.71 g in 10.5 ml DMF ,, 
Rink amide ChemMatrixTM 
resin 
 PCAS Biomatrix, Inc.  
(Canada) 
Acetylation solution 20 % Acetic anhydride in 
DMF 
Thermo Fisher Scientific 
(UK). 
Dimethylformamide (DMF)   ,, 
Activator solution: 1H-
Benzotriazol-1-
yloxy)(dimethylamino)-N,N-
dimethylmethaniminium 
hexafluorophosphate (HBTU)  
HBTU in DMF AGTC Bioproducts (UK) 
De-protection solution 20 % Piperidine in DMF Thermo Fisher Scientific 
(UK). 
Cleavage solution (10 ml) 95 % Trifluoroacetic acid, 
2.5 % Triisopropylsilane, 
2.5 % ddH2O 
’’ 
Acetonitrile (MeCN) 0.1 % TFA in MeCN used in 
HPLC 
Fisher Scientific (UK) 
Table 2.15 Amino acids and reagents used for 45-54W peptide synthesis. 
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Peptides were synthesized on a 0.1 mmol scale on a PCAS BiomatrixTM Rink amide resin 
employing Fmoc solid-phase techniques in which the cleavage reactions are less harsh and 
the use of different protecting group reduces the side chain reactions during cleavage. 
Coupling reaction was performed with Fmoc amino acid (5 eq), HBTU (4.5 eq) and 
diisopropylethylamine (10 eq) in 5 ml of DMF for 5 mins with 20 watt microwave irradiation 
at 900C.  De-protection was carried out by adding 20 % piperidine in DMF for 5 mins with 20 
watt microwave irradiation at 80°C. Coupling, de-protection and washing with 5 ml of DMF 
was repeated four times in between each step. Following synthesis, the peptide was 
acetylated using 2.63 ml of acetylation solution for 20 min) and then cleaved from the resin 
with simultaneous removal of side chain-protecting groups by treatment with 10 ml of 
cleavage solution for 4 hours at room temperature. Triisopropylsilane along with TFA in the 
cleavage solution acts as scavenger to chemically trap highly reactive species formed during 
cleavage reaction and thereby preventing the peptide from un-desired side chain reactions. 
Suspended resin was removed by filtration. The peptide was precipitated using three rounds 
of crashing in ice-cold diethyl ether, vortexing and centrifugation. The pellet was then 
dissolved in 50 % Acetonitrile in ddH2O and freeze-dried. Finally the purification was 
performed by RP-HPLC using a Phenomenex Jupiter Proteo (C12) reverse phase column (4 
μm, 90 Å, 10 mm inner diameter × 250 mm long). The eluents used were solution A (0.1 % 
TFA in H2O) and solution B (0.1 % TFA in MeCN). The peptide was eluted by applying a linear 
gradient (at 3 ml/min) of 20 to 60 % B over 40 min. Fractions collected were examined by 
electrospray mass spectrometry, and the desired product were pooled, lyophilized and 
stored at -800C for future use.  
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2.5 Characterisation of proteins and peptides; Amyloid fibril study 
Biophysical experiments: buffers and reagents 
Buffers and reagents Composition 
Potassium phosphate (KPP) buffer (1 
litre) 
100 mM, pH 7.0 (38.5 ml 1 M KH2PO4, 61.5 ml 1 
M K2HPO4 , 900 ml ddH2O) 
Phosphate buffer 10 mM with salt, pH 
7.0 used for aggregation studies 
100 ml KPP, 100 ml 1 M Potassium fluoride (KF), 
0.05% NaN3, 800 ml ddH2O 
Hexafluoro-2-propanol (HFIP) 100 % (Sigma aldrich, UK) 
Tris (hydroxymethyl)-aminomethane 
(Tris) 
10 mM (0.601 g in 500 ml ddH2O) 
Thioflavin T (ThT)  500 µM (31.9 mg in 200 ml of 10 mM Tris),      
pH 7.5 
Table 2.16 Buffers and reagents used for amyloid fibril studies. 
PCA peptides  
Name Target Scaffold used for design Sequence 
WTA wild type α-syn1-140 71VTGVTAVAQKTV82 Ac-VTGVTANPQRTV-NH2 
WTB wild type α-syn1-140 ,, Ac-VTGVTADVQETV-NH2 
WTC wild type α-syn1-140 ,, Ac-VTGVTAPDKGTV-NH2 
A30P W α-synA30P1-140 ,, Ac-VTGVTAHPQNTV-NH2 
E46K W α-synE46K1-140 ,, Ac-VTGVTANQNNTV-NH2 
H50Q 
W 
α-synH50Q1-140 ,, Ac-VTGVTANSSDTV-NH2 
A53T W α-synA53T1-140 ,, Ac-VTGVTADNKETV-NH2 
45-54W wild type α-syn1-140 45KEGVVHGVAT54 Ac-KDGIVNGVKA-NH2 
Table 2.17 Winner peptide sequences against each target derived from PCA. 
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2.5.1 Monomerisation of Protein before aggregation studies 
Prior to use, the proteins were monomerised using HFIP (Madine et al., 2008) to ensure that 
the amyloid growth was initiated from the same monomeric state free from pre-formed 
aggregated species. Proteins were undergone three rounds of dissolution with HFIP (1 ml to 
2 mg of protein), vortexing (2 mins), sonication (2 mins at 250C in water bath sonicator), and 
evaporating completely under a regulated stream of air. Finally the solid sample was 
dissolved in ddH2O, concentration was calculated and the samples were aliquoted to 
appropriate concentrations needed for further experiments and lyophilised using a freeze 
drier.   
2.5.2 Thioflavin T (ThT) assay  
ThT inhibition assays were performed with monomerised α-syn or mutants at a 
concentration of 450 µM; in the presence or absence of peptides, resuspended and 
incubated with 10 mM Phosphate buffer pH 7.0, at 370C for 10 days shaking at 300 rpm.  
The PCA peptides were resuspended in 10 mM Phosphate buffer, added in (target v/s 
peptide) molar ratio of 1:0.1 (45 µM), 1:1 (450 µM), 1:2 (900 µM), 1:5 (2250 µM) and 1:10 
(4500 µM). An additional sub-stoichiometric ratio of 1:0.01 was also considered in the case 
of 45-54W peptide (Chapter 5). All the peptide solutions were thoroughly vortexed to 
ensure complete dissolution. The peptides were aliquoted in Eppendorf tubes as per the 
desired concentrations and lyophilized using a freeze drier. Finally 500 µl of reaction mixture 
containing 450 µM target protein added to each Eppendorf tube containing various molar 
ratios of peptide. The final mixture was vortexed and incubated at 370C for 10 days. The 
working stock ThT solution was prepared from a stock of 500 µM. The stock was aliquoted 
into 1 ml tubes, covered with aluminium foil and kept frozen until it was needed. The stock 
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was thawed at room temperature for 10 mins and diluted 25x using 10 mM Tris pH 7.5. A 
total of 197 µl of ThT solution and 3 µl of each inhibition/ reversal assay sample were mixed 
thoroughly with pipette and transferred to appropriate well in the 96 well microtitre plate. 
All the samples were analysed in triplicates (technical replicates) as a part of single 
experiment. The fluorescence was then measured using Perkin Elmer Luminescence 
Spectrometer LS55 (FLWin program) set at 450 nm (excitation) and 482 nm (emission). For 
inhibition assays, fluorescence was measured at the day of reaction set up, then for five 
consecutive days and the final reading at day 10. For the reversal assays, peptides were 
added at 10th day to the matured target and incubated together for further 3 days. 
2.5.2.1 Continuous growth ThT experiments 
The peptide 45-54W (Chapter 5) was characterised by continuous growth ThT experiments. 
Prior to the experiment, the ThT concentration was optimised as 90 µM which was found to 
be required for saturating amyloid fibrils formed by 450 µM protein. It was analysed by 
plotting a graph between ThT fluorescence intensity (mAu) of 450 µM target protein mixed 
with ThT at seven different concentrations (0, 1, 10, 50, 100, 250, and 500 µM). The ThT 
signal reached the saturation point at a concentration of approximately 90 µM and was 
considered as optimum for continuous growth experiments. The 45-54W peptide was 
lyophilized in the molar concentration ratio as 1:1 with target protein. The reaction mixture 
containing 450 µM wild type α-syn and peptide was incubated in 90 µM ThT, 10 mM 
Phosphate buffer (pH:7.0), 100 mM KF and 0.05 % NaN3 at 370C with continuously mixing at 
10xg using a magnetic flea in a Perkin Elmer Luminescence Spectrometer LS55 for 4500 mins. 
The same experiment was repeated three times for both peptide free sample (1:0) and for 
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45-54W (1:1 stoichiometry) containing solutions. The peptide 45-54W was lyophilized in 
aliquots of various stoichiometries ranging from 1:0.01, to 1:1. 
2.5.3 Circular Dichroism (CD) assay 
CD analysis was used to investigate the secondary structure formation of proteins 
with/without PCA peptides. CD measures the differences in absorption of Left-hand circular 
(LHC) and Right-hand circular (RHC) polarized light. The polarisation transitions is typically 
observed at a wavelength between 195-200 nm for random coil, 218 nm for β-sheet and 
between 209-222 nm for α-helix appear as minimum (negative ellipticity) in the CD spectra. 
The CD experiments were undertaken using aliquots taken from the same samples from 
which aliquots were taken for ThT experiments. The final protein concentration used for CD 
scan was 10 µM in Phosphate buffer (pH 7.0). Scans were taken using Applied Photophysics 
Chirascan CD Spectrometer (UK) in the far UV scanning from wavelength of 190 nm to 300 
nm, with a step size of 1 nm, bandwidth of 4 nm, at 200C, using 0.1 cm cuvette (Helma). 
Spectra were recorded as the average of three scans.  
CD spectra were analysed using Gaussian distribution approach using the below formula; 
G = I ∗ e
(−0.5∗(
X−µ
σ
)
2
)
 
 
 
 
Separate distributions were fitted for the two minima at 200 nm (random coil) and 218 nm 
(β-sheet). Both were then added to get the best fit for the CD scan. Then squared the 
difference between sum fit value and scan value. Sum of the squared difference was 
Where; I = peak intensity,  
              X= X value (wavelength in nm),  
              µ=mean peak, 
              σ= Standard deviation 
 
(Eq: 3) 
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minimised using Solver tool in Microsoft excel thereby corrected the base line transition in 
each scan.  
2.5.4 Atomic force microscopy (AFM) 
Samples were imaged in noncontact mode using a XE- 120 Atomic Force Microscope (Park 
Systems, South Korea). NSC 15 silicon nitride cantilevers with a spring constant of 40 N/m 
were used for imaging at a scan rate of 1.0 Hz and a resolution of 256 x 256 pixels. All 
images were taken at room temperature. 5 μl of samples were taken from each reaction 
conditions and placed on freshly cleaved mica (thickness 0.3 mm). Following adsorption of 
the protein aggregates (2 min), the mica was washed with 5 ml of ddH2O. Excess water was 
removed and the samples were dried using a stream of nitrogen gas. Samples were 
immediately analysed by AFM. The image files were flattened before processing (Kad et al., 
2001 & 2003) and examined for average volume by keeping a threshold value to omit the 
base level noises using WSxM v5.0 (Nanotec Electronica S.L.). 
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2.5.5 Cell viability assay 
Cell viability (MTT) assay: buffers and reagents 
Buffers and reagents Source/Composition 
20 % Dimethylsulphoxide (DMSO) Sigma aldrich, UK 
RPMI 1640 + 2 mM Glutamine Invitrogen 
10 % Horse serum (HS) Invitrogen 
5 % Foetal bovine serum (FBS) Invitrogen 
Gentamicin (20 mg/ml) Invitrogen 
MTT buffer Invitrogen 
10x Phosphate buffer saline (PBS) 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4. 
Adjust to pH 7.4 with HCl, made up to 1 liter with 
ddH2O and autoclave. 
Table 2.18 Buffers and reagents used for MTT assay. 
2.5.5.1 Rat phaeochromocytoma (PC12) cells  
The PC12 cells were maintained in 4x106 density, 370C, 5 % CO2 grown in medium containing 
RPMI 1640 + 2 mM Glutamine, supplemented with 10 % HS, 5 % FBS and 20 mg/ml 
gentamicin (all from Invitrogen). The cells were stored as 1 ml stock (20 % DMSO in FBS) in 
cryogenic tubes, in liquid nitrogen for long term. Whenever needed, the cells were taken 
out, immediately thawed using water bath at 370C, resuspended in 10 ml of pre-warmed 
sterile RPMI medium as mentioned above, followed by centrifugation for 5 mins at 2000 
rpm. The supernatant was discarded and the cell pellets were resuspended in new 15 ml of 
medium. Finally the cells were transferred into a culture flask and incubated at 370C, 5 % 
CO2 until it reached appropriate cell density.  
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2.5.5.2 MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay 
MTT assays were carried out using rat phaeochromocytoma (PC12) cells to access the 
cellular toxicity of aggregated species formed by the α-syn with/without PCA peptides. The 
assay is based on the reduction reaction occurring in active live cells in turning yellow 
coloured MTT into insoluble purple coloured formazan. The assay is based on the amount of 
formazan which was monitored as absorbance at 570 nm correlates with the number of 
viable cells. MTT Vybrant® Cell Proliferation Kit (Invitrogen) was used for the assay. The 
assays were performed with 5 µM target protein without/with peptides at various molar 
ratios between targets: peptide (1:0.1, 1:1, 1:2, 1:5 and 1: 10) incubated for 10 days under 
sterile conditions. PC12 cells were transferred into a sterile 96 well microtitre plate with 
3x104 cells per well.  All the experiments were done in triplicates (technical replicates) as a 
part of single experiment. A required volume of target-peptide reaction mixture was added 
to appropriate wells containing PC12. A total of 100 µl was made up using RPMI media in 
each well. The plates were then incubated for 24 hours at 370C and 5 % CO2. After 24 hours, 
10 µl of MTT dye was added to each well and incubated for further 4 hours at 370C and 5 % 
CO2. A total of 100 µl DMSO was added to each well and incubated for another 10 mins. The 
absorbance was measured at 570 nm using a Bethold Tristar LB942 plate reader. 
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Chapter 3: A Protein-fragment Complementation approach using an α-syn71-82 
template to derive peptide antagonists of α-syn aggregation 
3.1 Introduction 
In PD, α-syn aggregates are found to deposit as inclusion proteins in the neuronal tissue, 
eventually leading to neuronal death (Lesage et al., 2009). Although fibrillar α-syn is a major 
component of LBs, recent findings show pre-fibrillar, oligomeric intermediates as the toxic 
species (Winner et al., 2011, Emadi et al., 2009, Outeiro et al., 2008). α-syn belongs to a 
family of ‘synucleins’ along with β-synuclein and ϒ-synuclein expressed primarily in neural 
tissues (George, 2001). α-syn is expressed in different brain regions and is found to interact 
with a variety of cellular membranes which is considered critical for at least some of its 
normal functions. One of its function is found to be as a key factor in determining the 
complex-I activity of the mitochondrial respiratory chain (Liua et al., 2009). Although 
knowledge about the normal function of α-syn is limited, its association with pre-synaptic 
vesicles and plasma membranes has been well studied (Snead, and Eliezer, 2014). The 
protein usually dissociates from the vesicles and re-associates slowly during synaptic activity 
when there is an electrical stimulation inside the dopaminergic neurons (Fortin et al., 2005). 
Whereas misfolded α-syn is unable to incorporate in the storage of dopamine at pre-
synaptic terminal leading to the mis-regulation of dopamine pathway and causes the onset 
of PD symptoms. 
α-syn plays a prominent role in the pathogenesis of several neurodegenerative disorders. 
The 35 residue long central hydrophobic region known as NAC (Non amyloid component) 
and its precursor (NACP) were found to show high propensity of β-sheet secondary 
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structure (Ueda et al., 1993; Bodles et al., 2001). The lack of these amino acid residues 
within the hydrophobic region of β-synuclein makes it unable to aggregate even though its 
structure is homologous to α-syn (Uversky et al., 2002; Hashimoto et al., 2001). In the NAC 
region, α-syn71-82 reflects an extensive and irreversible self-aggregation property and the 
majority of the amino acids are involved in the formation of a parallel β-sheet conformation. 
The deletion of 71-82 in the NAC region of human α-syn was found to prevent protein 
aggregation. The importance of α-syn71-82 for fibril formation was realised when many 
studies observed a prolonged lag phase for β-synuclein to polymerize into fibrils (Bodles et 
al., 2001; Giasson et al., 2001, Bedard et al., 2014). To further narrow down the importance 
of amino acids within this region, shorter deletion mutants (Δ74-82, Δ74-79, Δ76-77) shows 
a propensity to form spherical oligomers and are unable to assemble into mature fibrils 
(Waxman et al., 2010). A decrease in the aggregation rate was studied after the substitution 
of Alanine76 either with positive Arginine or negative Glutamic acid residue (Giasson et al., 
2001), and also found to contribute to the structural and assembly behaviour of full length 
α-syn fibrillisation. The significance of a four residue ‘signature motif’, Gly-Ala-XX, (where X 
is an amino acid with an aliphatic side chain) was found to be crucial for the aggregation of 
amyloidogenic proteins such as β-amyloid, prion protein, islet amyloid polypeptides and α-
syn (El Agnaf et al., 1998; Uversky et al., 2002; Bodles et al., 2004; Du et al., 2003). The role 
of this ‘signature motif’ in α-syn is significant as, the deletion or incorporation of charged 
residues to 68GAV70 prevents β-sheet formation. The lengthy lag phase in fibrillisation of ϒ-
synuclein which lacks this signature motif also suggests its importance in the aggregation 
process. Thus 68GAV70 along with 71VTGV74 sequence plays an important role in regulating 
fibrillisation (Du et al., 2003). An important therapeutic strategy for preventing amyloid 
deposition is to identify the agents that can interrupt the fibrillisation process thereby 
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inhibiting the propagation of fibril growth or accelerating aggregation to non-toxic insoluble 
deposits or stabilizing the native structure of α-syn (Gilead et al., 2004; Hard et al., 2012). 
One approach is to synthesize modified short peptides that can bind to the parent protein 
and prevent its further aggregation. Such modifications include amino acid substitutions, 
side chain modifications, insertion of Proline or use of D-amino acids into or adjacent to 
fibrillogenic domains, peptide terminal end modifications, addition of N- and C- terminal 
blocking groups, peptide cyclization and replacement of amide bonds with ester linkages 
(Sciarretta et al., 2006; Madine et al., 2008). Many groups have considered adding a N-
methyl group while designing peptide inhibitors. The concept is; N-methyl group reduces 
hydrogen bond propensity due to replacement of the amide hydrogen and it leads to the 
disruption of hydrogen bond network which is essentially required for the formation of a 
stable β-sheet fibril. A peptide inhibitor based on α-syn68-78, N-methylated at Gly73 has been 
developed with encouraging results (Bodles et al., 2004). Madine and colleagues developed 
a several N-methylated peptides based on α-syn71-82 (mVTGVTA, VTGmVTA, VmAQKTV, 
VAQKTmV and VmAQKTmV). They undertook solid state NMR analysis and identified a 
peptide VAQKTmV as an effective candidate in preventing the aggregation of full length α-
syn to form large insoluble fibrils (Madine et al., 2008). El-Agnaf and co-workers designed 
another peptide inhibitor (RGAVVTGR) based on α-syn68-72 by incorporating one or two 
hydrophilic residues (R and G) at the N- and/or the C-terminus of 68GAVVT72 peptide (El 
Agnaf et al., 2004).  
This chapter focuses on characterising new antagonists of α-syn aggregation developed by 
screening peptide libraries in vivo using a protein-fragment complementation assay (PCA) 
methodology. PCAs have shown promise as a method to screen for specific therapeutic 
58 
 
peptides of numerous protein-protein interactions (PPIs), including amyloid-based systems 
(Acerra et al., 2014; Mason et al., 2006; Remy et al., 2007; Pelletier et al., 1999).  In PCA two 
proteins of interest are fused to incomplete complementary fragments of a third essential 
protein (‘reporter’). The specific protein-protein interaction is dependent on not just 
proximity but also the peptides must organize precisely in space to allow further folding into 
the native structure thereby reconstituting its activity. The ‘reporter’ activity is detectable 
by the survival of cells expressing the fusion proteins and growth in selective minimal 
medium. Here murine dihydrofolate reductase (mDHFR) is the enzyme used as ‘reporter’ in 
which α-syn1-140 is fused to one half and peptide library fused to the other half. The 
activation of mDHFR is essential for the growth of E coli cells on minimal M9 medium in 
which the bacterial mDHFR has been selectively blocked using trimethoprim. Therefore if a 
binder from the peptide library interacts with α-syn, it will bring the two halves of mDHFR 
into close proximity and recombine the enzyme to constitute cell growth under selective 
conditions. The E coli DHFR is selectively inhibited by the antifolate trimethoprim which has 
12000 fold more sensitivity than mDHFR (Pelletier et al., 1998). The colony growth under 
selective pressure of trimethoprim along with IPTG is highly restricted only for the cells 
expressing both mDHFR fragments. PCA has advantageous attributes as it is carried out in 
vivo, meaning that aggregation prone, insoluble, protease sensitive, unstable, and weak 
binders will be removed at the screening level itself. No assumptions were made during PCA 
regarding the mechanism of action or the oligomeric state of α-syn that becomes populated. 
The only pre-requisite for peptide selection was the peptides bind to α-syn such that split 
reporter enzyme is recombined and expressed. Thus the library members binding to α-syn 
thought to reduce its toxicity and confer cell survival (Acerra et al., 2013).  The strategy to 
design peptide inhibitors was based on α-syn71-82 scaffold which should interact specifically 
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with full length α-syn, interrupt its aggregation or breaking down preformed fibrils to less 
toxic oligomers. These studies have provided some successful peptide candidates harbour 
the potential to be further developed into drugs in the future. 
3.2 Experimental approach 
This chapter describes the purification process of wild type α-syn and characterization of 
antagonistic peptides generated using semi rational peptide design, combined with PCA.  
(1) Purification of α-syn: small ubiquitin related modifier (SUMO) fusion technology was 
used for enhanced functional α-syn expression in E coli cells (Lee et al., 2008; Marblestone 
et al., 2006; Butt et al., 2005; Malakhov et al., 2004; Mossessova et al., 2000). SUMO is 
found to be more effective and productive over other fusion tags in enhancing expression 
and solubility of recombinant protein. The direct fusion of the target protein to SUMO 
produces a generation of recombinant protein with native N-terminal sequences. SUMO tag 
has the ability to associate with SUMO protease enzyme (ULP1) which has the advantage of 
recognizing the tertiary structure of SUMO (Marblestone et al., 2006). Thus SUMO fusion 
system was found to be ideal for soluble expression of proteins compared to other 
traditional gene fusion systems. Efficient removal of SUMO tag by ULP1 in vitro facilitated 
the production of pure α-syn. The purified protein was monomerised using hexafluoro-2-
propanol (HFIP) treatment (Madine et al., 2008- See chapter 2) before using it for any 
aggregation studies. 
(2) Peptide characterisation: The effect of peptides designed using α-syn71-82 scaffold 
against full length α-syn were studied using Thioflavin T (ThT) dye binding experiments 
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(Wolfe et al., 2010; Khurana et al., 2005) and circular dichroism (CD) for the quantification 
of secondary β-sheet structures. Atomic force microscopy (AFM) was used for direct imaging 
to confirm the ThT and CD data (Kad et al., 2001 & 2003). The peptides were analysed for 
their inhibitory as well as the reversal effects on α-syn aggregation. In this chapter, 450 µM 
of α-syn (Madine et al., 2008) was incubated with 450 µM of each peptide in 500 µL of 
potassium phosphate buffer (10 mM, pH 7.0), KF (100 mM) and NaN3 (0.05 %) buffer at 37
0C 
with continuous shaking in an orbital incubator at 10xg for 10 days in inhibition assay and 
three more days (post-mix) in reversal assay. Finally, the effect of peptides on the viability of 
PC12 cells (by reducing α-syn toxicity) was investigated using the MTT cell toxicity assay. 
MTT assay was performed at 5 µM α-syn with five different molar concentration ratios of 
peptide (1: 0.1, 1, 2, 5, and 10). Control experiments by incubating peptides alone without 
α-syn were undertaken to verify the reliability of the peptides. In addition a negative 
(SGSSGTSSGTSG) and a positive [VAQKTmV (Madine et al., 2008)] control at molar ratio 1:1 
were also analysed along with peptide winners. The peptide; SGSSGTSSGTSG is the GS linker 
and is therefore a useful good control peptide in investigating the specificity of PCA derived 
peptides towards α-syn. 
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3.3 Results 
3.3.1 Purification of α-syn from bacterial culture 
The wild type α-syn was synthesized by over expression in E.coli (BL21 strain) using SUMO 
fusion technology. The transformed cells with SUMO fused α-syn were grown in Luria 
Bertani (LB) broth containing appropriate antibiotics (Amp and Cm; details in chapter 2) at 
370C and 220 rpm. The cells were induced with 1 mM Isopropyl β-D-thio-galactopyranoside 
(IPTG) when the cell density reached at OD600: 0.6 after approximately 3 hours. After that 
the cells were recovered by centrifugation, then sonicated and centrifuged to obtain a 
supernatant containing expressed SUMO fused α-syn. The fusion protein in the cell lysate 
was purified by Ni-NTA affinity column and an absorbance peak (A280) obtained using an 
AKTA prime purifier (GE health care) at an elution volume of approximately 60 ml as shown 
in Fig 3.1.a. Following Ni-NTA purification, the SUMO conjugated α-syn undergone cleavage 
reaction to remove SUMO tag using SUMO protease enzyme (ULP1). The cleaved protein 
was purified using size exclusion chromatography and obtained various fractions as shown 
in Fig 3.1.b. The un-cleaved protein, purified α-syn and SUMO protein were collected in 
various fractions. The purity of proteins were analysed by 15 % SDS PAGE gel as shown in Fig 
3.1.c, and the actual mass was confirmed by electrospray mass spectrometry as shown in Fig 
3.1.d. 
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Figure 3.1: (a) Ni-NTA affinity chromatogram showing the SUMO protein fusion eluted as a peak 
(Abs280). (b) The size exclusion (G75) chromatogram showing different peaks (Abs280) of: (1) 
Uncleaved protein at 42.26 ml, (2) purified α-syn at 54.24 ml and (3) SUMO protein at 70.37 ml as 
elution fractions. (c) SDS PAGE gel characterising various elutions from G75 Lane 1: Protein ladder, 
Lane 2: Uncleaved protein (27 kDa), Lane 3: pure α-syn (14.8 kDa), Lane 4: SUMO protein (12.2 kDa). 
(d) Mass spectrometry data showing purified protein with mass 14,840 Daltons. (Actual mass 
expected: 14843 Daltons). 
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3.3.2 PCA derived peptide characterization  
From a semi randomised library designed, three peptide winners were screened using PCA 
against α-syn1-140. The selection approach was based on α-syn71-82 which is known to self-
aggregate. Among 12 residues, the C-terminal residues 77VAQK80 was fully randomised as 
studies confirm it to be the most effective residues in forming ordered fibrils (Madine et al., 
2008). The peptide winners were generated by the project students previously and the 
characterisation studies were performed by me. The peptides were bought from Peptide 
Synthetics, Fareham, UK. 
Name Sequence 
WTA Ac-VTGVTANPQRTV-NH2 
WTB Ac-VTGVTADVQETV-NH2 
WTC Ac-VTGVTAPDKGTV-NH2 
 
Table 3.1: PCA derived peptide ‘winners’ from a screen against full length wild type α-syn. Library 
was designed by fully randomising four amino acid positions of α-syn at 77VAQK80.  Inclusion of N-
acetylation and C-amidation was used to provide additional hydrogen bond acceptors and donors. 
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3.3.2.1 ThT experiments 
The fluorescent dye ThT was used to identify the degree of amyloid fibrils formed by α-syn. 
It was monitored using 10 µM ThT solution (pH: 7.5; buffered using 10 mM Tris HCl). The 
ThT fluorescence was taken at the same time the peptides were added; this was considered 
a day 0 reading. The fluorescence was measured consecutively for next five days and the 
final reading was taken at day 10 (end point sample). The negative (SGSSGTSSGTSG) and 
positive [VAQKTmV (Madine et al., 2008)] control peptides at molar ratio 1:1 were also 
analysed after 10 days of incubation along with the PCA-selected peptides; WTA, WTB and 
WTC. The ThT experiments were performed in triplicates (technical replicates) as a part of 
single experiment using a micro-titre plate and the fluorescence was read with a Perkin 
Elmer Luminescence Spectrometer LS50B (FLWin program) set at 450 nm (excitation) and 
482 nm (emission). During intensity calculation, blank reading was considered and 
normalised the ThT value to 1:0 (peptide free wild type α-syn) sample.  
In the inhibition assay, all the three peptides lead to the reduction of ThT signal (Fig 3.2). It 
confirms the interaction of PCA peptide with α-syn during the aggregation process. In the 
case of WTA, the ThT signal was reduced relative to peptide free sample (1:0) until the 
endpoint sample which marked its inhibitory effect. Peptide WTB was actually facilitating 
the aggregation process by attaining matured fibrils by second day itself. From the data, 
WTB was least efficient candidate in inhibiting fibril growth, but it showed a reduction of 33 % 
in the endpoint sample. This sudden drop in ThT signal was later investigated by using CD 
and AFM. The peptide WTC showed a delayed inhibition in the initial phase until it regained 
its inhibition property after four days of incubation. In the inhibition assay, significant 
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reduction of ThT values in each molar ratio were seen compared to 1:0 which were analysed 
using ‘T’ test with the p values; WTA=0.0053, WTB= 0.0041 and WTC=0.0035 (threshold 0.05) 
in the day 10 samples and WTA=0.0009, WTB=0.347, WTC=0.019 in the reversal approach. 
The PCA selected peptides were compared with positive control peptide which at a molar 
ratio of 1:1; demonstrated a moderate reduction of amyloid content and the negative 
control peptide as expected showed no effect in the aggregation process. In the reversal 
assay (Fig 3.2), WTA was found to reduce the amyloid load more compared to the other two 
peptides, while WTB exhibited minimal effect. Collectively the three peptides have minimal 
effect in reverting or breaking down the matured fibrils. Positive control peptide showed no 
reversal effect as reported in the literature. Summarising the ThT data, PCA derived 
peptides have a moderate inhibitory effect on amyloid formation but minimal effect in 
disintegrating the matured fibrils.  
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Figure 3.2: ThT fluorescence data: (a) show the aggregation of wild type α-syn1-140 (1:0) for days 0, 1, 
2, 3, 4, 5, 10 (for inhibition) and 13 (for reversal) at a concentration of 450 µM and three peptides 
alone as control (0:1). (b) The ThT inhibition and reversal data of wild type α-syn1-140 in the presence 
of PCA peptides WTA, WTB and WTC (red, green, and purple bar respectively) at a stoichiometry of 
1:1 normalised to 1:0. The inhibition assay was performed on days 0, 1, 2, 3, 4, 5, 10 and the reversal 
assay at day 13 (post mix incubation of 3 days). ThT values were taken in triplicates (technical 
replicates) as a part of single experiment and the error bars were calculated as the standard 
deviation of all errors. With WTA, there is consistent reduction in ThT bound aggregates in all data 
points finally reducing to 36 % at the endpoint sample. While in WTB, the ThT bound from day 2 to 5 
show a minimal reduction leading to a sudden drop of 33 % at day 10 sample. A delayed aggregation 
process until second day can be seen in WTC with 37 % reduction in the end point sample. In the 
reversal assay, the data show a reduction of 24 % in WTA, 6 % in WTB and 19 % in WTC which 
appears to be less effective than inhibition assay. Positive and negative (solid and dashed black bars 
respectively) control peptides were also analysed by both inhibition and reversal approaches. 
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Positive control peptides showed 36 % reduction at 1:1 stoichiometry at 10th day of incubation but 
didn’t show any effect in reversing matured fibrils.   
3.3.2.2 CD assay 
The formation of secondary β-sheeted structure during α-syn aggregation was analysed by 
CD along with ThT experiments. The CD experiments were undertaken using aliquots taken 
from the same stock samples used for ThT experiments. The final α-syn concentration used 
for CD analysis was 10 µM. The data (Fig 3.3) shows the spectra with the transition of single 
negative peak from 200 nm (random coil) to 218 nm (β-sheet). The random coil signal for 
three peptides in isolation (Fig 3.3.f) confirms the peptides do not self-aggregate. 
A 10-30 % reduction found in the final day sample with all three peptides shows a decreased 
β-structure relative to 1:0. In accordance with ThT data, peptide WTC exhibits a slight delay 
in the aggregation process as greater random coil signal was retained until second day of 
incubation but 25 % fibrillar breakdown in reversal assay was in discrepancy with ThT data. 
WTB showed a greater β-signal compared to other two peptides throughout the process 
and has least effect in reversing fibril growth. Contradictory to ThT data, WTA appeared to 
have minimal effect in both aggregation and reversal processes. Approximately 50 % 
reduction was achieved by positive control peptide, but unexpectedly negative control also 
inhibited the β-sheet formation. The discrepancy in ThT and CD data regarding negative 
control was investigated by using AFM imaging. Along with ThT data, CD spectra collectively 
suggest that peptide WTC possess considerable inhibitory effects and partial reversal effects 
compared to other two peptides. The reduction of β-signal in the negative control is 
inconsistent with ThT data. GS linker was used in PCA and is a good negative control as it is 
not really hydrophobic, Gly and Ser don’t interact that strongly during β-formation. Though 
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there is a possible artefact in PCA that the linkers in peptide and target would bind to each 
other but is not enough for bringing the peptide closer to the target which shouldn’t be 
binding. The reduction in β-content with the negative peptide was further investigated using 
AFM. 
                       
                     
                                                                    
Figure 3.3: CD spectra of: a) α-syn1-140 (peptide free sample; 1:0) and with positive/negative control 
peptides after 10 days of incubation, b),c),d) Inhibition assay: α-syn1-140 with PCA peptides WTA, WTB, 
WTC respectively, e) Reversal assay, and f)  Three peptides alone (0:1) after 10 days of incubation. A 
single minimum at 200 nm indicates the presence of random coil structure and at 218 nm indicates 
the amount of β-content. The data shows a gradual transition of random coil to β-sheet in all spectra 
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in course of time. In support with the ThT data, a reduced amount of β-sheet compared to 1:0 can 
be found in the endpoint samples with three peptides. In Fig d) the delayed aggregation process in 
WTC can be seen as the existence of comparatively greater random coil signal until day 2 which is 
consistent with ThT data. The peptides were compared with positive control which shows 
approximately 50 % reduction relative to 1:0 but negative control also unexpectedly inhibited 
secondary structure formation. The reversal data show that WTA and WTB show minimal effect on 
reducing matured fibrils while a slight decrease of approximately 25-30 % can be seen with WTC 
which is inconsistent with 19 % in ThT data. 
 
3.3.2.2.1 Gaussian fit analysis of CD spectra 
Gaussian fit analysis assumes that there is only the presence of random coil or/and β-
structure. Prior to the analysis, the CD spectra of each peptide in isolation were subtracted 
from that of α-syn in the presence of peptides to identify the real structural changes of α-
syn incubated in each condition. Figure 3.4.a shows the range of negative ellipticity values at 
200 nm and 218 nm in inhibition assay after Gaussian fit analysis. A gradual decrease of 
random coil and increase of secondary β-structure can be seen in 1:0. Reduction of 10-30 % 
at 218 nm signal can be seen in the final sample of all the three peptides compared with 55 % 
reduction with positive control peptide. In WTC, retention of the random coil signal can be 
seen stronger even at second day as stated before. In reversal assay (Fig 3.4.b), WTA and 
WTB followed the profile of 1:0 while approximately 25 % fibril breakdown in WTC. Positive 
control showed a minimal effect in reverting fibrils. 
70 
 
 
                      
Figure 3.4:  The minima at 200/218 nm from all CD spectra after Gaussian fit analysis; 
 (a) Inhibition assay: 200/218 nm minima of wild type α-syn with and without WTA, WTB and WTC, 
positive & negative control peptides. Predominantly the delaying of random coil transition can be 
seen with WTC supporting the point of delayed aggregation process as seen in ThT assay. Reduction 
of 10-30 % in the final day sample with each peptide compared with 55 % reduction with positive 
control peptide can be seen. (b) Reversal assay: 200/218 nm minima in CD spectra of wild type α-
syn with and without peptides, positive & negative control peptides after 3 days (post mix) 
incubation. 25 % fibril breakdown in WTC can be seen with no effect in WTA and WTB. Positive 
control showed minimal effect in reverting fibrils. (c) A representative model of Gaussian 
distribution analysis displaying the sum of two individual curves (200/218 nm) fits the scan.  
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3.3.2.3 AFM imaging experiments 
AFM was performed on the same samples of wild type α-syn used for ThT and CD 
experiments for direct visualisation of different aggregated species formed with and without 
PCA peptides at a molar concentration of 1:1. Samples from both inhibition and reversal 
assays were imaged using AFM along with controls (peptides alone (0:1), positive and 
negative control peptides). The aim of imaging was to identify the amount of protein 
deposited as amyloid. All images were taken at resolution of 256x256 pixels at room 
temperature. The vertical resolution can be up to 0.1 nm in AFM. Consistent with ThT and 
CD data the peptides were moderately inhibiting the fibrillisation rather than reversing the 
process.  
3.3.2.3.1 AFM images: Inhibition assay 
AFM images were taken for the different species formed during the initial five days and day 
10.  The images were taken from the first day onwards to show the gradual increase of 
amyloid content. The absence of any structures at day 0 confirmed the absence of any pre-
formed fibrils achieved by monomerisation using HFIP. In the inhibition assay (Fig 3.5), 
clumps of short fibrils were seen in AFM images of α-syn in the absence and presence of 
peptides in the day 10 sample. Since it was difficult to visually distinguish the amount of 
fibril content from the images, they were analysed using histogram of volume average using 
WSxM v5.0 software.  
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Figure 3.5: AFM images showing α-syn1-140 (1:0) and α-syn with peptides WTA, WTB and WTC. In 
each condition, a representative image from the images taken in various locations of the mica sheet 
is shown here. Gradual development of amyloid fibrils was observed in all the conditions. 
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Comparative reduction of fibril content was observed in WTC on day 2 sample. It confirms the 
delayed formation of amyloid fibrils as seen in ThT and CD data. In addition, the endpoint samples 
show a similar pattern of fibril load as 1:0 in all the three peptides. All images were taken at 20 µm 
scan size. The image files were examined directly using WSxM v5.0 (Nanotec Electronica S.L., 
www.nanotec.es) and flattened before processing. (Kad et al., 2001 & 2003). 
3.3.2.3.2 AFM image analysis: Inhibition assay  
AFM images were analysed using WSxM v5.0 (Nanotec Electronica S.L., www.nanotec.es). In 
order to find the volume of aggregated protein covered on the mica surface, the images 
were flattened before processing (Kad et al., 2001 & 2003). The average volume was 
calculated by maintaining a constant threshold level manually to nullify the background 
noise, thereby eliminating the non-fibrillated or monomeric α-syn (Fig 3.6). Figure 3.5 
showed a representative image in each case from a total of five different areas randomly 
chosen on the mica sheet. For analysis the average volume of all the five images were 
considered and the error bars were calculated as the standard deviation of all errors. The 
analysis demonstrated a reduction of approximately 20-25 % fibril volume, compared to 1:0 
can be seen in the final day sample in the presence of three peptides. Consistent with the 
above assays, WTC distinctively showed a reduced fibril content on samples taken from day 
2 and 3 confirming the delayed formation of amyloid fibrils. 
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Figure 3.6: Histograms showing average volume of aggregated protein on the mica surface analysed 
using WSxM v5.0 software. In each condition, the development of fibrils can be seen along with 
incubation. WTC shows reduced volume at day 2 and 3 samples confirm the delayed amyloid 
formation. Reduced fibril content of approximately 20-25 % can be seen in the final day sample of 
three peptides compared to 1:0. Red, green, and purple bar represent WTA, WTB and WTC 
respectively. 
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3.3.2.3.3 Control experiments (AFM images of three peptides in isolation (0:1) and 
positive/negative control peptides): Inhibition assay. 
To demonstrate that the peptides do not self-aggregate, AFM imaging was undertaken at 
molar concentration of 0:1 along with ThT and CD assays. At a concentration of 450 μM 
each of the three peptides was incubated for 10 days under similar conditions used for α-
syn. In Figure 3.7, consistent with ThT and CD data the three peptides show absence of fibril 
formation after 10 days of incubation. Along with that the positive control peptide (1:1) 
facilitated the non-fibrillar structure formation and negative control peptide followed the 
fibril growth to that of 1:0. 
         
Figure 3.7:  AFM images showing the absence of fibril content in the three peptides (WTA, WTB and 
WTC) in isolation at a molar concentration of 450 µM. The two right side images show positive and 
negative control peptides. The positive control show non-fibrillar structure while clumps of short 
fibrils in negative control at stoichiometry of 1:1. 
 
 
 
 
 
 WTA (0:1)                WTB (0:1)              WTC (0:1)           Positive control   Negative control        
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3.3.2.3.4 AFM images: Reversal Assay 
In the reversal assay, the peptides were added to α-syn (after 10 days of maturation) at a 
molar concentration of 1:1 to break down the fully formed fibrils into monomers. The 
images were taken for all the samples after post mix incubation of three days (Fig 3.8). All 
the three peptides along with positive control peptide showed no effect in reversing the 
matured fibrils.    
                         
                      
 
 
 
Figure 3.8:  AFM images in the top row showing the reversal approach on α-syn1-140 (1:0) with 
peptides WTA, WTB and WTC after a post mix incubation of 3 days. In the bottom row, left two 
images demonstrates the reversal effect of positive and negative control peptides on α-syn. The 
histogram at the bottom right showing average volume of aggregated protein in each peptides case 
analysed using WSxM v5.0 software. Red, green, and purple bar represent WTA, WTB and WTC 
respectively. The three peptides along with positive control show no effect in breaking down of the 
fibrils.  
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3.3.2.4 Cell toxicity: MTT assay 
The aim of this study was to evaluate the effect of extracellular α-syn deposits on rat 
pheochromocytoma (PC12) neuronal-like cells. Though PCA was performed intracellularly in 
bacteria, MTT was investigating extracellular deposits of α-syn. It was justified by the recent 
studies which suggest that trivial amounts of α-syn contribute to the progressive spreading 
of α-syn pathology. Several environmental factors could gain access to the enteric nervous 
system where they induce α-syn aggregation which would be analogous to the transmission 
of prion disease (Olanow and Brundin, 2013). Another study suggest that the intragastric 
administration of the pesticide rotenone resulted in the formation of α-syn aggregates in 
the enteric nervous system, and the dorsal motor nucleus of the vagus nerve leading to PD 
symptoms (Montojo et al., 2010).   
MTT assay determines the cell viability using the reduction of water soluble MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) into insoluble purple coloured 
formazan. The concentration of formazan was then determined by the optical density at 570 
nm. The amount of formazan is directly proportional to the number of viable cells. All 
experiments were performed in triplicates (technical replicates) as a part of single 
experiment and the error bars were calculated as the standard deviation of all errors. First 
of all, the concentration of α-syn exhibiting PC12 toxicity was optimised. The experiment 
was performed with three different concentrations of α-syn 0.5, 5 and 45 µM. As a 
minimum concentration of target required for cellular toxicity, 5 µM was considered for the 
further peptide studies (Fig 3.9).  
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Figure 3.9: MTT assay showing the effect of α-syn at three different concentrations of 0.5, 5 and 45 
μM on PC12 cells.  5 and 45 μM show reduced percentage compared to PC12 cells in isolation. PC12 
with the buffer (used for aggregation experiments) was used as control which shows minimal effect 
in cellular toxicity. All the experiments were performed triplicates (technical replicates) as a part of 
single experiment and the error bars were calculated as the standard deviation of all errors. 
In the assay PC12 cells were grown in isolation, with 5 μM α- syn, with α-syn-peptide ratios 
(1:0.1, 1, 2, 5, and 10), with α-syn-positive/negative control peptides (1:1) and each of the 
three peptides; WTA, WTB and WTC in isolation (0: 0.1, 1, 2, 5, and 10) all incubated for ten 
days under aseptic conditions. After that cells were added and incubated for 24 hours 
followed by 4 hours in MTT dye.  Figure 3.10 shows the cell viability across a range of α-syn-
peptide ratios relative to PC12 cells in isolation. Apparently the fibril formed by α-syn is toxic 
to the cells. The aggregated species formed in lower ratios 1:1 and 1:2 in all the three 
peptides were less toxic compared to higher ratios. In the lower ratios approximately 30-55 % 
of cell viability was achieved by three peptides whereas super stoichiometric ratios found to 
be more toxic. Peptides were compared with positive control peptide and surprisingly the 
species formed found to be toxic to cells. Three peptides in isolation showed negligible 
effect on cell growth. 
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Figure 3.10: MTT toxicity assay showing cell viability with α-syn1-140 (1:0), α-syn with PCA peptides at 
various molar ratios (red, green and purple bars represent WTA, WTB, WTC respectively), with 
positive/ negative control peptides and the peptides (WTA, WTB, WTC) in isolation. The assay was 
performed by incubating PC12 cells and 5 µM α-syn in the presence and absence of peptides at 
different molar ratios (1: 0.1, 1, 2, 5, and 10) for 24 hours. The endpoint samples incubated for 10 
days were used in this assay. The data show that the species formed at molar ratios 1:1 and 1:2 
show a cell revival between 40-55 % in WTA and WTC whereas 30-56 % in WTB. The species formed 
at the higher stoichiometric ratios (1:5, 1:10) in all the three peptides show similar or greater toxicity 
on PC12 cells. In effect the aggregated species formed with 1:1 and 1:2 of all the three peptides are 
less toxic compared to 1:0. Positive control peptide showed no effect in cell recovery. The effects of 
the three peptides in isolation at any molar ratios were minimal on PC12 cells.  
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3.4 Discussion 
In this chapter I have characterised the peptides screened from the semi randomised 
libraries by intracellular PCA methodology to demonstrate peptide efficacy in binding to α-
syn1-140 and thereby lowering its toxicity. The hypothesis was that the α-syn aggregation can 
be inhibited by the specific binding of the ‘β-sheet breaker’ peptides to their native (i.e. α-
syn71-82 design scaffold) sequence in the α-syn molecule since it is known to self-aggregate. 
X-ray and electron diffraction studies have previously provided strong evidence for the 
hydrogen bonded cross β-sheet structure in which the β strands run perpendicular to the 
long fibre axis (Serpell et al., 2000; Eanes et al., 1968; Sunde et al., 1997). Solid state NMR 
studies suggest that the major extended β-sheet region is around residues 35-95 (Vilar et al., 
2008). In this chapter, the peptides were designed on α-syn71-82 scaffold since it is known to 
aggregate in isolation as well as play a major role in full length α-syn prompting 
amyloidogenesis. Collectively the data demonstrate that all the three PCA screened 
peptides lead to moderate levels of fibril reduction. ThT and CD data indicated that the 
peptides can prevent fibril formation by an average of 35 % reduction in the final day 
sample at which α-syn was thought to be fully aggregated in isolation, but have minimal 
effect in reversing it when added to these pre-formed fibrils. As ThT binds to a wide range of 
different aggregated species (i.e. oligomeric states) and CD measures only an average of 
overall secondary β-sheet content, direct visualisation using AFM was employed to study 
the efficacy of peptides. From the AFM data, as it was difficult to determine visually the 
amount of amyloid load with each peptide condition, average volume was calculated using 
WSxM v5.0 software and led to identification of an average reduction of 25 % fibril load in 
all the three peptides compared to peptide free α-syn sample (1:0). All together it is difficult 
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to declare which of the inhibitors are most effective. However, the delaying property of 
WTC was prominent in all the assays, providing a promising result for further investigation in 
derivatives that can further slowdown the progression of α-syn amyloidogenesis.  
The reason for the effectiveness of WTC (77PDKG80) is currently unknown; however I 
speculate that it could be due to the substitution of K80G which might have modified the 
packing of α-syn fibrils as NMR studies and thermodynamic studies shows that the glycine is 
a low propensity β-sheet forming residue (Nowick et al., 1997; Smith et al., 1994). Another 
point could be the presence of proline residue which facilitates the secondary structure as 
turns or helices by disfavouring β-strand conformations, as it reduces stability since its side 
chain can only form one hydrogen bond. The glycine and proline effect together might have 
made WTC performed comparatively well as β-sheet breaker relative to WTA or WTB. 
Studies show that Q/N rich sequences self-assemble to form amyloids (Perutz et al., 2002). 
Short peptides like WTA and WTB containing Q residues could have bound to the parent 
protein making it Q rich and thus favouring aggregation as seen in many prion and 
polyglutamine diseases. The uncharged polar side chain usually located on the outside of 
protein could be a protein-protein interaction module. In contrast to that, WTC lacks any Q 
residue which makes it comparatively a better peptide in slowing down the aggregation 
process. The hydrophobicity of the residues plays an important role in self aggregation of 
peptides. Therefore three PCA peptides represent reduced hydrophobicity relative to α-
syn71-82. The PCA method used here substituted V77 by charged or less hydrophobic 
residues in all the three peptides. Studies show that the deletion or substitution of V77 
prevents the formation of mature amyloid fibrils (Waxman et al., 2010). In the MTT assay, 
reduced toxicity was observed effectively in the lower stoichiometries of all the three 
peptides. Reduced toxicity supports the ThT, CD and AFM data that the equimolar ratios of 
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the peptides lead to non-fibrillar species during amyloidosis. Peptides derived in this study 
compared favourably with previously reported N-methylated VAQKTmV peptide (Madine et 
al., 2008) and a SGSSGTSSGTSG peptide. While designing the negative control peptide, four 
glycine residues were included so that the lack of side chain facilitates rotational freedom of 
the backbone conformation of the protein and G/S peptide is a mDHFR-peptide linker and is 
a good negative control as it shows no binding during the PCA process. Compiling all results; 
a better inhibitor can be designed by reducing hydrophobicity and introducing charged 
residues in the 71-82 region which provides a good chance to repel the incoming α-syn 
monomers on the outward growing face of the fibril. Structural studies reveal that the 
substitution of the hydrophobic residues in the NAC region with charged ones weaken fibril 
formation. Particularly the N-terminal half of NAC (61-78) is amyloidogenic region 
responsible for the aggregation and toxicity of α-syn (Giasson et al., 2000; El-Agnaf et al., 
1998). While selecting peptide residues, PCA ensures a balance between α-syn binding 
affinity and peptide solubility. In conclusion, I have used an in vivo selection approach to 
derive a range of peptides against α-syn aggregation. Further investigation needed as I have 
not directly quantified the affinity and specificity of the binding. This is because even though 
the peptides are reducing the amyloid load, they are not satisfactorily stopping or reversing 
the fibril growth as anticipated at the PCA level. Notably the delayed amyloid formation 
seen in WTC peptide shows a positive sign for future investigations and develops as a drug 
to delay PD progression and its symptoms. Our approach towards an α-syn71-82 scaffold was 
later changed to develop a library based on the wild type α-syn45-54 scaffold accommodating 
the point mutations implicated in the early onset of PD, which will be discussed in chapter 5. 
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Chapter 4: Use of PCA to derive peptide antagonists of α-syn mutant’s 
aggregation associated with early-onset PD 
4.1 Introduction 
There are a number of familial point mutations which have been identified in the SNCA gene 
that are associated with the early onset of PD (Berg et al., 2005). Among these, A53T was 
the most frequently found mutation reported in at least 12 families of Greek and Italian 
origin (Spira et al., 2001) and in a Korean family (Ki et al., 2007). The E46K mutation was 
identified in a Spanish family (Zarrenz et al., 2004), and the first brain study of a A30P 
mutant carrier patient was undertaken by Seidel and colleagues (2010) and reported that 
increased neuropathology was due to the significant load of insoluble α-syn. The H50Q 
substitution in α-syn was first identified by two different groups in a caucasian English 
female (Proukakis et al., 2013) and a person from a family of English/Welsh origin (Cresswell 
et al., 2013). Three families have been recently reported to have G51D with early onset ages 
ranging from 19 to 60 years (Lesage et al., 2013; Rutherford et al., 2014). 
The different mutations exhibit distinct effects on PD progression rate. Many previous 
studies suggest that; neither the natively unfolded nor the partially folded intermediate 
conformations are affected by these point mutations. A recent study suggest that these 
point mutations causes a change from stable tetrameric α-syn structure to monomers, 
decreases α-syn solubility and thereby induces neurotoxicity and deposition of inclusions in 
the neurons (Dettmer et al., 2015).  The α-syn region where the mutations are present and 
the residues within are clearly important in modulating amyloid formation by increasing α-
syn toxicity, decreasing α-helical propensity, increasing β-sheet propensity, and either 
increasing the rate or the amount of oligomers that are formed during the aggregation 
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process (Bussell et al., 2001; Greenbaum et al., 2005; Ghosh et al., 2013; and Rutherford et 
al., 2014). The major concern is, how a single point mutation in the natively unfolded α-syn 
can affect the rate of aggregation and fibrillisation processes. It can be explained in the 
scenario of ‘sequence repeats’ found in the N-terminal region of α-syn. Sequence repeats 
are a main feature of several neurodegenerative disorders that are characterized by protein 
aggregation. α-syn consist of seven 11-mer imperfect sequences (XKTKEGVXXXX) containing 
a KTKEGV hexameric motif which is not fully conserved in the sixth and seventh repeats. The 
repeat sequences in the N-terminal end is identified to decrease the tendency of β-sheet 
propensity shown by α-syn and favours an α-helix formation in the presence of lipid vesicles 
and also is likely to be important in maintaining the normal structure and deciding the 
pathological functions of α-syn (Kesler et al., 2003). As a partially folded intermediate of α-
syn is needed for amyloid fibril formation, KTKEGV repeats show a significant role in 
retaining the native unfolded structure of α-syn and thereby preventing aggregation (Sode 
et al., 2006). Mutation in these seven imperfect sequences show effects in the rate of 
aggregation by decreasing the lag time of fibril formation (Harada et al., 2009). All α-syn 
mutations lie in the imperfect 11 mer sequence except A53T, but it is in close proximity 
between the fourth and fifth repeats. It suggests that, the mutations inhibit the ability of the 
repeats to form nonpathogenic species and thereby increases the inherent β-sheet 
propensity of the repeats. The fibril formation induced by mutation is also found to inhibit 
the proteasome activity in vitro by binding to the 19S subunit in the 26S proteosome 
(Nonaka, and Hasegawa, 2009).  
The A53T and E46K mutants were found to increase the rate of self assembly and fibril 
formation by adopting β-sheet conformation to form pathological inclusions (Conway et al., 
2000, Li et al., 2001, Choi et al., 2004, and Greenbaum et al., 2005). A study performed by 
85 
 
Waxman and collegues (2008) on double mutants containing both E46K and A53T suggests 
that the fibrillisation rate was increased rapidly compared to A53T alone with its amino-
terminal region involved in pathological inclusions as detected by conformational specific 
antibodies . NMR studies suggest that the significant helical propensity shown by N-terminal 
region of wild type α-syn was changed by A30P mutation to increase the rate of formation 
of β-sheet protofibrils, while A53T results in modification of a small region around the 
mutation site providing a preference for extended β-sheet conformations (Bussel et al., 
2001). Some groups suggest that A30P shows a delayed fibril formation than wild type and 
decreased maturation of fibrils by enhancing the population of oligomers (Conway et al., 
2000, Bussel et al., 2001). The oligomeric intermediates rather than matured fibrils tend to 
build up more in A30P carriers and induces pathogenicity. The involvement of residue 30 in 
β-sheet formation would likely be hindered by the presence of proline mutation (as proline 
is a very poor ordered β-sheet forming residue: Chou, and Fasman, 1978) reflecting the 
reduced Ramachandran space available to the preceding residues. In A53T mutation, 
threonine has higher β-sheet propensity than alanine (Chou, and Fasman, 1978). E46K has 
been identified in the imperfect repeat sequences present in the N-terminal region leading 
to decrease in aggregation lag time to fibril formation. Substitution of a Glu for a Lys in the 
imperfect repeat sequences leads to a rapid conformational change in α-syn to a partially 
folded intermediate; this then oligomerises which act as a critical nucleus and finally leading 
to the formation of fibrils (Harada et al., 2009). The native, monomeric α-syn is stabilized by 
long range interactions  between N-, C- termini and the NAC region via electrostatic 
interactions which protects it from oligomerisation and aggregation (Bertoncini et al., 2005). 
Recent findings suggest that the stability is attained by the native tetrameric structure of α-
syn (Dettmer et al., 2013; 2015; Bartels et al., 2011). 
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 The C-terminus has been speculated to act as an aggregation regulator by docking with 
polycations which destabilizes these interactions and furthermore its truncation enhances 
aggregation. The high free energy of extended conformations with the solvent exposed NAC 
region facilitates the nucleation and aggregation processes (Fernandez et al., 2004). Though 
these intramolecular contacts were considered undisturbed in A53T and A30P, altered 
secondary structure propensity has been speculated to cause fibril formation. In contrast, 
the E46K mutation causes decreased net negative charge of α-syn, with the increased 
positive charge of the N-terminal lipid binding domain enhancing such contacts with 
negatively charged C-terminal domain, thereby accelerating fibril formation (Rospigliosi et 
al., 2009). NMR studies show that residue 46 is not present in β-sheets consisting of the 
cross-β region located within residues 30-110. Therefore the mutation promotes the 
formation of new β-sheets without disrupting the endogenous β-structures (Harada et al., 
2009; Mar et al., 2005; Chen et al., 2007). NMR studies suggest that, H50Q mutation causes 
conformational changes on C-terminal and increases the flexibility of this region 
considerably more than any other previously identified mutants.  And also H50Q causes 
chemical shift perturbations around the mutation site (residues 44-56) thereby modulating 
the interactions between the NAC region and the C-terminus, thus accelerating α-syn 
aggregation. Furthermore, His50 is an important residue for Cu(II) binding in α-syn and its 
replacement may affect the secondary structure of H50Q in the presence of Cu(II) in vivo 
(Rutherford et al., 2014). The recently identified G51D causes early onset of PD symptoms 
and its clinical features show similarities to those with SNCA triplications and to A53T cases 
(Kiely et al., 2013; Lesage et al., 2013). Further studies are needed to investigate how H50Q 
and G51D modulates the pathology of PD. The mutants cause a faster formation rate of 
fibrils, soluble oligomers, or amorphous aggregates than wild type α-syn (Li et al., 2001). 
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This chapter focuses on screening libraries and to derive and characterise new peptide 
inhibitors of α-syn aggregation using mutants associated with early onset PD. These include 
A30P, E46K, A53T and H50Q and uses ThT, CD, AFM and MTT assays (described in Chapter 3) 
to characterise the effects of these PCA derived sequences upon α-syn aggregation. The 
strategy to design peptide inhibitors was based on the α-syn71-82 scaffold which is known to 
aggregate in isolation (Periquet et al., 2007; Madine et al., 2008) and was therefore 
hypothesised to interact with full length α-syn mutant. By characterisation of peptides 
derived from building a library using these sequences as a design template I have aimed to, 
interrupt α-syn aggregation by preventing amyloid formation or breaking down pre-formed 
fibrils to less toxic oligomers. G51D has only recently been identified and hence was not 
investigated in this thesis. These studies would help us to provide some clues about peptide 
candidates which harness the potential to be further developed into drugs in the future. 
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4.2 Experimental approach 
This chapter describes the characterization of antagonistic peptides of α-syn aggregation for 
early-onset associated mutants. Peptides were generated using semi rational peptide 
design, combined with PCA.  
(1) Purification of α-syn mutants: Mutants were expressed and purified using SUMO 
technology as described in Chapters 2 & 3. 
(2) Peptide characterisation: The PCA derived peptides were characterised using ThT, CD, 
AFM and MTT assays as described in Chapter 3. The peptides were analysed for their 
inhibitory effect as well as the reversal effects on aggregation. In this chapter, 450 µM each 
of the α-syn mutants were incubated with PCA derived peptides at various molar ratios; 
1:0.1, 1:1, 1:2, 1:5 and 1:10 (mutant: peptide), in 500 µL of potassium phosphate buffer (10 
mM, pH 7.0), KF (100 mM) and NaN3 (0.05 %) at 37
0C with continuous shaking in an orbital 
incubator at 10xg for 10 days (A30P, E46K, A53T) and 20 days (H50Q) for the inhibition 
assay, and three days (post-mix) for the reversal assay. Finally, the effect of peptides on the 
viability of PC12 cells was investigated using the MTT cell toxicity assay. The assay was 
performed at 5 µM α-syn mutant with five different molar ratios as mentioned above. 
Control experiments by incubating peptides in isolation without target mutants were 
undertaken to verify the reliability of the peptides. In addition the negative control peptide 
(SGSSGTSSGTSG) and positive control peptide [VAQKTmV (Madine et al., 2007)] at molar 
ratio 1:1 were also analysed along with the PCA peptides. The peptide; SGSSGTSSGTSG is the 
GS linker which is a good control peptide to use to investigate the specificity of PCA derived 
peptides towards α-syn. 
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4.3 Results 
4.3.1 PCA derived peptide characterization  
PCA derived peptides against the aggregation of α-syn mutants were generated using semi-
rational peptide design approach using the 71-82 region of α-syn as a design scaffold, as it is 
known to self-aggregate (Table 4.1). Among those residues, C-terminal residues 77VAQK80 
were fully randomised to provide all 20 residue options at these four positions. 77-80 was 
chosen owing to the fact that solid state NMR studies have provided evidence for these to 
be the most effective residues in forming ordered fibrils in the 71-82 peptide (Madine et al., 
2007). The peptide winners were generated by the project students previously and bought 
from Peptide Synthetics, Fareham, UK for the characterisation studies performed by me. 
Name Sequence based on 71-82 region 
A30P Ac-VTGVTAHPQNTV-NH2 
E46K Ac-VTGVTANQNNTV-NH2 
A53T Ac-VTGVTADNKETV-NH2 
H50Q Ac-VTGVTANSSDTV-NH2 
Table 4.1: PCA derived peptide ‘winners’ from a screen against full length α-syn mutants. The library 
was designed by fully randomising four amino acid positions of α-syn mutants at 77VAQK80. The four 
residues selected between 77-80 region after PCA in each case is highlighted in yellow. Inclusion of 
N-acetylation and C-amidation was used to provide additional stability to the peptide as well as 
additional terminal hydrogen bond acceptors and donors.  
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4.3.2 Inhibition assay 
4.3.2.1 ThT fluorescence assay 
The ThT experiments for all the mutants were performed in triplicates (technical replicates) 
as a part of single experiment in a micro titre plate and the error bars were calculated as the 
standard deviation of all errors (Fig 4.1). The three mutants; A30P, E46K and A53T reached 
their stationary stable phase from day 10 onwards and is therefore considered as the end 
point for inhibition assay since no further growth was recorded. H50Q showed a longer lag 
phase reaching stationary phase at day 20 and is thus considered for taking the inhibition 
assay readings. In reversal assay, over a period of 3 days after adding peptide to the 
matured fibrils was considered as there is no further fibrillar modification observed during 
the stationary phase of mutants.  
 
Figure 4.1: Raw ThT fluorescence data: showing comparative growth of four α-syn mutants from 
day 0 to day 20 at a concentration of 450µM. The amount of fibrils formed is directly proportional to 
the ThT fluorescence emitted in course of time. A30P exhibits the maximum ThT signal 
approximately 1700 mAu at day 2 while H50Q showed the smallest fluorescence of approximately 
80 mAu at day 15. A53T reached a maximum of 805 mAu at day 3 while E46K showed 514 mAu at 
day 4.  
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In the case of all the mutants, blank reading was considered and normalised the ThT value 
at each time point to 1:0 (peptide free sample) during intensity calculation. ThT values were 
taken in triplicates (technical replicates) as a part of single experiment and the error bars 
were calculated as the standard deviation of all errors. According to the ThT data, in A30P 
mutant (Fig 4.2); an increased ThT signal was observed at day 0 when the PCA derived 
peptide was added. Though there was slight reduction of ThT signal in the following days of 
incubation until day 4, the effect of peptide is found to be minimal in inhibiting the fibril 
formation relative to 1:0. The PCA peptide was clearly unable to maintain reduced amyloid 
level beyond day 4 at any of the stoichiometries. Later MTT assay was performed assuming 
that it could explain whether the species formed are toxic or not.  
 
Figure 4.2: ThT fluorescence data showing inhibition assay of A30P using PCA peptide at five 
different molar stoichiometries (1:0.1, 1:1, 1:2, 1:5, and 1:10) in days 0,1,2,3,4,5 and 10. The ‘y’ axis 
values are relative to the peptide free (1:0) sample in %. The data shows an increase in ThT 
fluorescence at day 0 at the moment of adding PCA peptides. Gradually a tendency to lower the 
amyloid content can be seen in the following days of incubation, but the peptide failed to retain the 
decreased amyloid load further day 4. Increased ThT at the final day samples shows the inability of 
the PCA peptide to inhibit fibril formation in A30P.  
0
50
100
150
200
250
300
0 1 2 3 4 5 10
N
o
rm
al
is
ed
 T
h
T 
d
at
a 
to
 1
:0
 
Number of days 
A30P Inhibition assay 1 to 0.1
1 to 1
1 to 2
1 to 5
1 to 10
92 
 
In E46K mutant (Fig 4.3), similar to A30P; the PCA selected peptide at any molar ratios was 
unable to inhibit the aggregation process at any point during 10 days of incubation. Instead 
it was facilitating the amyloid load to a greater extent that at higher concentration it 
showed 7 times more signal relative to 1:0. A gradual increase of ThT signal was observed 
until day 2 in all stoichiometries. Then the ThT signal was seen to decrease towards the later 
phases of incubation. Overall, PCA peptide was identified to facilitate amyloid formation 
rather than inhibiting the process. 
 
Figure 4.3: ThT fluorescence data showing Inhibition assay of E46K using PCA derived peptide at 
five molar stoichiometries (1:0.1, 1:1, 1:2, 1:5, and 1:10) in days 0,1,2,3,4,5 and 10. The data shows 
the peptide is not identified to inhibit in any of the molar ratio, despite it increases the fibril load. An 
increase of ThT value towards day 2, which then gradually diminished near the later phase of 
incubation can be seen in all stoichiometries. At the highest ratio (1:10) the peptide showed an 
enhancement of amyloid load for about 7 times during day 1 and 2 and later it diminished to 3 times 
compared to 1:0.  
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In A53T mutant (Fig 4.4), 1:0.1, 1:1, 1:2 and 1:5 showed reduction in ThT fluorescence, but 
the peptide was seen to lose its inhibitory property in the later phases of incubation. The 
higher ratio of 1:10 possessed a gradual decrease in fluorescent intensity reaching a 
maximum of 34 % reduction in the day 10 sample. According to the ThT data, the PCA 
peptide appeared to be effective in higher stoichiometry to inhibit the fibril progression. CD 
and AFM assays were undertaken to confirm the efficacy of peptide at higher concentration.  
 
Figure 4.4: ThT fluorescence data showing Inhibition assay of A53T using PCA derived peptide at 
five molar stoichiometries (1:0.1, 1:1, 1:2, 1:5, and 1:10) in days 0,1,2,3,4,5 and 10. The data shows 
that there is a 20-30 % reduction in ThT fluorescence in the initial days with 1:0.1 which was unable 
to retain its inhibitor property towards the final phase. 4-15 % reduction was seen in other ratios 
(1:1, 1:2, and 1:5) at day 3 sample which were found to be ineffective inhibitor ratio in the later 
phase. Contrast to all these ratios, 1:10 possessed an increased ThT signal initially which subsided 
with a reduction of 34 % in the final day sample. 
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In the case of H50Q (Fig 4.5), an increase of ThT fluorescence was identified with an increase 
in peptide concentration. The only reduction of 6 % was seen in early stages of equimolar 
ratio. Other lower stoichiometries showed an increase in fluorescence at various time points. 
A massive increase of amyloid load was seen in the higher stoichiometries of 1:5 and 1:10. 
The PCA peptide was found to facilitate the aggregation of H50Q as it formed high ThT 
signals compared to 1:0. The samples were later studied using CD, AFM and MTT assays.  
 
Figure 4.5: ThT fluorescence data showing Inhibition assay of H50Q using PCA derived peptide at 
five molar stoichiometries (1:0.1, 1:1, 1:2, 1:5, and 1:10) in days 0,1,2,3,4,5 and 10. The data shows 
an increase in ThT fluorescence in a dose dependency manner. 10-15 % increase in fluorescence was 
found in 1:0.1 ratio. In 1:1, there was a reduction of 6 % in fluorescence but later increased by 30-
50 %. In 1:2, an increase of 30-80 % fluorescence was seen. A massive increase of 2-3 times in 
fluorescence was identified in the higher molar ratios depicting the amount of amyloid fibrils 
increases with increase in peptide concentration. Increased ThT at day 20 samples shows that the 
peptide was unable to inhibit but enhances the H50Q amyloid load.  
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4.3.2.2 CD assay 
The CD experiments of mutants were undertaken using aliquots taken from the same stock 
samples used for ThT experiments at a final concentration of 10 µM. The CD spectra show 
the transition of single negative peak from 200 nm (random coil) to 218 nm (β-sheet) (Fig 
4.6). CD spectra were analysed using Gaussian distribution analysis (Fig 4.6.c). Prior to the 
analysis, the CD spectra of the peptide in isolation were subtracted from that of target with 
peptide to identify the structural changes of mutant when incubated in each condition. 
In A30P (Fig 4.6.b), greater β-signal at 218 nm for all molar ratios can be seen in the final day 
sample. The slight decrease of amyloid content in ThT data during the mid-phase of 
incubation is not supported by CD data as it exhibits an increased 218 nm signal in all 
stoichiometries relative to the peptide free (1:0) sample. The CD data confirms the PCA 
derived peptide appeared to facilitate the formation of secondary β-structure in all molar 
ratios and failed to inhibit the fibril formation.  This could be assumed at this level as the 
peptide might have served as nucleus to facilitate aggregation. To confirm this discrepancy 
in data, the samples were analysed using AFM and MTT assays later. 
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Figure 4.6: Raw CD spectra of: (a) day 0 samples, (b) day 10 samples of A30P with PCA derived 
peptide at molar stoichiometries; 1:0.1, 1:1, 1:2, 1:5, and 1:10 relative to the peptide free (1:0) 
sample and (c) Gaussian fit analysis data showing 200/218 nm minima of A30P with and without 
peptides at day 0 to 5 and day 10. In the figs a) and b), it shows a gradual transition of random coil to 
β-sheet in all molar ratio in course of time. Consistent with the ThT data, the day 10 samples show a 
greater 218 nm signal indicating an increased amyloid content in the presence of peptide at all molar 
ratios compared to 1:0. 2-3 times more β-sheet secondary structure can be seen in all ratios. 
Contrary to ThT, amyloid load relative to 1:0 at day 4 is seen increased in all the samples. The greater 
218 nm minima at 1:5 and 1:10 suggest that, the more peptide present; the more it facilitates β-
sheet formation. 
In E46K (Fig 4.7), a gradual increase of greater β-signal at 218 nm confirms the increased 
amyloid content in all molar ratios during 10 days of incubation. The increase of β-signal was 
in a dose dependence manner. The greater the peptide content, the more β-sheeted 
structure formed. Inconsistent with the ThT data, the higher ratio 1:10 exhibited a gradual 
increase in the amyloid content rather than an increased secondary structure during day 1 
and 2 as seen in ThT data (Fig 4.7 b and c). The peptide appeared to facilitate the formation 
of secondary β-structure in all molar ratios instead of inhibiting the process.  
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Figure 4.7: Raw CD spectra of: (a) day 0 samples, (b) day 10 samples of E46K with PCA derived 
peptide at molar stoichiometries; 1:0.1, 1:1, 1:2, 1:5, and 1:10 relative to the peptide free (1:0) 
sample and (c) Gaussian fit analysis data showing 200/218 nm minima of E46K with and without 
peptides at day 0 to 5 and day 10. The data shows a gradual transition of random coil to β-sheet in 
all spectra in course of time. In Fig (b), the 1:10 ratio possesses the highest β-content among all 
stoichiometries. In consistent with the ThT data, day 10 samples in all stoichiometries show a 
gradual increase of 218 nm signal in a dose dependant manner confirms the peptide facilitating 
amyloid formation. 
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In A53T (Fig 4.8), the peptide in all molar ratios exhibited an increased β-signal relative to 
peptide free sample (1:0) in the day 10 sample. Even though the day 3 samples showed a 
slight reduction in 218 nm signal as seen in ThT data which confirms the delayed 
aggregation process in lower stoichiometries, the signal is much greater compared to that of 
1:0. In contrast to the ThT data, 1:10 showed a greater β-signal suggesting an accumulation 
of the secondary species which were unable to bind ThT dye. The peptide appeared to 
facilitate the formation of secondary β-structure in all molar ratios inconsistent with the 
reduced ThT value at higher peptide concentration. Further structural analysis was 
undertaken on the same samples using AFM imaging. 
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Figure 4.8: Raw CD spectra of: (a) day 0 samples, (b) day 10 samples of A53T with PCA derived 
peptide at molar stoichiometries; 1:0.1, 1:1, 1:2, 1:5, and 1:10 relative to the peptide free (1:0) 
sample and (c) Gaussian fit analysis data showing 200/218 nm minima of A53T with and without 
peptides at day 0 to 5 and day 10. The PCA peptide in all molar ratios has enhanced β-sheet 
secondary structure (2-4 times) formation relative to peptide free (1:0) sample. Contrary to ThT data, 
1:10 showed highest β-signal at the end of the incubation. Consistency with ThT data, slight 
reduction in the 218 nm signals at day 3 (Fig: c) portrays the delay in amyloid formation, but it is 
much greater value compared to that of 1:0. The peptide was found to induce amyloid formation. 
Gradual increase of 218 nm signal is found in 1:5 and 1:10. The peptide at highest concentration 
(1:10) showed the highest β-signal compared to other ratios in all day samples. 
 
In H50Q (Fig 4.9), CD spectra were undertaken on days 0, 10, 15 and 20. As a representation 
only day 0 and day 20 are shown here. The data confirms the increase of secondary β-sheet 
with an increase of peptide concentration. There was a fast transition of random coil to β-
sheet seen in higher molar ratios. The β-signal in the last day of incubation confirms that the 
peptide is facilitating secondary β-structure formation rather than inhibiting it. Compared to 
other mutants the 218 nm CD signal is found to be very low indicating a reduced amyloid 
load in H50Q aggregation process. Further analysis of the nature of secondary structure 
formed was undertaken on the same samples using AFM imaging. 
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Figure 4.9: Raw CD spectra of: (a) day 0 samples, (b) day 20 samples of H50Q with PCA derived 
peptide at molar stoichiometries; 1:0.1, 1:1, 1:2, 1:5, and 1:10 relative to the peptide free (1:0) 
sample and (c) Gaussian fit analysis data showing 200/218 nm minima of H50Q with and without 
peptides at day 0, 10, 15 and 20. According to CD all molar ratio exhibits a 218 nm β-signal relative 
to 1:0 at day 20 samples. The reduced random coil signal at 1:5 and 1:10 compared to other ratios at 
day 10 confirms a fast transition to β-sheet in the presence of more peptide. Consistent with ThT 
data, slight increase in β-signal at 218 nm can be seen increasing with the peptide concentration at 
day 20 samples. Thereby confirming the peptide is facilitating amyloid fibril formation rather than 
inhibiting it.   
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4.3.2.3 AFM experiments  
The aim of AFM imaging was to identify the amount and nature of amyloid fibrils formed 
during aggregation process. Since each assay is measuring a different output, AFM is very 
useful as it is a much more direct assay than ThT or CD. AFM was performed to identify the 
amount of aggregated mutant with or without PCA derived peptides. Aliquots of same 
samples used for ThT and CD experiments were used for direct visualisation of different 
aggregated species formed at various molar ratios. Inhibition samples were imaged using 
AFM along with controls (Peptides alone, positive and negative control peptides). All images 
were taken at 20 µm scan size. The image files were examined directly using WSxM v5.0 
(Nanotec Electronica S.L., www.nanotec.es) and flattened before processing. (Kad et al., 
2001 & 2003). The length and volume of the fibrils were measured. 
In A30P, the AFM images (Fig 4.10) and average volume analysis (Fig 4.11) showed a gradual 
increase in amyloid load as the incubation progresses. Long, distinct amyloid fibrils were 
seen in lower molar concentration ratios. At higher ratios of 1:5 and 1:10, the aggregates 
were appeared as clumps of protein showing their abundance across the entire mica sheet 
surface. It was clear that the peptide was enhancing the formation of aggregates at higher 
concentrations while long fibrils were formed in the lower ratios. The peptide appears to 
enhance nucleation stage to initiate the aggregation process in a dose dependant manner. 
This can be justified by the appearance of oligomeric structures at comparatively early stage 
(day 3) in 1:5 and 1:10. Consistent with the ThT and the CD data, AFM image of day 10 
samples showed enormous amount of fibrils confirms the inability of peptide in inhibiting 
the fibrillisation process.  
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Figure 4.10: AFM images showing A30P alone (1:0) and A30P with PCA derived peptide at different 
molar concentrations 1:0.1, 1:1, 1:2, 1:5, and 1:10. At each molar ratio and time point, a 
representative image from the images taken in various locations of the mica sheet is shown here.  
On the final day sample, long amyloid fibrils of approximately 4-8 µm can be seen in 1:0, 1:0.1, 1:1, 
and 1:2. The peptide at higher concentrations (1:5 and 1:10) directed to the formation of clumps of 
aggregates which was entirely covering the mica sheet. This confirms the stronger secondary 
structure signal produced by final day CD data. At the higher concentrations, the peptide appears to 
facilitate more aggregates and at lower concentrations didn’t show any sign of preventing its 
formation.  
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Figure 4.11: Histograms showing average volume of aggregated A30P on the mica surface. A gradual 
increase of fibril load can be seen in all stoichiometries. The higher ratios were seen to enhance 
amyloid load by decreasing the lag phase and increasing the nucleation phase.  
In E46K (Fig 4.12 and 4.13), the AFM images show that amyloid fibrils of approximately 4-8 
µm in length were formed during 10 days of aggregation process.  In the presence of 
peptide, morphologically different oligomeric structures of 1-2 µm in length were formed at 
molar ratios 1:0.1, 1:1, 1:2 and 1:5 despite long fibrils seen in 1:0. Those were identified as 
protein clumps co-existing along with <4 µm long fibrils abundantly on the mica sheet at day 
10. Short fibrils inter-twisted to form thick bundles of fibres were seen in higher molar ratio 
of 1:10. Structural changes and its contribution in fibril elongation attributed with the PCA 
peptide were identified in all molar ratios. Consistent with ThT data and CD data, AFM 
image confirmed the inability of the peptide in inhibiting the fibrillisation process at all five 
stoichiometries. 
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Figure 4.12: AFM images showing E46K (1:0) and E46K with PCA peptide at molar concentrations 
1:0.1, 1:1, 1:2, 1:5, and 1:10. At each molar ratio and time point, a representative image from the 
images taken in various locations of the mica sheet is shown here. At the final day sample, long 
amyloid fibrils of approximately 4-8 µm can be seen in 1:0. The aggregates formed in the presence of 
peptide at various concentrations vary in their appearance. At the ratios 1:0.1, 1:1, 1:2 and 1:5, small 
oligomers of 1-2 µm were formed instead of long fibrils found in 1:0. Especially in 1:1, 1:2 and 1:5, 
the aggregates were found associated with each other and formed clumps of proteins scattered all 
over the mica sheet in the final day of incubation.  There were a few small fibrils of <4 µm were seen 
in those ratios. In 1:10, short fibrils were found inter-twisted to form relatively thicker fibril bundles 
abundantly on the mica sheet.  
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Figure 4.13: Histograms showing average volume of aggregated E46K on the mica surface. A gradual 
increase of fibril load can be seen in 1:0. Considerable increase in the amyloid load found in 1:10 
relative to 1:0. This might be due to the increase in the volume caused by association of fibrils in the 
higher ratios. Comparatively the ratios 1:1 and 1:2 appear to show slight inhibitory properties, but it 
is inconsistent with CD and ThT data. 
In A53T (Fig 4.14 and 4.15), a gradual increase of amyloid load can be seen as the incubation 
progresses. Amyloid fibrils of approximately 1-2 µm were formed in 1:0. In 1:0.1, the fibrils 
were less abundant when compared to 1:0 in the initial days of incubation. There was a 
delay in fibril formation seen in lower stoichiometries until day 3 which exhibited shorter 
fibrils of 1 µm accumulated as protein clumps later. Various morphological structures where 
seen in 1:5 concentration. Instead of distinct long fibrils, small oligomeric structures can be 
seen. In consistent with low ThT value, 1:10 showed an increase in fibril load with long fibres 
of 3 µm associated together to form thicker bundles covering all over the surface. In 
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summary, the peptide showed a slight inhibitory property in lower concentrations especially 
in 1:2, by delaying the process and preventing the formation of long fibrils.  
 
Figure 4.14: AFM images showing A53T (1:0) and A53T with PCA peptide at molar concentrations 
1:0.1, 1:1, 1:2, 1:5, and 1:10. At each molar ratio and time point, a representative image from the 
images taken in various locations of the mica sheet is shown here. The data shows a gradual 
development of amyloid fibrils of approximately 1-2 µm in A53T alone (1:0) during 10 days of 
incubation. At 1:0.1, initially the amount of fibrils visible was less relative to 1:0. 1:1 found to delay 
the fibril formation until day3 and consistent with CD data, 1:2 show comparatively less fibril load 
than 1:0. In 1:5, various morphological structures of protein aggregates were seen during the 
aggregation process. On day 2, short fibrils of average 1 µm can be seen which gradually changed to 
protein clumps entirely covering the mica sheet. The peptide appeared to enhance fibril formation 
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at 1:10. The abundance of long fibrils was greater than that of 1:0. The final day sample shows long 
(~3 μm), abundant and thick bundles of amyloid fibrils.  
The average volume analysis was performed by considering five random images in each 
molar ratio. The localised differences in the deposition of aggregated species on the surface 
of mica sheet could have reflected a reduced amyloid volume in 1:10 at day 3 which was 
inconsistent with that of AFM image. And also the height of the deposited aggregates also 
matters as a threshold value was introduced inorder to nullify the background noise of small 
oligomers or non-aggregated species.  
 
Figure 4.15: Histograms showing average volume of aggregated A53T on the mica surface. A gradual 
increase of fibril load can be seen in 1:0 with an exception in day 5 which could be due to the 
differences in the distribution over the mica sheet. Notably day 4 samples in the presence of peptide 
in all ratios show a decrease relative to 1:0. The final day sample indicates a reduction in the lower 
stoichiometries.  
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In H50Q (Fig 4.16 and 4.17), AFM images confirm the aggregation of H50Q forming fibrils of 
length approximately 1-2 µm. No fibrils, instead small oligomeric structures were seen 
initially in the course of incubation time. A delayed amyloid formation was seen in H50Q 
mutant compared to wild type α-syn and other mutants. Lower peptide stoichiometries 
showed a similar pattern of fibril formation as that of 1:0 while clumps of proteins appeared 
in higher molar ratio samples. The peptide appeared to mediate the association of fibrils 
rather than increasing the length or thickness of individual fibrils. The peptide enhances 
fibril formation rather than inhibiting in all stoichiometries.  
                            
Figure 4.16: AFM images showing H50Q alone (1:0) and H50Q with PCA peptide at molar 
concentrations 1:0.1, 1:1, 1:2, 1:5, and 1:10. At each molar ratio and time point, a representative 
image from the images taken in various locations of the mica sheet is shown here.  The data shows 
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the development of amyloid fibrils of approximately 1-2 µm in H50Q alone (1:0) during 20 days of 
incubation. A very few oligomeric structures and no fibrils were seen in the samples at day 10 and 15. 
A delayed amyloid formation was seen in H50Q compared to wild type α-syn and other mutants. At 
the lower stoichiometries, similar fibrils to that of 1:0 were found at the day 20 samples. In the 
higher stoichiometries of 1:5 and 1:10, association of small fibrils to form clumps of protein which 
were scattered abundantly on mica sheet were found. The peptide appears to involve in mutual 
association of fibrils in higher stoichiometries rather than increase in length or thickness of individual 
fibrils which causes the increased ThT and CD signal.  
 
Figure 4.17: Histograms showing average volume of aggregated H50Q on the mica surface. The 
lengthy lag phase in forming fully matured fibrils is confirmed by the massive amyloid signal at day 
20. The fibril load is more in higher stoichiometries compared to that at lower ratios. The presence 
of peptide enhances the fibril formation relative to 1:0.  
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4.3.3 Reversal assay 
The effect of PCA winners on breaking down the matured fibrils was also studied using 
reversal experiments. The peptides were added in molar ratios of 1:0.1, 1:1, 1:2, 1:5 and 
1:10 (mutant: peptide) to the fully grown matured fibrils. The amount of fibrils were 
characterised using ThT, CD, and AFM studies after 3 days of post mix incubation.  
4.3.3.1 ThT fluorescence assay 
According to Figure 4.18; with A30P, it shows that the fluorescence was seen to be reduced 
at certain molar ratios. At a ratio of 1:1 the peptide was found to be comparatively effective, 
with a 40 % reduction in signal relative to peptide free (1:0) sample. However, inconsistency 
in concentration dependence was identified at 1:2. In E46K, the peptide was able to break 
down fibrils as a reduced ThT signal of 5-15 % relative to 1:0 was observed in all molar ratios 
except in 1:10. The peptide at 1:10 ratio, interacted with matured fibrils and exhibited a 
greater increase in the fluorescence intensity. According to ThT data, the PCA peptide at any 
molar ratio was unable to breakdown or reverse the aggregation process in A53T. An 
increase of 8-25 % in the lower stoichiometries and 40 % in higher molar ratio was observed 
in reversal approach. In H50Q, 20 day old matured fibrils were used for this assay and the 
ThT data shows a slight reduction of 5 % in 1:5 molar ratio. 
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Figure 4.18: ThT fluorescence data(Reversal): In A30P (blue bar), 40 % fibril breakdown at 1:1, 10-12 
% breakdown at 1:5 and 1:10, but an increase found in 1:2. This discrepancy confirms the presence 
of a secondary structure unable to bind ThT which is later confirmed by CD and AFM.  In E46K (red 
bar), 5-15 % reduction in the ThT signal was found in smaller ratios of 1:0.1, 1:1, 1:2, and 1:5. But the 
ThT signal increased by 177 % in 1:10 might be showing an interaction of peptide at higher 
concentration with matured fibrils. In A53T (green bar), the peptide at any molar ratio is unable to 
breakdown matured fibrils. But an increase of 8-25 % in 1:0.1, 1:1, 1:2, 1:5 and 40 % in 1:10. In H50Q 
(violet bar), the peptide at 1:5 shows a slight reduction of 5 % in the amyloid content relative to 1:0. 
All the other ratios show an increased amyloid secondary structure.  
 
4.3.3.2 CD assay 
In the case of A30P (Fig 4.19.a), the inconsistency with concentration dependence was 
analysed using CD. CD data confirmed the presence of increased secondary β-structure in all 
molar ratios relative to peptide free (1:0) sample. The inconsistency with ThT data might be 
due to the presence of some species which are unable to bind ThT.  In E46K (Fig 4.19.b), the 
spectra showed the retention of 218 nm signal similar to that of 1:0.  In A53T (Fig 4.19.c), 
the increase in ThT signals at all molar ratios is confirmed by CD showing more β-signal 
compared to 1:0. In H50Q (Fig 4.19.d), the CD spectra is inconsistent with ThT signal 
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identified in 1:5 and 1:0.1.AFM imaging was undertaken to visually identify the nature and 
amount of fibrils formed in each mutant during the reversal approach. 
  
  
Figure 4.19: CD Spectra (Reversal) of (a) A30P (b) E46K (c) A53T and (d) H50Q: In A30P, the CD data 
(Fig a) shows an increase in the secondary structure (218 nm signal) at all molar concentration and 
the discrepancy with ThT data confirms the presence of a secondary structure unable to bind ThT. In 
E46K, the CD data inconsistently shows an increased β-signal relative to peptide free (1:0) sample in 
all molar ratios (Fig b). Consistent with ThT data, CD (Fig c) confirms an increase in the secondary 
signal (218 nm) at all molar concentrations in A53T. In H50Q, 1:0.1 ratio shows a reduced 218 nm 
signal but in contrast no reduction was seen in the ThT signal (Fig d). 
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4.3.3.3 AFM studies                   
AFM imaging (Fig 4.20) and analysis (Fig 4.21) were undertaken for the aliquots taken from 
the same samples used for ThT and CD studies. In A30P and E46K, long fibrils were seen 
entirely covering the mica sheet surface in all samples. AFM images confirm the presence of 
fibrils consistent with CD data. In E46K, 1:0.1 exhibited a similar pattern of fibrils to that of 
1:0 with slightly less abundance. In 1:10, the mica sheet was entirely covered with bundles 
of matured fibrils. In A53T, there was no much difference in the amyloid load compared to 
1:0 in the lower stoichiometries. At higher ratios, abundant protein clumps were seen as if 
the peptide involved in association of fibrils to form clumps. In H50Q, abundant protein 
clumps were seen in all samples with no reduction in the amyloid load compared to 1:0 at 
any of the molar ratios. In summary, the PCA derived peptides has minimal effect in 
breaking down the fibrils or reversing the mutant’s aggregation process. 
                          
Figure 4.20: AFM images (Reversal): showing the presence of amyloid fibrils in the reversal 
approach. The images were taken for 1:0, 1:0.1, 1:1, 1:2, 1:5 and 1:10 after 3 days of post mix 
incubation. In A30P, long fibrils of 4-8 µm can be seen in 1:0. Addition of peptide at various molar 
concentrations show negligible reduction in the amyloid load. In E46K, inconsistent with the ThT 
A30P 
 
E46K 
 
A53T 
 
H50Q 
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signal, bundles of matured fibrils covering up the entire mica surface can be seen in 1:10. 1:0.1 
sample showed both long fibrils of 4 µm and clumps of aggregated species. Varied lengths of fibrils; 
approximately 1-4 µm were found in other molar ratios. In A53T, 1:0.1 to 1:2 resembles that of 1:0. 
Consistent with higher signals in ThT and CD, the rich clumps of protein fibrils can be seen initiated in 
1:5 where as it is abundant in 1:10 . Addition of peptides at various molar concentrations show 
negligible effect in reducing the amyloid load.  
 
Figure 4.21: Histograms showing average volume: of mutants in the presence or absence of PCA 
peptide on the mica surface. In A30P, increased amount of matured fibrils unaltered by peptide at 
all molar concentration confirms the inability of A30P winner to reduce amyloid content in reversal 
approach. In E46K, reduced amount of fibrils were seen in lower stoichiometries shows the absence 
of larger amyloid species compared to increased amyloid content in the higher stoichiometries. The 
peptide is comparatively effective in breaking down the matured fibrils at 1:1 and 1:2 ratios. In A53T, 
increased amyloid volume relative to 1:0 can be seen in all molar ratios confirming the presence of 
large amyloid structure not broken down by peptide at any concentrations. In H50Q, molar ratio 1:2 
shows a slight reduction relative to 1 to 0. Increased amyloid load were seen in all the other molar 
ratios.  
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4.3.4 Cell toxicity: MTT assay 
MTT cell viability assay was performed to verify the effect of extracellular mutant α-syn 
deposits on rat pheochromocytoma (PC12) neuronal-like cells. The assay determines the cell 
viability using the reduction of water soluble MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) into insoluble purple coloured formazan which was then 
determined by OD at 570 nm. The formazan concentration determines the number of viable 
cells. All experiments were performed in triplicates (technical replicates) as a part of single 
experiment and the error bars were calculated as the standard deviation of all errors. 
Mutant concentration of 5 µM was used for the MTT assay. In the assay PC12 cells were 
grown in isolation, with 5 μM mutant α-syn, with mutant: peptide ratios (1:0.1, 1, 2, 5, and 
10), and with peptides in isolation (0: 0.1, 1, 2, 5, and 10). A30P, E46K and A53T were 
incubated for ten days under aseptic conditions while H50Q incubated for 20 days. Then the 
PC12 cells were added and incubated for 24 hrs followed by 4 hrs in MTT dye.  Figure (4.22) 
shows that the cell viability across a range of mutants-peptide ratios relative to PC12 cells. It 
appeared that the matured fibrils formed by each mutant after their incubation period were 
toxic to the cells.  The A30P peptide and E46K peptide showed moderate cell revival in 1:1 
ratio. A maximum efficiency of 50 % was shown by A53T peptide in three molar 
stoichiometries. H50Q fibrils found to be less toxic compared to other mutants. The 
aggregated species in the presence of H50Q winner showed approximately 37 % cell survival.  
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Figure 4.22: MTT assay: showing cell viability with α-syn mutants alone (1:0) and with PCA peptides 
at various molar ratios. In A30P, only 1:1 showed a slight revival of 19 % PC 12 cells. In E46K, again 
the molar ratio 1:1 showed a reasonable cell revival of 45 %. In A53T, 1:1, 1:2 and 1:5 showed 50 % 
cell survival. Compared to all other mutants H50Q was less toxic to the PC12 cells, 25 % of cells were 
viable in 1:0. Among all ratios of H50Q peptide, 1:2 showed a 37 % cell survival. The aggregated 
species in all the other ratios of four mutants were considerably toxic to the PC12 cells. 
Following the (target: peptide) study, the effect of PCA peptides in isolation on PC12 was 
studied using MTT assay. Though the peptides in isolation showed minimal tendency of self-
aggregation in the ThT, CD and AFM assays, it causes considerable loss in PC12 cells (Fig 
4.23). The 10 day old A30P, E46K, A53T peptide winners and 20 day old H50Q peptide 
winner were used in this assay.  A30P winner peptide unexpectedly induced PC12 cell death 
in various molar ratios. Approximately 50 % cells died with E46K peptide winner at higher 
concentrations. A53T peptide and H50Q peptide were showing minimal effect on PC12 cells 
in various ratios.  
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.
 
Figure 4.23: MTT assay with PCA peptides in isolation at various molar ratios (0:0.1, 0:1, 0:2, 0:5 
and 0:10). The assay was performed by incubating PC12 cells for 24 hours; with peptides alone 
allowed to aggregate along with main characterisation experiment. The A30P winner showed 75-90 % 
toxicity to PC 12 cells in various stoichiometries range. Cell loss of 15-25 % in the lower ratios and 50 % 
at the higher concentrations were seen in E46K winner peptide. In A53T, 25 % reduction in PC 12 
cells was seen in lower stoichiometries. H50Q showed a cell death of 20-35 %. 
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4.3.5 Control experiments 
4.3.5.1 PCA derived peptide in isolation 
As a control experiment, the PCA derived peptides were studied in isolation using ThT, CD 
and AFM considering the same molar ratios used for the characterisation studies. The 
peptides at molar ratios; 0:0.1, 0:1, 0:2, 0:5 and 0:10 were incubated at same conditions 
used for mutant: peptide characterisation experiments. The ThT signal in each case was 
considerably smaller compared to peptide free (1:0) sample confirms the lack of self-
aggregating property of PCA peptides (Fig 4.24). The retention of 200 nm signal in the CD 
spectra for all the peptides in all molar ratios (Fig 4.25) confirms the random coil structure 
exhibited by peptide even after its full tenure of incubation. The absence of any oligomeric 
or fibril structure in AFM data (Fig 4.26) also supports the above points.  
 
Figure 4.24: ThT fluorescence data: of PCA peptides in isolation at concentrations of 0:0.1, 0:1, 0:2, 
0:5 and 0:10 (mutant: peptide) represented on the left side of the figure. The ThT signals of end 
point samples are considerably small compared to that of the peptide free (1:0) sample shown on 
the right side of the figure; plotted on a secondary ‘y’ axis (ThT fluorescence (1:0): A30P= 966.7 mAu, 
E46K= 476.4 mAu,  A53T= 604.9 mAu and H50Q= 46.78 mAu). 
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Figure 4.25: CD spectra: showing retention of random coil for the peptides at different ratios. This is 
a representative image as all the PCA derived peptides of each mutant exhibited similar pattern. The 
data confirms the lack of self aggregating properties of peptides at the end of incubation period. 
 
                            
Figure 4.26: AFM images: of PCA peptides at concentrations 0:0.1, 0:1, 0:2, 0:5 and 0:10. The images 
show that the peptide do not self-aggregate to form oligomers or fibrils in isolation even after 10 
days of incubation as consistent with ThT and CD data. In A53T peptide, small oligomeric structures 
were visible at 0:5 and 0:10 which could be anticipated as precipitation of peptide at high 
concentrations (2250 and 4500 µM respectively). 
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4.3.5.2 Positive and negative control experiments 
To confirm the reliability of mutants and PCA derived peptides, control experiments with 
negative control peptide (SGSSGTSSGTSG) and positive control peptide [VAQKTmV (Madine 
et al., 2007)] were performed along with the peptide characterisation studies against all 
four mutants. The negative control (SGSSGTSSGTSG) peptide is a GS linker used in PCA. The 
N-methylated α-syn77-82 (VAQKTV) peptide was used as positive control to disrupt α-syn 
aggregation. ThT, CD and AFM assays were performed to analyse its effect on the 
aggregation of mutants. The mutants were allowed to fibrillise with each of the two control 
peptides at molar ratio 1:1 until it reached maturation. All the readings were taken at the 
final day of incubation i.e., day 10 for A30P, E46K, A53T and day 20 for H50Q. According to 
the ThT data (Fig 4.27), the positive control peptide showed approximately 5-25 % reduction 
in total amyloid load formed by various α-syn mutants. As expected the negative control 
peptide did not prevent the aggregation. 
 
Figure 4.27: ThT fluorescence data: shows the effect of positive control and negative control 
peptides on mutants at molar ratio 1:1 relative to peptide free (1:0) sample. The positive control 
peptide (blue solid bar) showed 23 % reduction in A30P, 17 % in E46K, 4 % in A53T and 11 % in H50Q 
in total amyloid content after 10 days of incubation. The negative control peptide (green solid bar) 
showed minimal effect on A30P, E46K and H50Q amyloid load relative to 1:0. It showed a 12 % 
increase in A53T. 
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CD experiments were undertaken using aliquots taken from the same stock samples used 
for ThT experiments. In the Fig 4.28, β-sheet structure was shown by four mutants at the 
end of incubation period. Consistent with ThT data, reduced β-signal was seen in A30P, E46K 
and H50Q mutants. There was co-existence of β-sheet with random coil seen in A53T in the 
presence of positive control peptide. The negative control peptide showed an increased 218 
nm signal in A53T. Following CD, AFM imaging was also performed to confirm the presence 
of fibrils in each condition (Fig 4.29). 
                          
                          
Figure 4.28:  CD spectra: showing the effect of positive control and negative control peptides on (a) 
A30P, (b) E46K, (c) A53T and (d) H50Q at molar ratio 1:1. All peptide free mutant samples (1 to 0) 
showed β-sheet structure at the end of incubation period. In A30P the positive peptide showed a 
reduced β-content along with a random coil signal and unaltered by negative control peptide. The 
effect of positive peptide in E46K and H50Q exhibited a dominant random coil signal. Consistent 
with ThT data, A53T showed an increased 218 nm β-signal co-existing with the random coil 
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structure. Increased β-signal is visible in A53T with the negative peptide as of in ThT. In contrast to 
ThT, H50Q showed a reduced β-signal with negative control peptide.  
 
                                       
Figure 4.29: AFM images showing the effect of positive and negative control peptide on aggregation 
of α-syn mutants. All mutants (1:0) formed fibrils or aggregates after the incubation period. The 
increased ThT and CD signal shown in A53T with positive control peptide was not visible as fibrils in 
AFM image. There were oligomeric structures found abundantly in mica sheet. Reduction of fibrils 
was seen in A30P and E46K with positive peptide. The fibrils found in H50Q in the presence of 
positive control peptide were not prominent compared to 1:0. Negative peptide replicated 1:0 
images in all mutants.  
 
 
 
 
 
A30P 
 
 
 
 
E46K 
 
 
 
 
 
A53T 
 
 
 
 
H50Q 
             1:0                  Positive C          Negative C 
123 
 
4.4 Discussion 
In this chapter the peptides screened from the semi-randomised libraries by PCA were 
characterised to identify the peptide efficacy in lowering the toxicity of full length mutant α-
syn1-140. As seen in the previous chapter the peptides were designed on scaffold of 71-82 
region and anticipated the inhibition by specifically binding to full length α-syn mutant. The 
ThT, CD and AFM data of endpoint samples in the Fig 4.30 shows the effect of peptides on 
each mutant during its aggregation in the presence of PCA derived peptides. 
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Figure 4.30:  (a) ThT data relative to peptide free sample (1:0, represented by black bold line) in %, 
(b) Ellipticity (mdeg) at 218 nm representing β-sheet formed during aggregation and (c) Average 
volume of fibrils seen in the AFM images. All these data represent the end point samples at different 
molar ratios of four mutants.  As seen in (Fig a), none of the peptides at any molar ratio inhibited the 
aggregation except 1:10 ratio of A53T. Among all the PCA peptides, ThT data shows that the A53T 
peptide is comparatively effective on A53T aggrgegation as the fibril growth is seen deteriorating . In 
consistent with the ThT data, CD data confirmed the development of β-sheet structure at higher 
stoichiometry showing the formation of fibril species that are unable to fix ThT dye (Fig b). The 
moderate inhibition or delaying property of A53T peptide can be seen reflected in AFM images (Fig 
c). 
Collectively the data confirms that the PCA screened peptides lead to moderate levels of 
antagonistic property against A53T aggregation, while low efficacy against A30P, E46K and 
H50Q. MTT assay also assured a 50 % cell survival with A53T peptide at lower 
stoichiometries.  
In the case of A30P, even though a small reduction was observed in ThT signal during the 
mid-phase of incubation, it was inconsistently denied by CD results which confirmed the 
development of increased β-signal as the incubation progresses. A slight delay in the 
aggregation process was seen in ThT data confirmed later by AFM images especially in the 
lower stoichiometries while higher ratios were identified to enhance fibril formation. The 
proline residue in A30P peptide winner (77HPQN80) was anticipated to facilitate the 
secondary structure into turns or helices and thus disfavouring β-strand due to its 
conformational rigidity of cyclic pyrrolidine side chain and inability to participate as 
hydrogen bond donor. There might have an overruling of ‘proline effect’ by adjacent 
residues in the later phases as they are polar and may have participated in hydrogen bond 
formation. The peptide failed to inhibit the aggregation process as the residues 71-82 might 
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not be an appropriate target to design a peptide library against A30P. The MTT data also 
confirms the toxicity of aggregated species formed in all stoichiometries which are non-
viable to the cells. Further studies needed so that the residues in a different target region 
can be considered for developing potent peptide inhibitors against A30P aggregation.  
In E46K, the peptide in all ratios caused enormous increase in ThT and CD signal confirming 
the formation of considerable load of amyloid fibrils. Notably small fibres were identified in 
all stoichiometries compared to that formed in 1:0. The higher ratio 1:10, showed a 
distinguishable association of fibrils into bundles. A small reduction was seen in ThT during 
reversal approach in lower stoichiometries but was not supported by CD. The volume 
histogram analysis of AFM data showed a slight decrease of fibril content in lower 
stoichiometries supports ThT data. MTT assay showed the aggregated species in all 
stoichiometries induce cell toxicity. The E46K peptide has randomised residues; 77NQNN80 
which are polar and favours β-confirmation by hydrogen bond formation. N and Q have 
opposite effects on amyloid formation. I assumed that the N richness would promote the 
formation of benign, self-ordered amyloids. Although short peptides like A30P and E46K 
winners contain glutamine which could bind to the target protein, making it Q rich. Q 
residue is known to produce toxic, non-amyloid disordered conformations. The uncharged 
polar side chain usually locates on the outside of protein could be a protein-protein 
interaction module (Halfmann et al., 2011). In summary, E46K peptide failed to inhibit 
amyloid formation and as suggested previously the target region 71-82 might not be 
suitable for designing peptide inhibitors.  
The inhibitory effect shown by A53T winner peptide was moderate. The peptide has 
randomised residues 77DNKE80, shows a reduced hydrophobicity relative to α-syn71-82. The 
substitution of hydrophobic residues may pass the threshold required to prevent 
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fibrillisation. The peptide was identified to reduce the ThT signal in the mid-phase after a 
larger fluorescence exhibited during initial phase in the lower stoichiometries. And also 
prominent cell recovery was identified in MTT assay suggests a less toxic species formed in 
the lower stoichiometries. A higher proportion of polar/charged residues being selected 
were assumed to show anti-amyloid property. A reduced ThT signal of 34 % was identified in 
the higher ratio of 1:10. Though it wasn’t supported by CD data or AFM images, as if there 
was an accumulation of distinct β-sheet structure which is unable to bind ThT dye. A few 
physical differences in the generation of fibrils can cause fluorescence differences. ThT 
binding would be less efficient on thick, large clumps of fibrils as the dye may not penetrate 
thick clumps as isolated fibrils (Petkova et al., 2009). More structural studies like labelling 
fibril samples and solid-state NMR spectroscopy can give a clue to define the effect of PCA 
peptides on the possible ThT binding sites (involving the benzyl group) on amyloid fibrils (Ye 
et al., 2008). The peptide was found to enhance the formation of thick bundles of fibrils at 
higher stoichiometries. As the peptide contains aspartate as well as glutamate which are 
frequently involved in protein active or binding sites (Betts and Russell, 2003), the peptide 
was found to have interacted with the target protein.   
The PCA peptide against H50Q aggregation with randomised sequence 77NSSD80, is found to 
enhance rather than inhibit fibrillisation. I speculate that the PCA peptides initiated the 
aggregation process as the ThT signals were comparable with that of other mutants in the 
inhibition assay as the signals were low in the sample without peptide (1:0). The presence of 
serine with its primary hydroxyl group participates extensively in hydrogen bond formation. 
The higher stoichiometries provided more serine residues to form abundant β-amyloid 
species as per ThT and CD data. Discrepancy was found in ThT and CD data in reversal assay 
suggesting the inability of H50Q peptide to function as a β-breaker. In contrast to all the 
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available studies about H50Q aggregation, there was a long lag phase observed, delaying 
the aggregation process. It is unclear that the H50Q mutant showed a small ThT value 
compared to the other mutants (section 4.3.2.1). All the PCA peptides in isolation did not 
exhibit any self-aggregating property and thus confirmed the signals are truly from the 
fibrils formed by mutants in various conditions.  A moderate level of efficacy was identified 
in the reversal approach in breaking down the matured fibrils among A30P and E46K but no 
reversal effect seen in A53T or H50Q. In conclusion, in vivo selection approach was used to 
derive a range of peptides against mutant’s aggregation. Though the peptides are not 
satisfactorily terminating the aggregation process as anticipated at the PCA level, we can 
conclude that the 71-82 region is inappropriate for the development of an antagonistic 
peptide. Later the study leads to focus on a different target region to develop inhibitor 
peptide against α-syn aggregation. 
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Chapter 5: Semi-rational design combined with PCA approach using an α-
syn45-54 template to derive peptide antagonists of α-syn aggregation 
5.1 Introduction 
Many researchers have focused on the 71-82 region of α-syn during design of inhibitors as it 
is responsible for the aggregation of the full length protein. As I discussed in the earlier 
chapters, the previous peptide libraries were designed based on this scaffold. In the 
literature; non-modified peptides (El Agnaf et al., 2004; Sciarretta et al., 2006) and N-
methylated peptides (Bodles et al., 2004, Madine et al., 2008) were also designed based on 
this region. However, many of the known point mutations in the α-syn gene associated with 
early onset PD are located between 45-54 region with A30P located in close proximity. This 
chapter thus focuses on designing a new library based on the fact that this region and its 
residues play a vital role in modulating the structure of α-syn and thereby influencing 
amyloid formation. These mutations lead to structural changes such as decreased α-helicity, 
increased β-sheet propensity, and an increase in either the rate or number of oligomers 
formed during α-syn aggregation (Conway et al., 2000, Li et al., 2001, Bussell et al., 2001, 
Choi et al., 2004, Greenbaum et al., 2005, Ghosh et al., 2013,  Rutherford et al., 2014). A 
peptide library containing 209,952 members was consequently created using α-syn45-54 as 
the template.  The amino acids options corresponding to E46K, H50Q and A53T were also 
included while designing the library. This chapter utilises an approach which successfully 
produced a peptide sequence that could antagonise α-syn aggregation. This could provide a 
basis for future drug development against PD. 
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5.2 Experimental approach 
(1) Expression and purification of α-syn: The protein was expressed and purified according 
to the methodology in chapter 2 and 3. 
(2) PCA: The library was screened using PCA to derive a peptide capable of interacting with 
full length wild type α-syn. 
(3) Peptide 45-54W synthesis: The peptide was synthesized using a Liberty BlueTM 
microwave peptide synthesizer [CEM; Matthews, NC] according to the methods outlined in 
chapter 2. 
(4) Peptide characterisation: Continuous amyloid growth was monitored by ThT 
fluorescence to provide real-time information on the formation of amyloid. Structural 
studies were additionally monitored by CD and, AFM, while SDS-PAGE analysis was also 
performed. Collectively these approaches were used in order to assess the fibril load 
reduction and the changes in the fibril morphology. Along with that the toxicity of the 
amyloid fibrils was studied by MTT assay on PC12 cells.  
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5.3 Results 
A peptide library was generated based on the α-syn45-54 region and PCA used to screen for 
an interaction with the full length α-syn1-140 target. The library incorporated the wild-type 
sequence along with two, three or six residue options (at positions 46, 50 and 53) at each of 
the positions including three of the known point mutation residues associated with the early 
onset of PD (Fig 5.1). Unlike 71-82, the 45-54 region is not known to aggregate into toxic 
amyloid fibrils in isolation and has not been previously considered in the design of α-syn 
aggregation inhibitors.  PCA was next undertaken to identify the most effective peptide 
antagonist of wild type α-syn aggregation from the library based on 45-54 region. Single 
step selection and competition selection was undertaken, resulting in one clean dominant 
sequence; KDGIVNGVKA from a library size containing 209,952 members (Fig 5.1 and 5.2). 
Wild type α-syn  45K    46E      47G    48V     49V    50H     51G    52V    53A     54T 
Degenerate codons used 
for library construction 
 RAA  VAW  GBG   VTT   VTT  VAW  GBG  VTT  RHA   RCC 
Amino acid options 
encoded by each codon. 
   K         E        G        V       V       H        G       V       A       T 
   E         Q        A        I        I         Q        A       I        V       A 
              N        V        L        L        N        V       L        T 
              K                                       K                            I 
              D                                       D                           K 
              H                                       E                            E 
 
45-54W peptide    K         D        G         I        V       N        G       V       K       A 
Figure 5.1: The residues of wild type α-syn45-54 are shown in the top row with yellow highlight 
showing the three well studied point mutation sites (46, 50 and 53). The second row shows 
degenerate codons used for library construction (R=A/G, V=A/C/G, W=A/T, B=C/G/T and H=A/C/T). 
The amino acid options at each position to generate a 209,952 (2*6*3*3*3*6*3*3*6*2) member 
peptide library are shown in the third row. The wild type options and alternative options including 
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point mutations associated with early onset PD (underlined) are also considered in the library design. 
The PCA selected winner peptide 45-54W (KDGIVNGVKA) is shown in the bottom row. 
 
Figure 5.2: DNA sequencing results showing single-step selection (P0) and competition selection (P1, 
P2, and P6) steps involved in PCA. It shows the emergence of clear dominant peptide sequence 
KDGIVNGVKA from passage 2 until passage 6.  
The PCA derived peptide; KDGIVNGVKA (45-54W) was next synthesized using a Liberty 
BlueTM microwave peptide synthesizer (CEM; Matthews, NC) (methodology detailed in 
chapter 2). The efficacy of peptide to inhibit fibril formation was characterised using ThT, CD, 
AFM, MTT and SDS-PAGE assays. The peptide was also studied in isolation along with the 
characterisation experiments.  
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5.3.1. ThT continuous growth experiments 
ThT binding assay was used to quantitatively determine the amount of wild type α-syn fibrils 
formed in the absence or presence of the 45-54W peptide. Prior to the experiment, α-syn 
was monomerised to confirm the absence of any pre-formed fibrils and the ThT 
concentration was optimised as 90 µM (Fig 5.3) (details in chapter 2). Monomerised α-syn 
was incubated at a concentration of 450 µM and 370C with peptide at four different 
stoichiometries; 1:0.01, 1:0.1, 1:0.5, and 1:1. The peptide was added at time zero to a 
solution containing 90 µM ThT and a fluorescence reading was measured at every five 
minutes over a 4500 minute period. The experiment was performed by continuous mixing 
using a magnetic flea in an LS55 fluorescence spectrophotometer (Perkin Elmer). According 
to the data, the ThT signal was significantly reduced at a 1:1 molar ratio indicating the 
peptide can bind to α-syn and reduce its aggregation propensity. The molar ratio 1:0.5 slows 
down the aggregation rate, but does not prevent aggregation. Dose dependency was 
observed as reduced ThT signals were exhibited by lower stoichiometry ratios. The 
reference peptide; 71-82W (WT-B; shown in chapter 3) and the control peptide; wild type 
45-54 fragment (45-54wt) at 1:1 molar ratios had minimal effect upon α-syn, demonstrating 
sequence specificity for the 45-54W peptide. 
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Figure 5.3: ThT optimisation data showing ThT signal of 450 µM target protein mixed with various 
concentrations of ThT ranging from 0, 1, 10, 50, 100, 250, and 500 µM. The ThT signal was found to 
be flattened at approximately 90 µM and it was considered optimum for the continuous growth 
experiments. 
 
Figure 5.4: Continuous ThT growth. The data show a considerable reduction of   9̴2 % in ThT signal at 
1:1 stoichiometry with 45-54W peptide. The ThT signal at stoichiometry 1:0.5 shows a reduction in 
aggregation compared to that of wild type. At increasingly sub stoichiometric ratios, the greater ThT 
signal indicates a reduced peptide activity in an expected dose-dependent manner. The 0:1 sample 
(peptide 45-54W alone) showed no ThT binding, indicating that it does not have self-aggregating 
property. The control peptides 71-82W (WTB) and wild type 45-54 fragment (45-54wt) at 
stoichiometry 1:1 has no effect upon α-syn, demonstrating sequence specificity for the 45-54W 
peptide. Aliquots of samples at 17 different time points from lag phase, exponential phase and 
stationary phase for inhibitor free; 1:0 sample (black line) were collected for further analysis by CD 
and AFM. The time points were T0= 0 min , T1= 600 mins , T2=1525 mins , T3= 1625 mins , T4= 1700 
mins, T5= 1725 mins, T6= 1735 mins , T7= 1745 mins , T8= 1750 mins , T9= 1825 mins , T10= 1875 
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mins, T11= 1900 mins , T12= 1950 mins, T13= 2100 mins , T14= 2225 mins , T15= 2400 mins ,and 
T16= 4500 mins (End). Aliquots of three time points for the 1:1 sample (T0, T1 and End) were also 
collected for CD and AFM analysis. 
5.3.2 CD assay 
The structural characterisation of ThT continuous growth samples were performed by CD 
spectroscopy. According to the data, a single negative peak at 218 nm corresponding to β-
sheet structure developed. This, along with the loss of minima at   ͠  200 nm corresponding to 
the loss of a random coil structure was identified in 1:0 across the time course (Fig 5.5.a). 
Consistent with the ThT data, α-syn in the presence of 45-54W peptide at 1:1 stoichiometry 
did not progress to a β-sheet structure, but rather retained the random coil signal at 200 nm 
(Fig 5.5.b). The 45-54W peptide showed a similar random coil structure indicating the 
peptide lacks self-aggregating property in isolation (0:1 stoichiometry) after 4500 minutes of 
incubation. The absence of 218 nm signal for α-syn with 45-54W peptide could be 
recognised as increasingly aggregating or precipitating out of the solution. However, AFM 
experiments were undertaken for the same samples as the morphology of species formed 
can be clearly observed in imaging experiments. In these experiments, 45-54W in isolation 
showed no oligomers or fibrils. In addition, the control peptides; WTB or 45-54wt showed 
no effect upon the formation of β-sheet structure, again demonstrating the sequence 
specificity of the 45-54W peptide towards α-syn (Fig 5.5.c-d).  
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Figure 5.5: CD spectra (a) showing the gradual development of a minimum at 218 nm (β-sheet 
structure) across the time course along with loss of a minimum at 200 nm (random coil structure) in 
1:0. (b) The data shows the efficacy of peptide (45-54W) at 1:1 stoichiometry in retaining the 
random coil structure (~200 nm minimum) even after incubation for 4500 mins with no development 
of β-sheet structure. The peptide alone (0:1) showed a similar spectra indicating that it does not 
form β-sheet structure in isolation. (c) The data shows the wild type α-syn 45-54 sequence at 
stoichiometry 1:1 had no effect upon transition of random coil to the β-sheet structure. It also did 
not adopt β-sheet structure in isolation. (d) Similarly, the previously studied peptide; WTB based on 
α-syn71-82 considered here as a negative control which showed no effect upon conversion to the β-
sheet structure and loss of random coil at stoichiometry 1:1. And also the peptide in isolation did not 
adopt a β-sheet structure.  
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5.3.3 AFM imaging 
The samples used in ThT continuous growth experiments and CD assays were used for 
imaging. 5 µl of endpoint samples of all stoichiometries along with peptide in isolation (0:1) 
were imaged (Fig 5.6.a). Aliquots were taken and imaged in detail at different time points 
for 1:0 (Fig 5.6.b) and 1:1 since it was found to be the most effective in ThT experiments (Fig 
5.6.c).  At this stoichiometry, a significant reduction in the fibril content was observed 
relative to inhibitor free; 1:0 control. No fibrils were observed in 45-54W (0:1) in isolation. 
Gradual increase of fibril content was identified in 1:0 across 17 time points. The control 
peptides; WTB and 45-54wt had no effect upon fibril formation (Fig 5.6.d-e) confirming the 
specificity of α-syn towards 45-54W peptide. All images were taken at 20 µm scan size at 
room temperature. The image files were examined directly using WSxM v5.0 (Nanotec 
Electronica S.L., www.nanotec.es) and flattened before processing. (Kad et al., 2001 & 2003). 
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Figure 5.6: AFM images (a) showing the endpoint samples (4500 mins) for all molar ratios used in 
continuous ThT experiments. A considerable reduction in fibril load is observed at 1:1 stoichiometry. 
All other molar ratios showed no reduction of fibril load compared to 1:0. The 45-54W peptide (0:1) 
showed no aggregation in isolation. (b) Images showing gradual fibril growth along various time 
points (T0 to T16) for 1:0 as mentioned in ThT continuous growth experiments. (c) A considerable 
reduction of amyloid content along three time points (T0= 0 min, T1=2250 mins, and T2=4500 mins) 
was observed with 45-54W at 1:1 ratio. (d) Images showing no fibril reduction with wild type α-syn45-
54 fragment at 1:1 stoichiometry along three time points (T0=0 min, T1= 2025 mins, and T2=4500 
mins). (e) No amyloid reduction observed with negative control peptide (71-82W; WTB) at 1:1 ratio 
along three time points (T0=0 min, T1= 1725 mins, and T2= 4500 mins).  
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5.3.4 MTT cell toxicity assay 
To assess the effect of 45-54W peptide on cell viability as well as the ability of this peptide 
to prevent α-syn toxicity, MTT assays were performed using PC12 neuronal cells. Control 
experiments were performed to establish that neither ThT and/or buffer have any effect on 
the cell viability (Fig 5.7.a). Next, α-syn at a concentration of 5 µM with buffer and ThT 
leading to a large reduction in cell viability was performed. The experiments were next 
repeated using 45-54W at various sub- and super-stoichiometric ratios. The most efficient 
peptide ratio of 1:1 improved cell viability by 65-85 % relative to α-syn in isolation (Fig 5.7.b). 
Consistent with ThT and AFM data, the sub-stoichiometric ratios showed no effect of 
peptide on α-syn toxicity. A partial cell recovery in cell viability was observed at a molar 
ratio (α-syn: 45-54W) of 1:0.5, with the effect maximised at a ratio of 1:1. This effect was 
not improved at increasingly higher molar ratios was identified (Fig 5.7.b). In addition, MTT 
experiments using different time point samples taken during continuous growth assay 
demonstrated that the toxicity of α-syn increases progressively with time. The most toxic 
species was found within the stationary phase of fibril growth (Fig 5.7.c). MTT experiments 
using control peptides; WTB and 45-54wt demonstrate that the peptides have minimal 
effect upon α-syn toxicity, but are not toxic in isolation (Fig 5.7.d). Finally, increasing 
concentrations of 45-54W in isolation also demonstrated that the peptide is not toxic to the 
cells. 
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Figure 5.7: MTT cell viability assays showing inhibitory effect of 45-54W peptide on α-syn 
aggregation relative to PC12 cells alone. (a) Shown are i) PC12 cells alone, ii) PC12 cells in potassium 
phosphate buffer, iii) PC12 cells in buffer and ThT, iv) PC12 cells plus α-syn (5 µM) in buffer, v) PC12 
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cells with α-syn (5 µM) in buffer and ThT, and vi) PC12 cells with α-syn and 45-54W at 1:1 molar ratio. 
α-syn with 45-54W showed a cell revival of   ͠  85 %. (b) Increasing stoichiometries of α-syn: 45-54W 
showed dose dependency. No effect of cell revival observed in 1:0.01 or 1:0.1. A partial cell recovery 
of   ͠  28 % can be observed in 1:0.5 which increases at 1:1 to   ͠  65 % and becomes progressively less 
effective at increasingly higher stoichiometries. All the samples were endpoint samples taken from 
continuous growth experiments after 4500 mins under sterile conditions. (c) Data demonstrates that 
cyto-toxicity increases as the sample ages and reaches its maximum within the stationary phase of 
continuous growth experiment. (d) Control MTT experiments: Increase in concentrations of 45-54W 
in isolation and as a result, an unaltered MTT signal demonstrates that the peptide is not toxic to 
PC12 cells on its own.  MTT experiments using 45-54wt (bold surround) or 71-82W; WTB (hashed 
surround) peptides show that both had no effect on toxicity reduction at 1:1 and also not toxic in 
isolation. 
5.3.5 SDS PAGE analysis 
The endpoint samples from continuous growth experiments were used for the SDS PAGE 
analysis. In the Figure 5.8, two clear bands at   ͠  40 kDa and    ͠  60 kDa suggesting the presence 
of α-syn trimers (40/14.7 = 2.72) and tetramers (60/14.7 = 4.08) were found in 1:0, 1:0.01, 
1:0.1 and 1:0.5 samples.  At stoichiometries of 1:1 or higher these bands disappeared and 
were replaced by three lower molecular weight bands.  The α-syn: 45-54W complex may 
have appeared as a band at   ͠   15 kDa and the others two are below the resolution limit of 
the gel but could be representing monomeric α-syn (14.7 kDa) and inhibitor alone (1 kDa). 
The molecular weight was determined by graph analysis of log MW vs. relative migration 
distance. SDS analysis demonstrates that the peptide is able to interact with α-syn and 
lower oligomeric state possibly to the monomer. Since these species are observed on a 
denaturing gel, the precise oligomeric states observed must be treated with some caution. 
141 
 
However, the results provide further evidence that the 45-54W peptide is able to interact 
with α-syn and that the major effect is to reduce the size of oligomers that are populated 
within the sample. 
 
Figure 5.8: SDS PAGE analysis showing the endpoint samples of continuous growth experiments 
after 4500 mins. At 1:0, 1:0.01, 1:0.1, and 1: 0.5, two clear bands at   ͠  40 kDa and   ͠  60 kDa can be 
seen suggesting the presence of α-syn trimers and tetramers. At stoichiometries 1:1 or higher, these 
bands are absent and are replaced by three bands with lower molecular weight. The band at   ͠  15 
kDa may represent α-syn: 45-54W complex. The second and third bands are below the resolution 
limit of the gel but are likely to represent monomeric α-syn (14.7 kDa) and the inhibitor alone (1 
kDa).  
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5.4 Discussion 
To develop a peptide-based inhibitor the approach taken in this chapter was to create a 
peptide library scaffold on 45-54 region of wild type α-syn in which the known familial 
mutants in the early onset of PD are found. All the mutants were reported to increase the 
aggregation rate of α-syn, increased numbers of oligomers and its associated toxicity. All the 
residues in the 45-54 region were replaced by two, three or six residue options, which 
includes wild type options as well as the mutations, giving rise to a library containing 
209,952 members. In the PCA selected winner, the wild type residues were re-selected (at 
45K, 47G, 49V, 51G, 52V) in half of the ten positions while the remaining five resulted in 
new selections (E46D, V48I, H50N, A53K and T54A). As per the thermodynamic and NMR 
studies, these newly selected residues can be ordered according to their β-sheet propensity 
as D<A<K<N (Smith et al., 1994; Nowick et al., 1997). Among ten residues of the peptide, 
two are Gly which is expected to have low β-sheet propensity (Nowick et al., 1997; Smith et 
al., 1994; Minor et al., 1994). Asp residue in the 45-54W might have played a significant role 
in maintaining the stability of native α-syn. Studies suggest that the age-related chemical 
modifications of aspartyl residues to the form of succinimide or isoaspartyl methyl ester can 
initiate nucleation events in amyloidogenesis of many neurodegenerative disorders 
(Orpiszewski et al., 1999). However, the propensity for β-sheet depends on many factors 
such as the position of residues whether exposed or buried conformation, the folding 
properties such as the twist of a β-strand or association between two β- sheets (Fujiwara et 
al., 2012).  
According to the results, in the continuous amyloid inhibition growth at stoichiometry 1:1, 
ThT signal is held at   ͠   8 % relative to the inhibitor free (1:0) sample. At molar ratio 1:0.5, 
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fibrillisation is considerably delayed, taking approximately twice the time to reach the 
fluorescent intensity of the 1:0 sample. An expected dose dependency is observed in 1:0.1 
or lower stoichiometries as the inhibitory property is lost and followed the sigmoidal curve 
similar to that of inhibitor free sample; 1:0. The peptide efficacy shown in continuous ThT 
growth experiments is supported by CD data which showed the retention of random coil 
signal at 1:1 sample. Moreover, the absence of fibrils is observed directly by AFM imaging. 
The MTT data showed that the toxicity associated with α-syn aggregation is almost reduced 
and showed a cell survival of   ͠   65-85 % in the presence of 45-54W peptide. Finally, the data 
is verified by SDS-PAGE analysis that shows a shift from higher to lower molecular weight 
species, in the presence of 45-54W at 1:1 stoichiometry or higher.  
In conclusion, I have combined semi-rational design with intracellular PCA to validate this as 
an effective approach for the development of α-syn antagonists. Based on 45-54 region, I 
have designed a library and have created a potent peptide inhibitor against α-syn 
aggregation. In the future it may be possible to derive more potent inhibitors based on this 
region or this point to a new target for designing new inhibitors which can be modified into 
drugs to slow or even prevent the onset of PD.  
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Chapter 6: General Discussion and Conclusion 
This thesis focuses on semi-rational design combined with intracellular PCA to screen for 
peptide antagonists of wild type and mutant α-syn aggregation. Specifically, I sought to 
identify peptides capable of preventing or reversing the formation of toxic oligomers. 
Structural studies on α-syn have revealed a crucial region which is responsible for the 
aggregation of α-syn (Waxman et al., 2010; Madine et al., 2008; Giasson et al., 2000; El-
Agnaf et al., 1998). Therefore peptides were screened using library templates based on 
amino acids 71-82 initially and later on the 45-54 region of α-syn in which many key 
mutations associated with early onset PD are found. In both cases I targeted the peptide-
based libraries at the wild type protein or again by using mutated versions associated with 
early onset PD. In our work, PCA was preferred over other library screening strategies for 
several reasons. The most prominent being that, as it is carried out in vivo; aggregation 
prone, insoluble, bacterial protease sensitive, unstable, and weak binders will be removed 
at the screening level itself. Thus, the first phase of this thesis (Chapter 3) successfully 
employed PCA to screen three peptides against full length wild type α-syn. The ability of the 
PCA peptides to prevent or revert the aggregation were analysed using ThT, CD, and AFM 
assays while the ability to reduce α-syn toxicity was verified by MTT assay using Rat 
phaeochromocytoma (PC12) neuronal like cells. According to the data, the peptide WTC 
functioned moderately by delaying the formation of α-syn. As discussed in Chapter 3, these 
effects of WTC are speculated to be of different amino acid substitutions in the peptide 
compared to the target sequence. For instance, V77P and K80G; the two substitutions of 
residues in the peptide sequence might have reduced the fibril propensity of the parent 
protein (Nowick et al., 1997; Smith et al., 1994; Waxman et al., 2010). Reduced toxicity was 
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observed during MTT assay effectively in the lower stoichiometries (1:1 and 1:2) in all the 
three peptides as it showed 30-55 % of cell survival. The three peptides were confirmed to 
have minimal effect during the reversal assay. However, from the initial phase; the main 
objectives achieved were: PCA was successfully used to screen three peptides, one peptide 
showed a positive result in delaying the aggregation, and finally the peptides showed 
moderate signs of reducing α-syn toxicity during MTT assay. Following this work, Chapter 4 
dealt with the characterisation of the PCA peptides against aggregation of α-syn mutants. 
Peptides were screened against full length A30P, E46K, A53T and H50Q. The A53T peptide 
only showed a moderate level of antagonistic property against A53T aggregation, while 
minimal efficacy was exhibited by A30P, E46K and H50Q peptides. MTT assay also assured a 
50 % cell survival only with A53T peptide at different stoichiometries (1:1, 1:2, and 1:5). A 
moderate level of efficacy was identified in the reversal approach in breaking down the 
mature fibrils among A30P and E46K but no reversal was seen in A53T or H50Q. The 
peptides did not satisfactorily prevent the aggregation process as anticipated at the PCA 
level; we concluded that the 71-82 region is inappropriate for the development of an 
antagonistic peptide. Later Chapter 5 solved this issue by using a new library based on a 
different target α-syn45-54. This sequence was considered as it accommodates many of the 
known point mutations associated with early onset PD. It was based on the fact that this 
region plays an important role in modulating the structure of α-syn and thereby influencing 
the rate of amyloid formation. At the PCA level all the residues in the 45-54 region were 
replaced by different options that included wild type and mutations, to create a library of 
almost 210,000 members. The derived peptide KDGIVNGVKA (45-54W) and its effect on 
aggregation of full length α-syn was characterised by continuous ThT growth experiments, 
CD, AFM, MTT and SDS-PAGE assays. The peptide was confirmed to have efficient inhibitory 
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property at 1:1 stoichiometry. In the presence of peptide, the ThT data showed 92 % 
reduction in the amyloid growth relative to the inhibitor free (1:0) sample, which was later 
confirmed by the retention of random coil signal shown by CD and the absence of fibrils 
seen in AFM images, using the same sample as that in the ThT experiments. The molar ratio 
1:0.5 showed a significant delay in the aggregation process and an expected loss of 
inhibitory effect in a dose dependency manner was observed in the lower stoichiometries. 
The MTT data showed a cell survival of   ͠   65-85 % in the presence of peptide and found the 
peptide to be non-toxic in isolation. Moreover, SDS-PAGE analysis, again taken from the 
same sample, showed a shift from higher to lower molecular weight species in the presence 
of peptide at 1:1 stoichiometry or higher. As described in Chapter 5, the inhibitory effect of 
45-54W can be attributed to the nature of residues selected and their β-sheet propensities. 
I have therefore demonstrated that the PCA derived peptide is effective in reducing the α-
syn aggregation toxicity in vitro and in vivo.  
In summary, several α-syn targeted peptides based on two different targets within α-syn 
were selected using PCA. At the PCA level, no assumptions were made regarding the 
mechanism of action for the selected binders or oligomeric state of α-syn that becomes 
populated. The characterisation assays showed that, some of those selected peptides had 
the effect of delaying or even preventing the aggregation process, with others providing 
more subtle effects in reversing the fully formed amyloid fibrils, while some peptides 
enhancing the fibrillisation process. In the case of mutants, I speculate that the conflicting 
information regarding α-syn toxicity in PCA and MTT studies could be attributable to 
different factors such as interaction with other proteins, cofactors, protease, and structural 
rearrangements in vivo. Further investigation needed as I have not directly quantified the 
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affinity and specificity of the peptide binding. Structural studies such as solid state NMR and 
analysing the effectiveness in different model systems (for example, fruit flies or assays 
using primary neurons) may demonstrate the specificity, structural rearrangement and 
efficacy further. It would also provide insights into the binding sites of the target protein 
and affinity of the peptides towards it. The peptide-protein interaction also depends on the 
residues, whether they are conserved in the binding sites or exposed and later decides the 
structural stability on folding (Ma et al., 2003). In the future, when attempting to translate 
these peptides as drugs; the major concerns would be bioavailability issues, 
pharmacokinetics, protease degradation susceptibility, effect of oxidants, immune 
responses, poor metabolic stability, limited permeability across the blood-brain barrier or 
cell membranes, rapid clearance and high production costs. Despite the limitations, these 
peptide-based drugs have many advantages such as high potency, high selectivity, broad 
range of targets, potentially less toxicity, low tissue accumulation and chemical/biological 
diversity (Craik et al., 2013). Most of the research to develop α-syn targeted PD drugs 
focuses on preventing the protein from aggregating in the first place, to break up 
aggregated species, or to halt the toxic effects of the aggregates. The peptides derived 
mostly interfere with the β-sheet formation by preventing propagation of hydrogen bonds 
along the long axes of β-sheets. Stabilising the native structure of protein is another strategy 
that can be used in developing PD drugs as recent studies suggested that, α-syn forms a 
stable helically folded tetrameric structure able to resist aggregation (Wang et al., 2011; 
Bartels et al., 2011). Due to ambiguity in the native structure and normal biological function 
of α-syn, wide spread research is needed for developing new therapeutic interventions 
against PD. As the formation of amyloid fibrils characterizes the PD pathology, another 
approach is anti-amyloid therapies based around the concept of inhibiting protein-protein 
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interactions. Though, a group of researchers from the Stanford University showed that 
amyloid fibrils composed of hexapeptides act as active biological agent that can lessen the 
neuroinflammation in multiple sclerosis and autoimmune encephalomyelitis (Kurnellas et al., 
2013 and 2014). These studies begin to suggest the new idea that full length, amyloid 
forming proteins produced by the body may have in fact protective behaviour rather than 
destructive. In conclusion, I have demonstrated that the PCA strategy can be used as a basic, 
generalised method for deriving peptide inhibitors against α-syn aggregation. In the future, 
it may be possible to derive more potent inhibitors of the mutagenic versions of α-syn using 
scaffold of 45-54 region. As per the encouraging results in Chapter 5, it may be possible to 
derive more α-syn antagonists or use this new target; 45-54 region for designing more 
effective new inhibitors that can be modified into drugs to slow or even prevent the onset 
of PD. 
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Intracellular Screening of a Peptide Library to Derive a Potent
Peptide Inhibitor of -Synuclein Aggregation*
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Background: Deposition of -synuclein into Lewy bodies is considered the primary event in Parkinson disease.
Results: A peptide selected via PCA library screening functions by inhibiting fibril formation.
Conclusion: A semirational design combined with intracellular PCA is an effective methodology to develop -synuclein
aggregation antagonists.
Significance: The technique can be applied to a number of diseases from Parkinson to Alzheimer.
Aggregation of-synuclein (-syn) into toxic fibrils is a path-
ogenic hallmark of Parkinsondisease (PD). Studies have focused
largely on residues 71–82, yet most early-onset mutations are
located between residues 46 and 53. A semirationally designed
209,952-member library based entirely on this region was con-
structed, containing all wild-type residues and changes associ-
ated with early-onset PD. Intracellular cell survival screening
and growth competition isolated a 10-residue peptide antago-
nist that potently inhibits-syn aggregation and associated tox-
icity at a 1:1 stoichiometry. This was verified using continuous
growth measurements and 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide cytotoxicity studies. Atomic force
microscopy and circular dichroismon the same samples showed
a random-coil structure and no oligomers. A new region of
-syn for inhibitor targetinghas beenhighlighted, togetherwith
the approach of using a semirational design and intracellular
screening. The peptides can then be used as candidates formod-
ification in drugs capable of slowing or even preventing the
onset of PD.
Deposition of -synuclein (-syn)3 into neuronal inclusions
known as Lewy bodies is considered the causative agent in the
pathogenesis of Parkinson disease (PD), a debilitating disease
that results principally in rigidity, tremor, and slowness of
movement and that accounts for 15% of all dementias (1, 2).
The accumulation of toxic Lewy bodies in the cytoplasmic
space of dopaminergic neurons in the substantia nigra pars
compacta region of the brain leads to cell death, decreased dop-
amine levels, and ultimately the symptoms of the disease. There
is a substantial and growing body of evidence implicating -syn
in PD (3), including (i) synthetic -syn rapidly aggregates into
-sheet-rich fibrils similar to those found in Lewy bodies; (ii)
rare familialmutations that increase fibril aggregation rates and
toxicity lead to early-onset PD; (iii) -syn gene duplications
lead to increased protein expression and therefore accelerate
disease onset; and (iv) -syn oligomers are toxic to therapeuti-
cally relevant cells in culture. To intervene in PD, we utilized a
novel intracellular screen to identify peptides capable of bind-
ing to and reducing the associated toxicity of a-syn aggregation.
Our approach has the potential to address recent findings that
suggest that prefibrillar oligomers are the toxic species (4).
There is a wealth of experimental data demonstrating that
region 71–82 is responsible for aggregation of the full-length
140-amino acid protein (5–7). Indeed, numerous groups have
used this region as a starting point for the design of inhibitors.
This has included unmodified peptides (8) and N-methylated
peptides (9). Given the interest in this region and its require-
ment for aggregation of the full-length protein, many groups
have focused their efforts on producing libraries based on this
scaffold. However, of the known point mutations in the -syn
gene associated with early-onset PD, three (E46K, H50Q,
A53T) are located between residues 46 and 53, with the fourth
(A30P) located in close proximity. More recently, a fifth muta-
tion (G51D) was identified (10). This region and the residues
within are clearly important in modulating amyloid forma-
tion such that toxicity associated with the -syn protein
increases, with the changes leading to decreased -helicity,
increased -sheet propensity, and an increase in either the
rate or number of oligomers that are formed (11–14).
In this study, we generated peptide inhibitors using a multi-
plexed intracellular protein-fragment complementation assay
(PCA) library screening system (15, 16), followed by direct
imaging of the samples. Successfully selected peptides must
bind -syn to reduce amyloid cytotoxicity and confer bacterial
cell survival. During PCA, no assumptions are therefore made
regarding the mechanism of action or the oligomeric state of
-syn that becomes populated. The only prerequisites for pep-
tide selection are that (i) peptides bind to -syn such that the
split reporter enzyme is recombined and (ii) the result is lower
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toxicity such that cell survival is facilitated. In addition, the PCA
approach is predicted to select peptides that are resistant to
degradation by bacterial proteases, soluble, nontoxic, and tar-
get-specific in the presence of other cytoplasmic proteins.
Using -syn(45–54) as a template for our library design, we
created a 209,952-member peptide library 10 amino acids in
length that spans residues 45–54, containing the wild-type
45–54 sequence, including residue options corresponding to
E46K, H50Q, and A53T, which, whenmutated, give rise to ear-
ly-onset PD. PCA was used to screen the peptide library for an
interaction with wild-type -syn. The effectiveness of an amy-
loid/PCA-selected peptide (45–54W) was subsequently tested
by performing four key experiments upon the same sample: a
continuous amyloid growth assay,monitored using thioflavinT
(ThT) fluorescence; CD, to report on changes in -sheet con-
tent; and atomic forcemicroscopy (AFM) and SDS-PAGE anal-
ysis, to directly image any reduction in fibril load and changes in
the fibril morphology. We found the peptide derived using this
approach to be capable of binding to the disease-relevant wild-
type -syn and reducing associated amyloid formation by
90%. In this study, we both successfully verified the method-
ology for producing anti--syn aggregation peptide inhibitors
using the amyloid/PCA approach and produced a lead peptide
sequence that is expected to provide a scaffold for future drug
candidates.
Our data collectively indicate that the PCA-derived winner
sequence (45–54W) is able to prevent the aggregation of wild-
type -syn at a stoichiometry of 1:1. The ThT fluorescence sig-
nal associated with amyloid formation did not progress beyond
8% of the original 1:0 sample. AFM experiments showed that
in the same continuous growth samples, there was a striking
decrease in the number of fibrils relative to the 1:0 samples.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) cytotoxicity studies using the same samples
showed a reduction in cell death of 65–85% compared with
-syn in isolation. Finally, CD experiments using samples taken
from the same continuous growth experiment once again
showed that the conversion from a random-coil structure to a
-sheet-rich structure was almost completely abolished in the
1:1 sample. At a molar ratio of 1:0.5, the formation of the
mature amyloid fibrils found in the 1:0 sample was slowed but
ultimately not prevented (see Fig. 3a). At stoichiometries of
1:0.1 and 1:0.01, the rate of amyloidosis was not significantly
lowered relative to the 1:0 sample.
EXPERIMENTAL PROCEDURES
Primers and Library Cloning—Primers were designed such
that the desired library could be generated using overlap-exten-
sion PCR. Bases overlapped in a non-randomized region of the
primers to give an approximate annealing temperature of 66 °C.
Correct amplification was enabled via an elongated reverse
primer and verified by agarose gel electrophoresis. The correct
PCR product was then digested using NheI and AscI restriction
enzymes for subcloning the library into the pES230d vector
(restriction enzyme recognition sites shown). Primer sequences
used were 5-C TGG GCT AGC RAA VAW GBG VTT VTT
VAW GBG VTT RHA RCC GGC GCG CCG CTA GAG
GCG-3 (forward) and5-TTTTTTTTTATAATATATTATA
CGC CTC TAG CGG CGC GCC-3 (reverse). An additional 30
residues on the 5-end of the reverse primer were used to observe
the correct PCR product prior to restriction digestion.
Single-step Selection PCA—Escherichia coli XL-1 cells were
used for construction and cloning of libraries as described pre-
viously (16–18). First, pES300d--syn target and pREP4 (for
expression of the Lac repressor protein; Qiagen) were cotrans-
formed into BL21-Gold cells (Stratagene) and plated onto
LB agar with the appropriate antibiotics (kanamycin and chlor-
amphenicol). These cells were next made electrocompetent
before transformation with the pES230d-45–54 library plas-
mid. Transformed cells were plated onto three different media.
One-twentieth of the cells were plated onto LB agar with three
antibiotics (kanamycin, ampicillin, and chloramphenicol) as a
positive control of transformation efficiency. Another one-
twentieth of the solution was plated onto M9 minimal agar
containing 1 g/ml trimethoprim and the same three antibio-
tics as a negative control. Finally, the remaining 90% of the
transformed cells were plated onto M9 minimal agar in the
presence of the three antibiotics, 1 g/ml trimethoprim, and 1
mM isopropyl -D-thiogalactopyranoside to induce expression
of the two dihydrofolate reductase fragment-fused peptides.
This single-step selection PCA led to 200 colonies from the
initial library of 209,952, meaning that 99.9% of all library
members were removed at this stage.
Competition Selection PCA—To increase selection stringency,
growth competition experimentswere undertaken. Selected colo-
nieswerepooled fromtheplate, grown inM9minimal agar under
selective conditions (containing kanamycin, ampicillin, chlor-
amphenicol, trimethoprim, and isopropyl-D-thiogalactopyra-
noside), and serially diluted over five passages. Using these
sequential rounds of competition selection, subtle differences
in growth rate can become amplified, increasing the stringency
of selection relative to the single-step method. Competition
selection therefore allows the most effective one or two
sequences to be isolated from the200 -syn binders initially
identified during single-step selection. At each passage, glyc-
erol stocks were prepared, and sequencing results were
obtained (Source Bioscience, Nottingham, United Kingdom)
for DNA pools and individual colonies. For each passage, 50 l
of liquid culture was added to 50 ml of fresh M9 minimal agar,
resulting in anA600 of0.01. Cells were incubated at 37 °Cuntil
anA600 of0.4 was reached (typically 2–3 days) before moving
to the next passage.
Protein Expression and Purification—Wild-type -syn was
synthesized by overexpression in the E. coli BL21 strain using a
small ubiquitin-like modifier (SUMO) fusion protein (19).
SUMOmodulates protein structure and function by covalently
binding to the lysine side chains of the target protein to enhance
expression and solubility of the -syn protein. E. coli BL21
competent cells were transformed with the pET21b plasmid
construct, grown on LB agar plates containing ampicillin and
chloramphenicol, and grown overnight. Single colonies were
next picked, inoculated in LB broth containing ampicillin and
chloramphenicol, and shaken at 37 °C. These cultures were
then used to inoculate 2 liters of liquid LB broth containing
ampicillin and chloramphenicol and grown to mid-log phase
(A600 0.6–0.8) before being further induced by 1 mM isopro-
Intracellular Selection of an-Synuclein Aggregation Inhibitor
MARCH 20, 2015•VOLUME 290•NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 7427
 at U
niversity of Bath on M
arch 25, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
pyl -D-thiogalactopyranoside for 3 h at 37 °C. Cells were
obtained by centrifugation at 4000 rpm for 20 min at 4 °C in a
Sorvall RC Superspeed centrifuge. Cell pellets were then resus-
pended in binding buffer (50 mMNaH2PO4, 300 mMNaCl, and
10 mM imidazole (pH 8)) and homogenized using a magnetic
stirrer for 15 min on ice, followed by sonication (40% amplifi-
cation). Lysed cells were next centrifuged at 18,500 rpm for 20
min at 4 °C using an SS-34 rotor (Sorvall RC Superspeed cen-
trifuge). The supernatant containing the protein was stored at
20 °C.
The fusion protein was purified by applying the supernatant
from the cell lysate to a nickel-nitrilotriacetic acid affinity col-
umn three times at a flow rate of 3 ml/min to allow the protein
to bind. The columnwas next washedwith 40ml of wash buffer
(50mMNaH2PO4, 300mMNaCl, and 30mM imidazole (pH 8)),
and the protein was eluted using elution buffer (50 mM
NaH2PO4, 300 mM NaCl, and 500 mM imidazole (pH 8)). The
protein sample was then exchanged to cleavage buffer (20 mM
Tris and 0.5 mM DTT (pH 8)) using a PD-10 desalting column.
The His6-SUMO tag was removed using the SUMO protease-
specific UlP1 enzyme (1 mg/ml for 10 mg/ml target protein) at
30 °C for 16 h.
His6-SUMO was finally removed using a size-exclusion col-
umn. A SephadexG-75 columnwaswashed three timeswith 10
mM MES and 150 mM NaCl (pH 8.0). The protein was concen-
trated to 2 ml and injected onto the column, and fractions were
eluted according to their molecularmass. Finally, SDS-PAGEwas
used to determine the purity of the -syn and to verify the
expected molecular mass of different fractions containing -syn
(14.5 kDa), SUMO protein (12.2 kDa), and SUMO protease (27
kDa). The correctmass of-synwas further confirmedby electro-
spray mass spectrometry. The protein concentration was deter-
mined in a Varian Cary 50 spectrophotometer. The purified pro-
tein was lyophilized using a freeze drier and stored at80 °C.
Monomerization of Protein for Aggregation Studies—Tomono-
merize the protein prior to aggregation experiments, 1 ml of
hexafluoro-2-propanol was added to 2 mg of lyophilized pep-
tide. This was next vortexed for 2 min to fully dissolve the
peptide, followed by sonication at 25 °C for 5 min in a water
bath sonicator. Hexafluoro-2-propanol was allowed to evapo-
rate completely under a regulated stream of air. The process
was repeated three times, followed by dissolution of the peptide
sample in double-distilled water, vortexing for 3 min, and
lyophilization for further use (9).
Peptide Synthesis—Rink amideChemMatrix resinwas obtained
from PCAS BioMatrix Inc. (Saint-Jean-sur-Richelieu, Quebec,
Canada). Fmoc-L-amino acids and (1H-benzotriazol-1-yloxy)-
(dimethylamino)-N,N-dimethylmethaniminium hexafluoro-
phosphate were obtained from AGTC Bioproducts (Hessle,
United Kingdom). All other reagents were of peptide synthesis
grade and obtained from Thermo Fisher Scientific (Loughbor-
ough, United Kingdom). Peptide 45–54Wwas synthesized on a
0.1-mmol scale on PCAS BioMatrix Rink amide resin using a
Liberty Blue microwave peptide synthesizer (CEMCorp., Mat-
thews, NC) employing Fmoc solid-phase techniques (for
review, see Ref. 20) with repeated steps of coupling, deprotec-
tion, and washing (4 5 ml of dimethylformamide). Coupling
was performed as follows: Fmoc-L-amino acids (5 eq), (1H-
benzotriazol-1-yloxy)(dimethylamino)-N,N-dimethylmetha-
niminium hexafluorophosphate (4.5 eq), and diisopropylethyl-
amine (10 eq) in dimethylformamide (5 ml) for 5 min with
20-watt microwave irradiation at 90 °C. Deprotection was per-
formed as follows: 20% piperidine in dimethylformamide for 5
min with 20-watt microwave irradiation at 80 °C. Following
synthesis, the peptide was acetylated (acetic anhydride (3 eq)
and diisopropylethylamine (4.5 eq) in dimethylformamide
(2.63 ml) for 20 min) and then cleaved from the resin with
concomitant removal of side chain-protecting groups by treat-
ment with a cleavage mixture (10 ml) consisting of TFA (95%),
triisopropylsilane (2.5%), and H2O (2.5%) for 4 h at room tem-
perature. Suspended resin was removed by filtration, and the
peptide was washed by three rounds of crashing in ice-cold
diethyl ether, vortexing, and centrifugation. The pellet was then
dissolved in 1:1 MeCN/H2O and freeze-dried. Purification was
performed by reverse-phaseHPLCusing a Phenomenex Jupiter
Proteo (C12) reverse-phase column (4 m, 90 Å, 10 mm, inner
diameter  250 mm long). Eluents used were as follows: 0.1%
TFA in H2O (eluent A) and 0.1% TFA inMeCN (eluent B). The
peptidewas eluted by applying a linear gradient (at 3ml/min) of
20–60% eluent B over 40 min. Fractions collected were exam-
ined by electrospray mass spectrometry, and those found to
contain the desired product exclusively were pooled and lyoph-
ilized. Analysis of the purified final product by reverse-phase
HPLC indicated a purity of95%.
Peptide Preparation—Stock solutions of 1 mM inhibitor and
control peptides were dissolved in ultrapure water. At this con-
centration (a 2–200-fold excess of that used in experiments), no
aggregation or precipitation was observed. In addition, bioin-
formatics tools (e.g. Waltz (21), AmylPred (22), PASTA (23),
Zyggregator (24), andTANGO (25)) did not predict the peptide
to contain amyloidogenic sequences or to aggregate in isola-
tion. Finally, dye-binding experiments demonstrated that this
sequence did not bind ThT or aggregate and form random coil-
like species in isolation by CD (see Figs. 3 and 4).
Continuous Growth ThT Experiments—Peptides were lyoph-
ilized at the molar concentration of the target protein and
inhibitory peptide (1:1). The reaction mixture containing 450
M wild-type -syn and inhibitory peptide was incubated in 90
M ThT, 10 mM phosphate buffer (pH 7.0), 100 mM KF, and
0.05% NaN3 at 37 °C with continuous mixing using a magnetic
stir bar in an LS 55 fluorescence spectrophotometer (Perkin-
Elmer Life Sciences) for 4500min (75 h). The same experiment
was repeated three times for both the 1:0 sample- and peptide
45–54W-containing solutions at a variety of stoichiometries, as
well as at 1:1 molar ratios with the wild-type 45–54 and
71–82W (Ac-VTGVTADVQETV-NH2) control peptides. The
PCA winner peptide, 45–54W, was lyophilized in aliquots of
different molar concentrations of target protein and inhibitory
peptide ranging from 1:0.01 to 1:1.
CD Experiments—Far-UV CD spectra were recorded using
an Applied Photophysics Chirascan spectrometer at 20 °C
using the same samples from the continuous growth ThT
experiments. Spectra were recorded over the 190–300-nm
range at a scan rate of 10 nm/minwith step size of 1 nm. Spectra
were recorded as the average of three scans. Peptide (10 M in
10 mM potassium phosphate buffer (pH 7.4)) was added to a
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0.1-cm cuvette (Hellma Analytics). Spectra were recorded as
raw ellipticity.
AFM Experiments—Samples were imaged in noncontact
mode using an XE-120 atomic force microscope (Park Sys-
tems, Suwon, South Korea). NSC15 silicon nitride cantile-
vers with a spring constant of 40 newtons/m were used for
imaging at a scan rate of 1.0 Hz and a resolution of 256 256
pixels. All images were obtained at room temperature. The
AFM data were taken from continuous growth experiments.
A 5-l sample was taken from the 450 M -syn continuous
growth experiment and placed on freshly cleaved mica
(0.3-mm thickness). Following adsorption of the protein
aggregates (2 min), the mica was washed with 5 ml of double-
distilled water. Excess water was removed, and the samples
were dried using a stream of nitrogen gas. Samples were
immediately analyzed by AFM. The image files were exam-
ined using WSxM 5.0 (Nanotec Electronica S.L.) and flat-
tened before processing (26).
MTT Cell Toxicity Assay—MTT experiments were under-
taken using rat pheochromocytoma (PC12) cells to assess the
cytotoxicity effect of -syn. PC12 cells are known to be partic-
ularly sensitive, and their use in this assay is well established
(27). A Vybrant MTT cell proliferation assay kit (Invitrogen)
was used to measure conversion of the water-soluble MTT dye
to formazan, whichwas then solubilized, and the concentration
was determined by a purple color change monitored via absor-
bance measurement at 570 nm. The change in absorbance can
be used as an indicator of PC12 cell health in this assay. The
assay was performed with a 5 M -syn and peptide stoichiom-
etry corresponding to 1:1. PC12 cells were maintained in RPMI
1640 medium and 2 mM glutamine mixed with 10% horse
serum and 5% fetal bovine serum and supplemented with 20
mg/ml gentamycin. Cells were transferred to a sterile 96-well
plate with 30,000 cells/well, and experiments were performed
in triplicate. The required volume of peptide and target solu-
tions was added to PC12 cells. A total of 100 l of PC12/RPMI
1640 medium combined with an appropriate volume of pep-
tide/-syn target mixture (5 M peptide  5 M -syn target)
was transferred to a 96-well microtiter plate. Because the sam-
ples contained 90MThT, control experimentswith PC12 cells
and -syn alone both with and without ThT were undertaken.
These samples were incubated for 24 h at 37 °C and 5% CO2
prior to the addition of theMTT dye. A total of 10l of the dye
was added to each well and incubated for an additional 4 h at
37 °C and 5% CO2. A total of 100 l of dimethyl sulfoxide was
then added to each well and allowed to stand for 10 min. The
absorbance was measured at 570 nm using a Berthold TriStar
LB 942 plate reader.
SDS-PAGE—Gel analysis was carried out using 15% Tris
bisacrylamide gels operated at a constant voltage of 150 V. The
running buffer was 25 mM Tris-HCl, 193 mM glycine, and 0.1%
SDS (pH 8.3). 3 l of 450 M -syn and peptides at different stoi-
chiometries was mixed with 7 l of loading buffer containing 50
mMTris-HCl (pH6.8), 1% SDS, 5% glycerol, and 25%bromphenol
blue.10l of eachsamplewas then loaded ineachwell.Thegelwas
stained with 0.1% Coomassie Blue R-250.
RESULTS
-syn(45–54) Library Generation—PCA was undertaken
with the full-length -syn(1–140) target using a library based
on the -syn(45–54) region, in which three of the four -syn
mutations associated with early-onset PD are located (KEGV-
VHGVAT, wild-type 45–54). Unlike-syn(71–82), this is not a
region of the molecule known to aggregate into toxic fibrils in
isolation (28–30) and therefore has not been exploited as a
starting point for deriving -syn binders capable of inhibiting
aggregation. The library incorporated the wild-type sequence
while introducing two-, three-, or six-residue options at each of
the 10 amino acid positions (Fig. 1). This corresponded to a
library size of 209,952. Single-step selection on M9 plates was
undertaken, followed by competition selection in liquid M9
medium, resulting in one clean sequencing result by passage 6:
KDGIVNGVKA (Fig. 2).
FIGURE 1. a, shown are residues 45–54 of wild-type -syn (KEGVVHGVAT), as well as the three well studied point mutation sites (positions 46, 50, and 53).
Degenerate codons for library construction are shownbelow (RA/G,VA/C/G,WA/T, BC/G/T, andHA/C/T).b, shownare amino acid options at each
position to generate a 209,952-member peptide library. The wild-type residue options (top line) and alternative options, including those point mutations
associated with early-onset PD (shown in boldface), were also considered in the library design. c, the PCA winner peptide (KDGIVNGVKA) emerged from
single-step selection, followed by two rounds of competition selection PCA.
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Peptide Characterization—PCA-derived peptide sequences
(Fig. 1) were synthesized and characterized using a number of
experiments, including ThT dye binding, CD, AFM, and MTT
cytotoxicity experiments, to verify that the peptides do not
aggregate in isolation and to determinewhether they are able to
reduce aggregation and/or breakdown preformed fibrils to a
nontoxic species.
Continuous Growth ThT Experiments Demonstrate a Signif-
icant Reduction in Fibril Load—To determine the ability of
PCA-derived peptides to reduce fibril assembly (inhibition)
and/or to breakdown preformed fibrils (reversal), ThT binding
was used to quantify amyloid species. First, -syn was rendered
monomeric (9) and aggregated into amyloid by resuspending
and incubating at 37 °C. For the continuous growth assay, pep-
tides were added at time 0, and a reading was taken every 5 min
over a 75 h period. The ThT signal was significantly reduced at
a 1:1 molar ratio, indicating that the peptides were able to bind
-syn and reduce aggregation levels. At increasingly lower sub-
stoichiometric ratios, we observed progressively reduced activ-
ity consistentwith a general dose dependence. The control pep-
tide 71–82W and the wild-type 45–54 sequence at 1:1 molar
rations had no effect on aggregation, demonstrating -syn
specificity for peptide 45–54W.
AFM Indicates a Large Reduction in Amyloid Levels—As a
second direct qualitative measure of fibril formation, samples
used in continuous growth experiments were imaged using
AFM (Fig. 3, b–f). A stoichiometry of 1:1 (450 M) was chosen
for AFMexperiments, as this was found to be themost effective
in ThT experiments (Fig. 3b). At this stoichiometry, a major
reduction in the amount of amyloidwas observed relative to the
-syn control across several time points (Fig. 3d). No fibrils
were observed for peptide 45–54W in the absence of-syn. The
control peptide 71–82W and the wild-type 45–54 sequence
had no effect upon fibril formation (Fig. 3, e and f), supporting
-syn specificity for peptide 45–54W.
CD Demonstrates a Large Reduction in -Sheet Content—
Because amyloid fibrils are predominately-sheet, we also used
CD spectroscopy for structural characterization of the aggre-
gates in the continuous growth ThT experiments. The data
presented in Fig. 4a show spectra over 17 time points of the
continuous growth assay. A single negative peak at 218 nm
develops across the time course, along with the loss of the min-
imumat200 nm, consistentwith the gain of-sheet structure
and the loss of a random coil. As predicted from the ThT data
above, the -structure did not form for -syn incubated with
peptide 45–54W at a 1:1 stoichiometry (Fig. 4b). In addition,
the minimum at 200 nm did not significantly diminish. A
similar spectrum was observed for peptide 45–54W alone (i.e.
0:1 stoichiometry) after 75 h of incubation, indicating that this
peptide does not aggregate in isolation. The lack of CD signal
FIGURE2.a, PCA. Peptide librarymembers that bind towild-type-syn(1–140) recombinemurinedihydrofolate reductase (mDHFR) and lead to colonies under
selective conditions (bacterial dihydrofolate reductase is specifically inhibited using trimethoprim). Those peptides that bind with the highest affinity to the
-syn target are able to confer cell growth by (i) reconstitutingmurine dihydrofolate reductase to restore activity and (ii) reducing the toxicity associatedwith
any given oligomeric amyloid state. In competition selection, subsequent passages in liquid medium isolate potential PCA winners with the highest efficacy.
Because PCA is performed in the cytoplasmof E. coli, the nonspecific, unstable, aggregation-prone (insoluble), protease-susceptiblemembers are removed. b,
DNA sequencing results of library pools for passages 0–6. Both single-step selection (P0) and competition selection (P1, P2, and P6) are shown. The peptide
sequence KDGIVNGVKA was seen to dominate from passage 2 onwards. CmR, chloramphenicol resistance; AmpR, ampicillin resistance.
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FIGURE 3. a, continuous ThT growth. The data show a significant reduction in ThT signal (92%) at a 1:1 stoichiometry. The ThT signal at a molar ratio of 1:0.5
shows that the amyloid growth rate was significantly reduced compared with the wild type. At increasingly substoichiometric ratios, the ThT fluorescence
indicates reducedpeptide activity in an expecteddose-dependentmanner. Peptide 45–54Walone (0:1 sample) showednoThTbinding, indicating that it does
not aggregate in isolation. Aliquots of samples were collected at 17 different time points for the 1:0 sample (lag phase (T0 and T1), exponential phase (T3, T7,
and T14), and stationary phase (End) are shown) and three time points for the 1:1 sample (T0, T1, and End) for further analysis by AFM and CD. b, AFM images
showing the end point samples (75 h) for all stoichiometries used in continuous growth ThT experiments. A considerable reduction in fibril loadwas observed
at amolar ratio of 1:1. All other stoichiometries showed nomajor reduction in amyloid content relative to the 1:0 sample. Peptide 45–54W (0:1 sample) did not
aggregate in isolation. c, AFM images showing the gradual increase in amyloid content along various timepoints for the 1:0 sample. Shown are six samples (T0,
T1, T3, T7, T14, and End) taken from the lag, exponential, and stationary phases. The time points for these were 0, 10, 33.3, 37.5, 49, and 75 h, respectively. d, a
large reduction in amyloid contentwasobserved for the1:1 samplewithpeptide45–54W. For these images, T00h, T137.5h, and T275h. e, no reduction
in amyloid contentwas observed for the 1:1 samplewith thewild-type 45–54 sequence. For these images, T0 0 h, T1 33.75 h, and T2 75 h. f, no reduction
in amyloid contentwasobserved for the1:1 samplewithpeptide 71–82W. For these images, T00h, T128.75h, and T275h. For all samples,many images
were taken at each time point to confirm the morphology and number of fibrils present in each image.
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intensity at 218 nm for -syn incubated with peptide
45–54W is unlikely to be attributed to increased aggregation
or precipitation. This is because any peptides causing
increased precipitation would also generate large increases
in ThT binding and would be clearly observed in AFM imag-
ing experiments. Neither wild-type -syn(45–54) nor pep-
tide 71–82W had any effect upon conversion to the -struc-
ture (Fig. 4, c and d), again demonstrating -syn specificity
for peptide 45–54W.
MTT Studies Demonstrate Reduced Amyloid Toxicity of
Cells—MTTcell toxicity experimentswere performed using rat
pheochromocytoma (PC12) neuron-like cells to assess the tox-
icity of -syn and the preventative effects of peptide 45–54W
generated in this study.MTT assayswere performed at a-syn/
peptide 45–54W ratio of 1:1 and are presented as raw A570
signal (Fig. 5a). At this stoichiometry, peptide 45–54W
improved cell viability by 65–85% relative to -syn in isolation.
Dose dependence experiments demonstrated that at molar
ratios of 1:0.01 and 1:0.1, there was no effect on toxicity. At
1:0.5, the recovery was improved, maximizing at 1:1 and
becoming less pronounced at increasingly higher molar ratios
(Fig. 5b). In addition, MTT experiments using samples taken
throughout the continuous growth experiment demonstrated
that -syn became progressively more toxic with time and was
most toxic within the stationary phase of fibril growth (Fig. 5c).
As predicted from ThT, CD, and AFM experiments, MTT
experiments using the wild-type 45–54 sequence or peptide
71–82W demonstrated that although these peptides were not
toxic in isolation, they had very little effect on -syn toxicity
(Fig. 5d). Finally, increasing the concentrations of peptide
45–54W in isolation demonstrated that it was not toxic.
SDS-PAGE Analysis Demonstrates that Peptide 45–54W Is
Able to Interact with -syn and Lower the Oligomeric State—A
range of samples were taken from the end point (75 h) of the
continuous growth experiments and subjected to SDS-PAGE
analysis (Fig. 6). Two clear bands at40 and60 kDa (as deter-
mined by graph analysis of log molecular mass versus relative
migration distance; data not shown)were found to be present in
the 1:0 sample, as well as in the 1:0.01, 1:0.1, and 1:2 samples
and, to a lesser extent, the 1:5 sample, suggesting the presence
of -syn trimers (40/14.5 2.8) and tetramers (60/14.5 4.1).
No bands corresponding to dimers or 5–8-merswere observed.
At a molar ratio of 1:1 or higher, these bands were found to
absent andwere replacedwith three lowmolecularmass bands.
One band at 15 kDa may represent the -synpeptide
45–54W complex. The second and third bands are below the
resolution limit of the gel but are likely to representmonomeric
-syn (14.5 kDa) and the inhibitor alone (1 kDa). Although
under denaturing conditions (therefore precluding more
detailed interpretation), this experiment demonstrated that
FIGURE4.a, CD spectra of the same samples used in the ThT andAFMexperiments. Shown is thegradual development of aminimumat 218nmacross the time
course along with the loss of a minimum at 200 nm, consistent with the gain of -sheet structure and the loss of a random coil in the 1:0 sample. b, in the 1:1
samples, theminimum at200 nmwas prominent even after 75 h of incubation, with no development of a 218 nm signal, confirming the efficacy of peptide
45–54W inpreventing the formationof-sheet structure. A similar spectrumwasobtained for peptide 45–54W (0:1 samples), confirming that thepeptidedoes
not adopt a -sheet structure in isolation. c, a 1:1 sample with the wild-type 45–54 sequence had no effect upon conversion to the -sheet structure and loss
of a randomcoil. Thewild-type45–54 sequence in isolation (0:1 samples) didnot adopt a-sheet structure in isolation.d, similarly, a PCA-derivedpeptidebased
on region71–82of-synhadnoeffect upon conversion to-sheet structure and loss of a randomcoil. Againpeptide 71–82W in isolation (0:1 samples) didnot
adopt a -sheet structure in isolation.mdeg, millidegrees.
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FIGURE 5.MTT cytotoxicity assays using rat pheochromocytoma (PC12) cells and-syn and the inhibitory effect of peptide 45–54Won-syn aggre-
gation.a, shown from left to right are PC12 cells only, PC12 cells plus buffer, PC12 cells plus buffer andThT, PC12 cells plus-syn (5M) inbuffer, PC12 cells plus
-syn (5 M) in buffer plus ThT, and -syn with peptide 45–54W at a 1:1 stoichiometry. The latter led to a large restoration of activity (85%). b, increasing
-syn/peptide 45–54Wmolar ratios demonstrates a dose dependence. Samples were taken from the end point of the continuous growth experiment (75 h)
and show that no effect on toxicity was observed at 1:0.01 or 1:0.1 and that amolar ratio of 1:0.5 was needed to partially rescue the cells (28% recovery) from
the cytotoxic effect of-syn. This increased at 1:1 (63%) andbecameprogressively less pronounced at increasingly highermolar ratios. c, effect of incubation
timeon toxicity using samples taken directly from the continuous growth experiment. Results demonstrate that toxicity progressively increased as the sample
aged andwas at its maximum in the stationary phase of continuous growth. d, increasing concentrations of peptide 45–54Wdemonstrate that the peptide in
isolation was not toxic to PC12 cells. MTT experiments using wild-type 45–54 sequence or peptide 71–82W demonstrate that the peptide was not toxic in
isolation but at a ratio of 1:1 with -syn had almost no effect upon toxicity. All experiments were undertaken in triplicate, and errors are shown as S.D.
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peptide 45–54W was able to interact with -syn and lower the
oligomeric state, possibly to the monomer.
DISCUSSION
In conclusion, we employed a semirational design combined
with intracellular PCA to demonstrate this as an effectivemeth-
odology for developing -syn aggregation antagonists. To date,
themajority of -sheet breaker compounds either are designed
to target or are based specifically on region 71–82 of the protein
because it is known to aggregate in isolation and therefore
thought to be responsible for instigating amyloidosis of the par-
ent protein. Inhibitors include N-methylated derivatives of the
same sequence (9), single-chain antibodies (31), and small-mol-
ecule compounds such as curcumin (32) and epigallocatechin
gallate (33).
In contrast, our approach has focused on the development of
a library centered on sequence 45–54, in which four of the five
known -syn familial mutants implicated in early-onset PD are
found. All of the knownmutations in this region result in either
increased-syn aggregation rates or increased numbers of olig-
omers and therefore increased levels of toxicity. All residues in
sequence 45–54were therefore scrambled to give two, three, or
six options, giving rise to a library of 209,952 members (Fig. 1).
This was constructed to include all wild-type options and the
mutations found in E46K, A53T, and H50Q, respectively. Half
of the 10 positions reselected the wild-type residues, whereas
the remaining five resulted in new selections. Thesewere E46D,
V48I, H50N, A53K, and T54A. In amyloid inhibition experi-
ments (i.e. inhibitor andmonomeric -syn mixed at time 0 and
amyloid growth continuously monitored) and at a stoichiome-
try of 1:1, we observed that the classical sigmoidal amyloid
growth for an inhibitor-free (1:0) sample was abolished.
Instead, the signal was held at8% of the signal observed in the
stationary phase of the 1:0 sample. At a stoichiometry of 1:0.5,
amyloid growth was significantly slower, taking approximately
twice as long for the fluorescence intensity to match that of the
1:0 sample. In accordance with an expected dose dependence,
at a 1:0.1 stoichiometry or lower, the inhibitory effect was lost.
The impressive efficacy of the 1:1 sample in continuous growth
ThT experiments is supported by both CD data, which show
that the conversion from a random coil-like structure consis-
tent with native -syn to a classical amyloid -sheet signal did
not occur in the 1:1 sample, and MTT data, which show that
toxicity associated with -syn aggregation was almost com-
pletely reversed in the presence of peptide 45–54W.Moreover,
a clear reduction to almost no fibrils was observed by direct
AFM imaging. This was corroborated by SDS-PAGE experi-
ments showing the loss of lowmolecular mass oligomers in the
presence of peptide 45–54W at a 1:1 stoichiometry or higher.
We have designed a library based on sequence 45–54 of wild-
type-syn and have created a potent peptide inhibitor of aggre-
gation. In the future, it may be possible to derive more potent
inhibitors of the mutagenic versions of -syn that are in turn
more effective with the wild-type protein. Not only does this
point toward a new target for the design of new inhibitors, the
peptide derived here using PCA has the potential itself to be
modified into drugs to slow or even prevent the onset of PD.
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Abstract: The b-amyloid (Ab) peptide aggregates into a number of soluble and insoluble forms, with
soluble oligomers thought to be the primary factor implicated in Alzheimer’s disease pathology. As
a result, a wide range of potential aggregation inhibitors have been developed. However, in addi-
tion to problems with solubility and protease susceptibility, many have inadvertently raised the
concentration of these soluble neurotoxic species. Sandberg et al. previously reported a b-hairpin
stabilized variant of Ab42 that results from an intramolecular disulphide bridge (A21C/A31C; Ab42cc),
which generates highly toxic oligomeric species incapable of converting into mature fibrils. Using
an intracellular protein-fragment complementation (PCA) approach, we have screened peptide
libraries using E. coli that harbor an oxidizing environment to permit cytoplasmic disulphide bond
formation. Peptides designed to target either the first or second b-strand have been demonstrated
to bind to Ab42cc, lower amyloid cytotoxicity, and confer bacterial cell survival. Peptides have con-
sequently been tested using wild-type Ab42 via ThT binding assays, circular dichroism, MTT cyto-
toxicity assays, fluorescence microscopy, and atomic force microscopy. Results demonstrate that
amyloid-PCA selected peptides function by both removing amyloid oligomers as well as inhibiting
their formation. These data further support the use of semirational design combined with intracel-
lular PCA methodology to develop Ab antagonists as candidates for modification into drugs
capable of slowing or even preventing the onset of AD.
Keywords: amyloid; protein misfolding; protein–protein interactions; library screening; protein-
fragment complementation assay; Alzheimer’s disease
Introduction
It has been widely speculated that small soluble
oligomers of Ab play a major role in the pathology of
Alzheimer’s disease (AD).1–4 However, developing
drugs that prevent the accumulation of these species
has proven difficult. Initial studies that sought to
Abbreviations: Ab42, b-amyloid 1–42 variant; CD, circular dichroism; HFIP, hexafluoroisopropanol; MTT, (3-(4,5-Dimethylthiazol-
2-yl)22,5-diphenyltetrazolium bromide; PCA, protein-fragment complementation assay; PPI, protein–protein interaction; TEM,
transmission electron microscopy; TFA, trifluoroacetic acid; ThT, Thioflavin-T; OAF, oblique angle fluorescence; AFM, atomic
force microscopy
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breakdown large insoluble oligomers have in some
instances led to an accumulation of small toxic spe-
cies,5 while more recent work has shown that even
dimers or trimers of Ab are toxic and able to impair
synaptic function.6 In screening libraries to identify
peptides capable of modifying aggregation, an ele-
gant approach would be to lock Ab42 into a toxic con-
formation. This would ensure population of an
oligomeric state that is pathogenically relevant to
the disease. Sandberg et al. previously studied the
effect of an intramolecular disulphide-bridged double
mutant of Ab42 (A21C/A31C; Ab42cc).
7 In this
approach, conservative mutations were used to cre-
ate a disulphide bridge and force an otherwise
unstructured and monomeric Ab42 into the b-hairpin
conformation found in mature fibrils. The conforma-
tion, therefore, provides the structural basis for sub-
sequent amyloidogenesis.8 Disulphide tethering was
found to stabilize highly toxic Ab oligomers that
retained the conformational and biological properties
of wild-type Ab. Moreover, these molecules did not
go on to convert into mature fibrils and were shown
to contain SDS-stable dimeric and trimeric species.
Experiments using SH-SY5Y human neuroblastoma
cells demonstrated that Ab42cc oligomers or protofi-
brillar species formed by these oligomers were 50
times more potent inducers of neuronal apoptosis
than amyloid fibrils or samples of monomeric wild-
type Ab42, in which toxic aggregates were only tran-
siently formed.
A wide variety of approaches have been used to
create amyloid inhibitors, including small molecule,
antibody, and peptide-based inhibitors. These have
ranged from those that stabilize the native state,
sequester monomers, inhibit amyloid growth, as
well as those that initiate clearance via chaperones
and proteases (see Ref. 9 for an overview). In our
own studies, we previously presented a novel varia-
tion of the intracellular protein-fragment comple-
mentation assay (PCA) selection system whereby
bacteria were used to screen peptide libraries and
generate Ab aggregation antagonists10 and subse-
quently their retroinversed analogues.11 During
PCA a “core recognition element” Ab25–35, was used
as the target since, along with Ab15–21, it is known
to form amyloid fibrils in isolation and instigate
amyloid formation in the parental protein. Ab25–35
was fused to one half of murine dihydrofolate
reductase (mDHFR) with a peptide library fused
to the second half. Library members that bound
Ab25–35 resulted in a colony under selective condi-
tions. The most effective binders were then further
enriched by growth competition to isolate from
binders that led to lower growth rates. Reduced
bacterial growth rates are due to the inherent pro-
pensity for Ab to aggregate and lead to increased
cytotoxic effects.12,13 Three outcomes are possible
for any given library member:
A. Library members bind Ab, reduce its toxicity and
recombine mDHFR to confer cell survival.
B. Library members bind Ab and recombine
mDHFR but either populate or do not prevent
population of a toxic species. These result in
reduced cell growth relative to 1, or cell death.
C. Library members with no affinity for Ab and,
therefore, no effect on amyloid formation will not
recombine mDHFR, resulting in cell death.
Intracellular selection means no assumptions
are made regarding the mechanism of antagonist
action or which amyloid state becomes populated
during selection, aiding the removal of molecules
with undesirable properties from the library such as
those that are too hydrophobic hence insoluble,
those tagged for degradation, those susceptible to
protease action, and those that are nonspecific.
To further strengthen this approach, we report
on the use of full length Ab42cc as the target mole-
cule rather than Ab15–21 or the Ab25–35 amyloido-
genic regions of the molecule used previously.10 In
this experiment, PCA is undertaken using Ab42cc
under oxidizing conditions to ensure that:
1. During selection the Ab42cc target is constrained
into the b-hairpin structure associated with the
pathology of the disease
2. The “core recognition elements” of Ab42cc associ-
ated with instigation of amyloid formation remain
exposed, largely unmodified, and in the correct
conformation.
3. Ab42cc is able to form soluble oligomeric struc-
tures that are highly toxic and associated with
AD pathology, thus ensuring that a larger number
of structurally relevant epitopes are presented
relative to larger and/or insoluble fibrils popu-
lated in the absence of the bridge.
4. Expressing the increased toxicity variant Ab42cc
raises the sensitivity of the PCA relative to Ab42.
This is because cells in scenario B above are pre-
dicted to die more readily or grow at reduced
rates.
We find the peptides derived using this
approach to be capable of binding to the disease rele-
vant wild-type Ab42 and reducing associated amyloid
formation. To understand the mechanism of peptide
action we have studied the effectiveness of peptides
and found them to be capable of removing preformed
fibrils as well as preventing amyloid from forming.
These studies have successfully produced a number
of lead peptide sequences that are expected to pro-
vide a scaffold for future drug candidates.
Results
We have combined semirational design with intracel-
lular selection using amyloid-PCA to screen peptide
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libraries and select Ab42 aggregation antago-
nists.10,14,15 A disulphide-bridged variant of Ab42,
known as Ab42cc, has been used as the target for
library screening since it constrains the protein into
the b-hairpin structure found in amyloid structures
that form oligomers associated with AD toxicity
(Fig. 1). PCA libraries were initially screened and
selected on M9 minimal agar plates. Following this
initial single-step selection, colonies underwent com-
petition selection where they were pooled and grown
before dilution into liquid M9 minimal media. This
process was repeated multiple times as passages to
select for the most effective binding sequence. In
this process, 1–2 high affinity binders that inhibit
amyloid formation and reduce bacterial toxicity were
found to display the fastest growth and dominate
the bacterial pool. The selection process indicated
that only a very limited subset of library members
were able to bind Ab42cc (<1%) and that these can
be further separated during competition selection
PCA to isolate the most effective binders. DNA
sequencing continued throughout passaging until
selection arrived at one discrete peptide. All subse-
quent aggregation studies were undertaken using
Ab42 as Ab42cc is not found naturally, with ThT bind-
ing and TEM data demonstrating that fibrils do not
form when the intramolecular disulphide bridge is
intact.7 We demonstrate that the sequences identi-
fied using the Ab42cc target can be transferred to the
biologically relevant Ab42.
Library generation
PCA was undertaken using an Ab42cc target with
sequences corresponding to Ab15–21 (QKLVFFA)
Ab29–35 (GAIIGLM), and Ab36–42 (VGGVVIA) as
library templates. The first of these two regions are
known to aggregate into toxic fibrils in isolation16–18
and therefore provided a strong starting point for
deriving peptides known to bind to Ab42cc and poten-
tially capable of inhibiting aggregation. The third
sequence incorporates the two additional C-terminal
amino acids (Ile-Ala) that renders Ab42 much more
toxic than Ab40. The first library incorporated four
fully randomized residues at positions 17–20 of
Ab15–21, generating a library size of 160,000
(15QKxxxxA21), and resulted in one winner (cys1521;
Table I). Interestingly, this library had previously
resulted in no colonies when using either Ab42 or
Ab15–21 as target, suggesting an improved epitope
for binding on introduction of the cysteine-bridge.
Moreover, the selected sequence, QKVLLFA, bared
remarkable similarity to the Ab15–21 (QKLVFFA)
parental sequence on which it was based, having
been enriched during PCA from four fully random-
ized residues at positions 17–20. The Ab15–21 peptide
has been previously shown to form amyloid in isola-
tion and found to be toxic in MTT experiments.19,20
The second library incorporated four fully random-
ized positions at 29–30 and 34–35 of Ab29–35, with
residues 31–33 fixed from a previous selection,10
generating a 160,000 member library (29xxKATxx35),
Figure 1. The PCA for amyloid systems. Selection is undertaken using SHuffle cells that harbor an oxidizing cytoplasmic envi-
ronment to promote disulphide bond formation. Library members that bind to Ab42cc lead to the recombination of murine DHFR
and lead to a colony under selective conditions (bacterial DHFR is specifically inhibited using trimethoprim). Subsequent com-
petition selection in liquid media isolates winners of highest efficacy. Those library members that bind the target and are able
to confer faster growth rates by reducing the toxic effects of the amyloid protein most effectively will be selected. As the assay
is performed in the cytoplasm of E.coli, any nonspecific, unstable, aggregation prone (insoluble), protease susceptible members
are removed.
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and resulted in two amyloid-PCA winners (cys2935a and
cys2935b; Table I) with no sequence homology to the amy-
loid template on which they were based. The last library
fixed residues 38–40 of Ab36–42 as “GVV” as is found in
wild-type Ab40 and Ab42, but was fully randomized at
residues 36–37 and importantly at residues 41–42 asso-
ciated with the increased toxicity of Ab42, generating a
160,000 member library (36xxGVVxx42), and resulting
in one winner (cys3642; Table I).
Peptide characterization
PCA derived peptide sequences (Table I) were syn-
thesized and characterized using a number of
experiments that included thioflavin-T (ThT) dye
binding, circular dichroism (CD), oblique angle fluo-
rescence (OAF), and atomic force microscopy (AFM).
The results demonstrate that the peptides do not
aggregate in isolation, and are able to prevent Ab42
aggregation and/or remove preformed fibrils. In
addition, growth competition assays using E.coli
under PCA conditions in M9 media and an MTT
assay using PC12 cells, both using the Ab42 parent
peptide, were undertaken to establish cytotoxicity to
bacterial and mammalian cells. The growth competi-
tion experiments simultaneously demonstrate that
peptides bind to Ab42 and reduce its associated tox-
icity during bacterial selection. MTT experiments
were used to establish that the toxicity associated
with extracellular Ab42 to mammalian cells could be
reduced when incubated in the presence of PCA
selected peptides.
Cell growth experiments
The effect of inhibitors on the growth of E.coli har-
boring pES300d-Ab42cc-DHFR2 target and pES230d-
antagonist-DHFR1 fusion plasmids as present in the
final PCA selection round were tested (Fig. 2). In
this experiment, cells were grown in a shaking incu-
bator from a starting OD600 of 0.02 under PCA
conditions in M9 minimal media containing Cm,
Amp, and Kan to retain target and antagonist
expressing plasmids as well as pREP4 for expression
of the lac repressor. In addition Tmp was included
for inhibition of bacterial DHFR and IPTG to induce
high levels of target and antagonist expression. This
experiment monitors both mDHFR reassembly, and,
therefore, binding of antagonist to the Ab42cc target,
as well as the toxicity of the oligomeric state that is
populated. As expected, expression of the toxic
Ab42cc did not result in significant levels of growth
even though the protein is well documented to self-
associate (Fig. 2). In addition, western blots (Sup-
porting Information Fig. S5) show that Ab42cc is
expressed in the soluble fraction, suggesting that
the protein is both soluble and toxic and is, there-
fore, populating toxic protofibrillar structures. All
four antagonists in this study, along with the posi-
tive control cJun-FosW, were clearly able to restore
bacterial growth thereby providing strong evidence
for direct binding and reduced toxicity in the context
of this bacterial selection system.
ThT experiments demonstrate a reduction
in amyloid content
To determine the ability of PCA derived peptides to
prevent fibril assembly (inhibition) or to breakdown
preformed fibrils (reversal), ThT fluorescence was
used as an indicator of the degree to which Ab42
aggregates into amyloid fibrils. In these assays, Ab42
Table I. PCA Derived Sequences
Name Sequence
cys1521 Ac-QKVLLFA-NH2
cys2935a Ac-AGKATGL-NH2
cys2935b Ac-GAKATAN-NH2
cys3642 Ac-RWGVVWG-NH2
iAb5 Ac-LPFFD-NH2
Four libraries consisting of 160,000 members each and
based around residues 15–21, 29–35, and 36–42 of the Ab1–
42 were fully randomised at positions shown underlined to
allow options for all amino acids. A second library consist-
ing of 160,000 members was fully randomised at positions
29–30 and 34–35 with the KAT sequence from the first
selection fixed. Cys2935a/b is based on a previously selected
sequence that targeted Ab29–35.
10 Acetylation and amida-
tion of the protein was added to mimic the polypeptide
backbone and provide additional potential hydrogen-bond
acceptors and donors. The positive control sequence, iAb5,
is also shown.
Figure 2. To confirm that expression of Ab42cc-DHFR1 /
Ab42cc-DHFR2 fusions impedes the growth rate of E. coli,
and to ascertain substitution with antagonist-DHFR1 fusions
are able to reverse this effect, growth competition experi-
ments were undertaken in M9 liquid media in an identical
manner to that during the PCA selection process. In these
experiments, cells expressed either i) Ab42cc1Ab42cc, ii)
Ab42cc1 antagonist, or iii) nontoxic cJun1FosW. In this
experiment, only scenarios ii) and iii) led to significant growth
rates in E. coli, providing evidence that a high affinity interac-
tion is formed and that toxicity associated with expression of
Ab42cc has been lowered, leading to significant growth rates
relative to i).
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was rendered monomeric21 and freeze-dried before
being resuspended and incubated at 37C, leading to
formation of amyloid aggregates. For the inhibition
assay, PCA-selected peptides were added on Day 0
and their ability to prevent amyloid formation was
assessed after 3 days. For the reversal assay Ab42
was incubated in isolation for three days to allow
amyloid formation before addition of peptide, fol-
lowed by incubation for a further 3 days to monitor
the ability of peptides to breakdown amyloid aggre-
gates. In all cases, a positive control peptide from
the literature (iAb522,23) known to perform well in
ThT assays was used. Figure 3 shows the results of
inhibition and reversal experiments for the four
single PCA-selected peptides and two examples of
peptides administered in combination. Both inhibi-
tion and reversal experiments have been undertaken
at five different Ab42:peptide ratios ranging from 10-
fold substoichiometric to 10-fold superstoichiometric.
For every peptide, and at the majority of stoichiome-
tries, the ThT-bound signal was reduced for both
inhibition and reversal experiments, indicating that
peptides are able to bind Ab42 and lower the amount
of ThT-bound amyloid in solution. Consistent with
previous studies, changes in Ab42:inhibitor stoichi-
ometry altered binding although it was not clear if
this was dependent on dose.10,24 However, on aver-
age the effects observed at ratios of 1:0.1 are small
Figure 3. ThT Inhibition and Reversal data for a) individual peptides and b) peptides used in combination. The data show the
effects of different stoichiometries of the inhibitors cys1521, cys2935a, cys2935b, cys3642, cys15211cys2935a, cys15211 cys3642, and
iAb5 on the aggregation of 50 lM Ab42. The assay was undertaken at 3 days for the inhibition assay. For the reversal assay,
Ab42 was incubated in isolation before addition of peptides on Day 3 with the assay undertaken on Day 6. The assay was per-
formed at 10 lM Ab42 concentrations. All errors are expressed as the standard error of the mean.
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while ratios of 1:1 are lower than 1:2 or 1:4 (see
Supporting Information Fig. S4). These ratios were
required to consistently elicit an effect in both inhi-
bition and reversal experiments. Increasing the ratio
to 1:10 led to poorer levels of inhibition for several
peptides (and consequently increased ThT fluores-
cence). What is also clear from these experiments is
that ThT-bound amyloid can be frequently reduced
to less than 50% of the signal found in the Ab42 pos-
itive control, with peptides performing well in both
inhibition and reversal experiments. Reassuringly,
the positive control iAb5 peptide was also able to
reduce the ThT signal by >40%.
In addition, we have conducted experiments
where amyloid-PCA derived peptides predicted to tar-
get different regions of the disulphide tethered Ab42cc
have been combined [Supporting Information Fig.
3(b)]. These combinations were (a) cys1521/cys2935a and
(b) cys1521/cys3642. In both instances, these peptides
were derived from libraries based on (and, therefore,
predicted to independently target) the first and second
strands within the tethered b-hairpin structure of
Ab42cc. Indeed, cys2935a is based on a sequence that
was selected using the Ab25–35 target,
10 with the same
library unable to yield any binding sequences when
using the wild-type Ab42 or Ab15–21 as a target. In
addition, the library used to generate cys1521 was also
unable generate any hits against wild-type Ab42. This
is significant since it suggests that Ab42cc represents a
far more accessible target for intracellular library
screening and antagonist selection. Despite this, ThT
experiments in which these peptides were combined
generated only one instance where two peptides
assayed together were, within error, consistently more
effective across the stoichiometries than the average
of the individual component peptides [Fig. 3(b)]. This
was observed for inhibition experiments that com-
bined cys1521 and cys2935a. In this case, an additional
25–35% reduction in ThT fluorescence was observed
over the average of the individual peptides at 1:0.1,
1:2, 1:4, and 1:10 stoichiometries, indicating a benefit
in combining them [Fig. 3(b), green vs. purple]. At 1:1,
large cumulative errors precluded any interpretation.
In contrast, combinations of cys1521 and cys3642 gave
no consistent benefit in inhibition experiments. For
peptides tested in combination during reversal experi-
ments, no consistent benefit was observed over either
peptide assayed alone. Rather, combinations of cys1521
and cys2935a displayed signs of synergy at 1:1 to 1:2
molar ratios with the trend reversing for 1:4 and 1:10,
indicating that higher concentrations of peptide can
lead to increased ThT fluorescence. As increasing the
molar ratio did not lead to improvements in the rever-
sal of amyloid in most cases, this indicated that a two-
fold excess of peptide:Ab may be sufficient to reverse
fibril formation. A similar trend was true of combining
cys1521 and cys3642 in reversal experiments. However,
in both cases the trend was not observed in inhibition
assays, perhaps reflecting the fact that more binding
sites are available in monomerized Ab42 to which
inhibitor can bind and, therefore, remain soluble rela-
tive to aged and aggregated samples. Lastly, it cannot
be ruled out that the combined peptides do not inter-
act with each other; however, mixing peptides does
not result in any gain in amyloid formation as
increased ThT signals are not observed.
CD experiments demonstrate a reduction in
b-sheet content
As amyloid fibrils are predominately b-sheet, we
used CD spectroscopy to provide an end-point char-
acterization of the aggregates formed once ThT
experiments were complete. Consistent with a b-
sheet structure, spectra show a negative peak at
218 nm. At higher molar ratios (1:2 or greater for
inhibition and 1:4 or greater for reversal) an addi-
tional large minima of up to 211 millidegrees was
observed at 200 nm for the majority of peptides,
indicating the adoption of a mixture of b-sheet
(Ab42) and random coil-like structures (peptides).
This minima was noticeably less pronounced for the
cys3642 peptide and was not observed for iAb5, which
adopted a spectrum consistent with a b-sheet struc-
ture at all concentrations. During CD experiments,
we observed a decrease in b-sheet content in the
majority of samples, supporting the ThT data by
demonstrating that peptides reduce the global b-
sheet content relative to the Ab42 sample and, there-
fore, the amyloid content. These experiments there-
fore suggest that peptides can bind Ab42 and exert
their effect by reducing the amount of protein in the
amyloid form. Lastly, ThT and CD spectroscopy
experiments undertaken on peptides in isolation
that have been incubated at 50 lM for 3 days under
conditions identical to those used in aggregation
assays using Ab42 demonstrate that peptides do not
bind significant amounts of ThT, and that the CD
signal for all peptides (at 0:1) is consistent with that
of a random coil or weakly helical conformation.
OAF microscopy
Samples used in ThT and CD experiments were also
imaged using OAF microscopy for both inhibition
and reversal experiments. To prevent bias toward
any one sample the experiment was carried out
blind.25 This technique allows for surface associated
and stacked aggregates of amyloid fibers to be
directly imaged. It was possible to assess the
amount of protein deposited as amyloid and its mor-
phology. OAF experiments were undertaken for both
inhibition and reversal at all of the molar ratios
assayed in ThT experiments (Fig. 4). In almost every
case, for both inhibition and reversal experiments, a
reduction in the amount of amyloid was observed
relative to Ab42 incubated in isolation under
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identical conditions. In a number of cases amyloid
deposits much smaller in size were observed.
Atomic force microscopy
Again samples used in ThT and CD experiments
were imaged using AFM as a second direct
qualitative measure of fibril formation (Fig. 5). A stoi-
chiometry of 1:2 (50 mM:100 mM) was chosen for AFM
experiments as this was the concentration at which
peptide inhibitors were on average deemed to be
most effective in ThT experiments. AFM was under-
taken for both inhibition and reversal experiments on
Figure 4. OAF Microscopy data for all inhibitors at all stoichiometries. During inhibition experiments, Ab42 was grown with
inhibitor for 3 days and assayed for peptide induced inhibition of amyloid formation. During reversal experiments, Ab42 was
grown without inhibitor for 3 days, after which inhibitor was added at a stoichiometry of 1:1 and followed by a further 3 days
incubation to assay for peptide induced reversal of amyloid deposition. Each sample was then imaged by fluorescence micros-
copy and panels showing representative images obtained. To quantify amyloid deposition the mean grey value over a 160 px 3
160 px (13 lm 3 13 lm) area randomly chosen for five separate images is plotted as fluorescence intensity. Each data point is
scaled to overcome the “background noise” by taking Ab (1:0) as the maximum and iAb5 as the minimum [i.e., (signal-iAb5)/
(Ab42-iAb5)]. This defines the range over the positive and negative controls.
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cys1521, cys2935a, and cys15211cys2935a as an additional
measure of the extent to which these peptides are
effective when mixed. A major reduction in the
amount of amyloid was observed for all samples rela-
tive to the Ab42 control. No fibrils were observed for
peptides in the absence of Ab42, either alone or when
mixed. For inhibition experiments in the case of
cys15211 cys2935a no fibrils were observed; with mix-
ing appearing to remove fibrils present for the cys1521
sample. For reversal experiments, the residual fibrils
observed in the cys2935a were also largely removed on
mixing with cys1521.
Cell-toxicity experiments
MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide)) cell toxicity experiments were per-
formed using Rat phaeochromocytoma (PC12)
neuronal-like cells to reflect the nature of toxicity in
the disease via the reduction of a redox dye (Fig. 6).
We assessed the toxicity of extracellular Ab42 depos-
its on PC12 cell integrity and its amelioration by
preincubation of Ab42 with peptides. Cells incubated
with buffer alone resulted in a reduction of the
redox dye MTT, leading to a color change from
yellow to purple that can be measured by a change
at A540. In contrast, incubation of cells with Ab42
resulted in a large decrease in cell viability and con-
sequently the ability to reduce MTT, leading to a
smaller signal change. To study, the ability of inhibi-
tors to reverse the effect on cell viability MTT assays
were performed with a range of molar ratios relative
to Ab42 and normalized relative to cells in isolation
(normalized as 0% death) and cells incubated with
Ab42 alone (normalized as 100% death). Although
the changes are small and the cumulative errors
resulting from comparatively small changes can be
large, we were nonetheless able to draw some gen-
eral conclusions from this assay. In particular, we
observed that effective peptides were able to gener-
ate modest reductions in toxicity of 5–20% in the
majority of cases. Neither cys2935a or cys2935b
appeared effective in this assay, displaying almost
no improvement across all stoichiometries. Cys1521
was able to elicit a small decrease of 5–15% in a
nondose dependent manner. Cys3642 demonstrated a
decrease across all molar ratios of 10–20%. A combi-
nation of cys15211 cys2935a or cys15211 cys3642 did
not conclusively lead to additional lowering of
Figure 5. AFM data. To demonstrate that inhibitors cys1521, cys2935a, and cys2935a1cys1521 do not aggregate in isolation, they
were grown alone for 3 days at a concentration of 100 mM (i.e., 0:2 molar ratio) under the same conditions as inhibition experi-
ments. In all cases, no fibril formation was observed. Inhibition experiments were undertaken at an Ab42:inhibitor stoichiometry
of 1:2 (row two). In this experiment, the same sample was used as for ThT experiments, in which Ab42 was grown with inhibitor
for 3 days at 37C. All of the peptides are inhibitory, in particular the combination of cys29351cys1521. For reversal experiments,
Ab42 was grown alone for 3 days, after which inhibitor was added at a stoichiometry of 1:2 and followed by a further 3 days
incubation to assay for peptide induced reversal of amyloid deposition. Each of the samples were imaged by AFM and panels
showing representative images obtained. Also in reversal experiments, it can be clearly observed that for all of inhibitors there
is a reduction of fibril, although this is less pronounced than for inhibition experiments. Scale bars are shown.
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toxicity [Fig. 6(b)]. Although reductions in toxicity
greater than the average of the component peptides
were observed, these were small; 5% for cys1521/
cys2935a at 1:10 and 10% for cys1521/cys3642 at 1:10.
At other molar ratios the errors were either too
large or no additional benefits over Ab42 alone were
observed. It should be noted that as PCA is under-
taken inside bacteria it is possible that intracellular
selection of peptides that are nontoxic to E.coli may
not be as effective when transferred into a mamma-
lian cell system. There, exposure to different off-
target interactions and a different protease pool
will occur, in addition to the necessity for the pep-
tide to function in the extracellular space, where
Ab is known to aggregate in the brain. This may
explain the discrepancy between the effects on
growth rates in E.coli and efficacy in MTT experi-
ments on peptides incubated with PC12 cells.
Discussion
We have used an intracellular PCA combined with
semirational library design to identify peptides that
can reverse and inhibit Ab42 aggregation by up to 80%
as well as lead to a modest reduction (5–20%) in its
toxicity. As a target during bacterial selection, we uti-
lized a double cysteine mutant Ab42cc (A21C/A30C
7)
that has been shown to lead to the population of path-
ogenically relevant soluble oligomers in the cytoplasm
of an E.coli strain that harbors an oxidizing cytoplasm
environment.10,26 An advantage of using PCA with
Ab42cc is that the disulphide bridge forces Ab into the
b-hairpin conformation that is associated with toxicity
in AD. The Ab42cc mutant has been shown to lead to
the population of highly toxic oligomers, suggesting
that this mutant can be used to improve the strin-
gency of the amyloid-PCA assay. In addition, as
oligomers are adopted, we envisage that this confor-
mationally restricted mutant generates an increase in
the number of exposed structural epitopes relative to
fibrils formed by wild-type Ab42, meaning that more
mDHFR activity can be attained within cells harbor-
ing binders of this disulphide mutant. To target, the
two b-strands either side of the hairpin, we used
Ab15–21, Ab29–35, and Ab36–42 as design scaffolds and
fully randomized residues at four positions to create
three libraries of 160,000 members. All three libraries
resulted in the identification of sequences able to bind
the target sequence. In the case of wild-type Ab42, it
Figure 6. Shown are a) the results from the MTT toxicity assay using Ab42 and selected inhibitors using different molar ratios
after 24 h of incubation with PC12 cells. The assay was performed with 10 lM Ab42 and different concentrations of inhibitor, for
example, 1:0.1 (1 lM), 1:1 (10 lM), 1:4 (40 lM), 1:10 (100 lM). b) a comparison of the MTT results for individual peptides
against those used in combination. All errors are expressed as the standard error of the mean.
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should be noted that it is possible that the peptide
inhibitors may be able to function by stabilizing mono-
meric Ab42 before it misfolds into the b-hairpin struc-
ture, thus preventing conversion into a pathogenic
structure. By using the restrained Ab42cc protein, and
because we were unable to identify full length Ab42
binders using many of the same libraries, we infer
that the wild-type structure is a poor target for antag-
onist recognition, possibly due to a lack of well-defined
structural epitopes in the nonamyloid or early oligo-
meric conformations of the molecule. Thus, the gener-
alized approach of using Ab42cc to screen libraries and
generate peptide hits before testing selected peptides
on wild-type Ab42 is potentially very exciting.
Combination experiments
As previously noted, we have identified hits from the
same 15–21 library that was unable to yield binders
for either wild-type Ab42 or Ab25–35 target proteins
(unpublished data). The failure to identify binders in
these previous PCA screens suggests that the epitope
presented was insufficient for effective binding. Thus,
we believe that the restricted conformation of Ab42 in
the disulphide bridged version represents an
improved target for our “recognition-element” based
libraries. As the 15–21 library was unable to provide
colonies under PCA conditions with Ab42, we instead
focused our efforts on the 25–35 region of the mole-
cule. We therefore envisage that the cys1521 winner is
able to target the first b-strand in the constrained
amyloid conformation of Ab42cc, with the cys2935 and
cys3642 libraries targeting the second b-strand. To look
for synergy when used in combination, we therefore
incubated the cys1521 winner with either cys2935a or
cys3642. In the case of cys1521 and cys2935a, we found a
reduction in bound-ThT signal of 20% over the aver-
age of the two individual peptides, indicating that
there is an added benefit in combining peptides, and
that they may occupy different regions within Ab.
MTT data produced large errors, however, improve-
ments in cell viability of 5–10% at some molar ratios
were observed, indicating that the combined effect of
the inhibitors is greater than the average of the two.
In agreement with this, OAF and AFM experiments
also suggest that there is an additional benefit in mix-
ing the cys1521 and cys2935a peptides.
This study has led to a number of peptides that
are capable of preventing assembly of amyloid
aggregates as well as breaking down preformed
amyloid and further investigation is warranted in
the search for molecules that can ultimately slow or
even prevent the onset of AD.
Materials and Methods
Mutagenesis and protein engineering
pES300d-Ab42cc-DHFR2 was created using overlap
extension PCR with codon changes corresponding to
A21C and A30C. These sites have been previously
chosen to constrain the peptide into a b-hairpin con-
formation7 and are located on nonhydrogen bonded
sites between b-strands either side of the hairpin
and in close proximity to each other.27
Choice of E.coli strain
PCA were undertaken using E. coli SHuffle Express
cells (New England Biolabs). SHuffle cells have been
engineered to possess an oxidative cytoplasmic envi-
ronment that favors disulphide bond formation. In
particular, SHuffle cells have been engineered to
lack thioredoxin reductase (trxB) and glutathione
reductase (gor) with an additional suppressor muta-
tion (ahpC) which is required to restore viability,
allowing the formation of stable disulphide bonds in
the cytoplasm. Under these conditions, thioredoxins
are in their oxidized state, converting them from
reductases to oxidases. Proteins that require disul-
phide bonds for their folding can, therefore, be oxi-
dized and form stable disulphide bonds within the
cytoplasm. This cell line also constitutively
expresses a chromosomal copy of the disulphide
bond isomerase DsbC. DsbC promotes the correction
of misoxidized proteins into their correct form.10,26
Single step selection PCA
pES300d-Ab42cc-DHFR2 and pREP4 (Qiagen; for
expression of the lac repressor protein) were cotrans-
formed into SHuffle Express cells (New England
Biolabs) and plated onto LB agar with the appropri-
ate antibiotics (Kan and Cm). These cells were next
made electrocompetent before transformation with
the appropriate pES230d-library-DHFR1 library
plasmid (E.coli XL-1 cells were used for construction
and cloning of libraries, as described previously10,14).
Transformed cells were next plated on three differ-
ent media; 1/20th of the cells were plated onto LB
agar with three antibiotics (Kan, Amp, and Cm) as a
positive control of transformation efficiency. A fur-
ther 1/20th of the solution was plated onto M9 mini-
mal medium agar with 1 lg/ml trimethoprim and
the same three antibiotics as a negative control.
Finally, the remaining 90% of transformed cells
were plated onto M9 minimal agar in the presence
of the three antibiotics, 1 lg/ml trimethoprim, and
1 mM IPTG (isopropyl-b-D-thiogalactopyranoside),
to induce expression of the two DHFR fragment
fused peptides). This single-step PCA selection typi-
cally led to approximately 50–100 colonies from
libraries of 160,000 members, meaning that at least
99% of all library members are removed at this
stage owing to their inability to bind Ab42cc and
reduce toxicity.
Competition selection PCA
To increase the selection stringency, growth competi-
tion experiments were undertaken. Using this
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approach, selected colonies were pooled from the
plate and grown in M9 minimal media under selec-
tive conditions (containing Kan, Amp, Cm, trimetho-
prim, and IPTG) and serially diluted over 5–10
passages. Using these sequential rounds of competi-
tion selection, subtle differences in growth rate are
amplified, increasing the stringency of selection rela-
tive to the single-step method. Competition selection,
therefore, allows the most effective 1–2 sequences to
be isolated from the 50–100 Ab42cc binders that are
initially identified during single step selection. At
each passage glycerol stocks were prepared and
sequencing results were obtained (GATC biotech,
London) for DNA pools as well as individual colo-
nies. For each passage, 50 lL of liquid culture was
added to 50 ml of fresh M9 minimal media, resulting
in an approximate OD600 of 0.01. Cells were incu-
bated at 37C until an OD600 of 0.4 was reached
(typically 2–3 days), before moving to the next
passage.
Ab peptide preparation
Ab42 was purchased as a pure recombinant peptide
from rPeptide (Stratech) and was used for all of the
experiments described. Prior to use, a quantity of
peptide was weighed using an analytical balance
before being treated to three rounds of dissolution in
hexofluoro-2-propanol (HFIP), sonication, drying,
dissolution in trifluoroacetic acid (TFA), sonication
and drying, according to the Zagorski protocol,21 and
then aliquoted into appropriately sized batches for
subsequent assays and dried via lyophilisation
before being dissolved in 10 mM potassium phos-
phate buffer (pH 7.4) to generate a final concentra-
tion of 50 lM. TFA/HFIP treatment was used to
ensure that amyloid growth always proceeds from
the same monomeric state, thus reducing errors in
amyloid formation measurements.
Peptide inhibitors
Peptides identified using amyloid-PCA (cys1521,
cys2935a, cys2935b, cys3642, and a positive control from
the literature, iAb522), were obtained by Peptide
Protein Research (Fareham, UK) as pure lyophilized
peptides. Peptides were weighed using an analytical
balance and stock solutions of 1 mM concentration
were subsequently dissolved in ultrapure water. At
this concentration (2–200x excess of that used in
inhibition and reversal experiments) no aggregation
or precipitate was observed. In addition, bioinfor-
matics tools (e.g., Waltz,28 Amylpred,29 Pasta,30 Zyg-
gregator,31 and Tango32) do not predict that any of
the peptides contain amyloidogenic sequences or
aggregate in isolation. Lastly, CD and ThT experi-
ments on peptide antagonists in isolation demon-
strate that these sequences do not bind ThT
and form random coil-like species in isolation (see
Supporting Information Fig. S1).
Growth competition experiments
To confirm that expression of Ab42cc-DHFR2 frag-
ment fusions impedes the growth rate of E. coli, and
to ascertain that amyloid-PCA derived peptides fused
to the DHFR1 fragment are able to reverse this
effect, growth competition experiments were under-
taken. These experiments were performed in M9
minimal media in an identical manner to that during
the PCA competition selection process. In these
experiments (Fig. 2), cells expressed either (i) Ab42cc
control, (ii) Ab42cc1PCA derived peptide, or (iii) the
nontoxic control cJun1FosW. The latter PCA-derived
pair is known to form a high affinity interaction,
leading to significant growth rates relative to (i).
Circular Dichroism
Far-UV CD spectra were recorded on an Applied
Photophysics Chirascan at 20C using the same
samples as for ThT experiments. Spectra were
recorded over the 200–300 nm range at a scan rate
of 10 nm/min with step size of 1 nm. Spectra were
recorded as the average of two scans. Peptide (10
lM in 10 mM Potassium Phosphate buffer pH 7.4)
was added to a 0.1 cm cuvette (Hellma). Spectra
were recorded as raw ellipticity.
Thioflavin T assays
ThT inhibition assays were performed with 50 lM
Zagorski treated21 monomeric Ab42 in 200 lL of
10 mM potassium phosphate, pH 7.4, with or without
each peptide inhibitor at a concentration of 5 lM (for
1:0.1 molar ratio), 50 lM (for 1:1 molar ratio), 100 lM
(for 1:2 molar ratio), 200 lM (for 1:4 molar ratio), and
0.5 mM (for 1:10 molar ratio). For the inhibition
assays, the target-inhibitor mixtures were incubated
together on day zero at 37C. Single ThT readings
were taken on day three at which maximal ThT bind-
ing was found. For the reversal assays, 200 lL of 50
lM target was incubated alone at 37C for 3 days
before adding to the required amount of lyophilized
peptide. The vortexed target-inhibitor solutions were
then incubated at 37C for a further 3 days, during
which time single ThT readings were taken on post-
mix Day 3. Experiments were undertaken in duplicate
and errors expressed as the standard error of the
mean. The ThT assay solution was prepared from a
253 stock containing 500 lM ThT in 250 mM Tris, pH
7.4. The stock was aliquoted and kept frozen until
required. It was then allowed to thaw at room temper-
ature for 10 min before dilution into the appropriate
Tris buffer, giving the required freshly prepared ThT
assay solution containing 20 lM ThT in 10 mM Tris
and buffer at pH 7.4. A total of 2960 lL of the ThT
assay solution was then added into 40 lL of each inhi-
bition/reversal assay mixture, thoroughly vortexed
and transferred into an appropriate cuvette. The fluo-
rescence of amyloid-bound ThT was measured by
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fluorescence spectroscopy using a Cary Eclipse fluo-
rescence spectrophotometer; bound ThT exhibits a
new excitation maxima at 450 nm and an enhanced
emission maxima at 482 nm.33
OAF microscopy experiments
Samples were imaged on a custom built OAF25 sys-
tem. The OAF system permits high signal to noise
imaging with greater sample depth penetration. Fluo-
rescence imaging was achieved through a 500LP
dichroic and clean up filter (Chroma, VT) before enter-
ing an Optosplit III triple color image splitter (Cairn,
UK), and was detected using an EMCCD camera
(Andor DU897, Andor, UK). The emission wavelength
range used was 500–565 nm, therefore, both the exci-
tation and emission wavelengths were off peak for
ThT, however, the image quality was excellent. All
samples were prestained with 10 lM ThT, pipetted
onto a clean glass slide, air dried and then imaged in
10 mM potassium phosphate buffer, pH 7.4, supple-
mented with 100 mM DTT to minimize photobleach-
ing. For consistency and cross-correlation, the same
samples were used for inhibition/reversal imaging as
those in ThT and CD experiments. In addition, all
OAF experiments were performed blind to prevent
bias toward any one sample.
AFM experiments
Samples were imaged in noncontact mode using a XE-
120 Atomic Force Microscope (Park Systems, South
Korea). NSC 15 silicon nitride cantilevers with a
spring constant of 40 N/m were used for imaging at a
scan rate of 1.0 Hz and a resolution of 256 3 256 pix-
els. All images were taken at room temperature. The
AFM data were taken from inhibitors alone as well as
inhibition and reversal experiments, using cys1521,
cys2935a, and the cys15211 cys2935a mixture. 5 mL sam-
ple was placed on freshly cleaved mica (thickness
0.3 mm). Following adsorption of the protein aggre-
gates (2 min), the mica was washed with 5 mL of dou-
ble distilled water. Excess water was removed and the
samples were dried using a stream of nitrogen gas.
Samples were immediately analyzed by AFM.
3-(4,5 Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide cell-toxicity assay
MTT experiments were undertaken using Rat phaeo-
chromocytoma (PC12) cells to assess the effect of the
toxicity of Ab42. PC12 cells are known to be particu-
larly sensitive and their use in this assay is well
established.34 The MTT VybrantVR MTT Cell Prolifer-
ation Assay Kit (Invitrogen) was used to measure the
conversion of the water soluble MTT dye to forma-
zan, which is then solubilized, and the concentration
determined by a color change monitored via absorb-
ance measurement at 570 nm. The change in absorb-
ance can then be converted to a percentage MTT
reduction which can be used as an indicator of the
PC12 cell health in the assay. The assay was per-
formed with 10 lM Ab42 and varying molar ratios of
peptide corresponding to 1:0.1 (0.1 lM), 1:1 (10 lM),
1:4 (40 lM), 1:10 (100 lM). PC12 cells were main-
tained in RPMI 16401 2 mM Glutamine medium
mixed with 10% Horse Serum, 5% Fetal Bovine
Serum, supplemented with a 20 mg/mL Gentamicin.
Cells were transferred to a sterile 96-well plate with
30,000 cells per well and experiments performed in
triplicate. Briefly, different concentrations of peptides
were screened in the presence of 10 lM Ab42. The
required volume from peptide and target stock solu-
tions was freeze-dried overnight. The freeze-dried pep-
tide and Ab42 target were resuspended in 100%
dimethyl sulfoxide (DMSO), each at 1003 stock con-
centration (i.e., 1, 2, 4, or 10 mM). For example, for
the molar ratio 1:1 a total of 5 lL from each of the
resuspended inhibitor/DMSO and target/DMSO was
mixed in a well of a 96-well preparation plate, thus
giving 10 lL of 1:1 mM inhibitor/target concentration
ratio in 100% DMSO. A total of 90 lL of RPMI media
was added to the 10 lL inhibitor/target mixture
(100:100 lM inhibitor/target ratio in 10% DMSO). A
total of 10 lL of the 50:50 lM inhibitor/target mixture
in 10% DMSO was then dispensed into 90 lL of
media/PC12 cells, at final peptide inhibitor and target
concentrations of 10 lM. These were incubated for 24
h at 37C, 5% CO2, prior to the addition of the MTT
dye. A total of 10 lL of the dye was added to each well
and incubated for a further 4 h at 37C, 5% CO2. A
total of 100 lL of the DMSO (stop/solubilization solu-
tion) was then added to each well and was allowed to
stand for 10 min. The absorbance was measured at
570 nm using a 96-well Versamax tunable microplate
reader. Assay values for incubation with buffer were
taken as 100% and inhibition of cell function by incu-
bation with buffer containing Ab42 alone taken as 0%.
Raw data were then scaled as follows: (raw data
point2Ab42 mean)/(buffer mean2Ab42 mean) 3 100.
The scaled mean for each data set was then plotted
with the error given by the standard deviation.
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